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Abstract
This thesis applies several statistical techniques which aim to provide informed clinical 
management in acute stroke. An introduction is given to issues arising in stroke 
management and expert systems methodology. Three linear discriminant scoring systems 
(the Allen, Siriraj and Besson scores) intended for the differential diagnosis between 
ischaemic and haemorrhagic stroke on the basis of clinical presentation are evaluated in 
chapter 2. Chapter 3 explores whether angiotensin converting enzyme DD genotype is a 
risk factor for acute stroke or influences stroke outcome as measured by lesion size. 
Chapters 4 and 5 assess computed tomography, mean cerebral transit time and single­
photon emission computed tomography scanning in terms of their accuracy in predicting 
functional outcome after acute ischaemic stroke. Chapter 6 broadens the search for 
prognostic factors, looking at the performance of the Guy’s prognostic score and 
established neurological scales (Canadian neurological scale, National Institutes of 
Health stroke scale, middle cerebral artery neurological scale) in predicting acute stroke 
outcome. A linear discriminant score, based on simple clinical measurements recorded in 
the acute stroke unit, is also developed. Chapter 7 looks specifically at the influence of 
plasma glucose level on survival following acute stroke, after adjusting for other known 
prognostic factors using Cox’s proportional hazards regression model. The remainder of 
the thesis is concerned with two aspects of acute stroke management. The first of these 
is the selection of an appropriate clinical trial for an individual patient. A computer 
program is developed to obtain, in an efficient manner, the information required to check 
the entry and exclusion criteria for each available clinical trial. The second aspect of 
stroke management considered is the choice of a suitable method for secondary 
prevention of stroke in individual acute ischaemic stroke patients. Candidate methods 
are long-term anticoagulation with warfarin, or aspirin antiplatelet therapy. Expert 
system methodology is used to combine positive indications for, and contraindications to 
each of these therapies with clinical data available in the acute stroke unit. The annual 
risks of recurrent ischaemic stroke, haemorrhagic stroke, myocardial infarction, other 
ischaemic complications and other haemorrhagic complications are estimated to allow an 
informed decision on the appropriate method of secondary prevention to be made.
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Chapter One: Introduction
Chapter One 
Introduction
1.1 Stroke
1.1.1 Definition
Stroke is defined as rapidly developing signs of focal (or global) disturbance of cerebral 
function, lasting longer than 24 hours or leading to death within 24 hours, with no 
apparent non-vascular cause. A stroke is reclassified as a transient ischaemic attack 
(TIA ) if the neurological deficit completely resolves within 24 hours of onset. If the 
deficit completely resolves between 24 and 72 hours of onset, the stroke is redefined as a 
reversible ischaemic neurological deficit (R IN D ). Despite the terminology, strokes which 
resolve within 72 or even 24 hours may be either haemorrhagic or ischaemic in nature.
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1.1.2 Epidemiology
The incidence of stroke in developed countries varies between 75 and 225 per 100,000 
population per year. (Thorvaldsen et al, 1995) Hence, about 120,000 people suffer a 
stroke in the UK every year. (Royal College of Physicians London, 1989) Stroke rates 
are higher in eastern European countries. (Wender et al, 1990; Rastenyte et al, 1995; 
Thorvaldsen et al, 1995) Comparisons of incidence rates between nations are difficult, 
however, due to differences in case ascertainment and routinely collected statistics, 
(Malmgren et al, 1987; Asplund et al, 1995) although one study compared stroke 
incidence in different countries by adjusting age and sex-specific rates using a standard 
population. (Alter et al, 1986) In addition to this there has been a decline in stroke 
incidence and mortality during the 20th century. (Whisnant, 1984)
About 30% of stroke victims die within one year, making stroke the third leading cause 
of death in developed countries after heart disease and cancer. Stroke is also the leading 
medical cause of chronic disability since a large proportion of survivors are left unable to 
live independently. Stroke therapy, rehabilitation, and long term care are therefore a 
large burden on health service resources, and account for 4.3% of National Health 
Service costs in Scotland. (Isard and Forbes, 1992) It follows that any improvement in 
stroke care has the potential to raise the quality of life for many thousands of patients 
while at the same time providing substantial savings in health service resources.
1.1.3 Pathology
The three main types of stroke are cerebral infarction, intracerebral haemorrhage, and 
subarachnoid haemorrhage. These pathologies respectively account for approximately 
85%, 10%, and 5% of strokes in the UK. (Bamford et al, 1990) The incidence of 
intracerebral haemorrhage is much higher in developing countries. (Poungvarin et al, 
1991)
2
Chapter One: Introduction
Impaired blood flow to brain tissue leads to ischaemia, and, if the blood flow deficit 
persists, the result is cerebral infarction. There are three main mechanisms which cause 
cerebral infarction. Large artery thrombosis causes narrowing (stenosis) or blockage 
(occlusion) of a blood vessel supplying the brain. Cerebral embolism occurs when a 
thrombus or other material forms elsewhere in the body (for example, in the heart), 
becomes dislodged and moves into the brain, blocking one of the blood vessels there. 
Artery-to-artery embolism occurs when material breaks off from a stenosed, ulcerated or 
occluded extracranial artery (for example, the internal carotid artery at its origin) or from 
a stenosis at the stem of any major cerebral artery.
Intracerebral haemorrhage is caused by the rupture of an artery in the brain. The 
underlying mechanism for this is uncertain but is thought in the majority of cases to be a 
direct result of hypertension. (Muller and Radu, 1983) Other possible causes include 
aneurysmal rupture, angioma or arterio-venous malformation, tumour, microangioma, 
poorly controlled anticoagulation, leukaemia, and abuse of amphetamines.
Subarachnoid haemorrhage is caused by bleeding into the subarachnoid space. Blood 
then spreads rapidly over the surface of the brain. The major cause of subarachnoid 
haemorrhage is the rupture of a saccular or ‘berry’ aneurysm. Several theories about the 
formation of these lesions exist (Sahs, 1983), the most recognised being that they form 
where deficiencies in the vessel wall exist at bifurcation points in the “circle of Willis”. 
Less common causes of subarachnoid haemorrhage include other types of aneurysm, 
angioma and haemostatic disorders.
Haemorrhagic transformation of ischaemic stroke may occur due to spontaneous 
reperfusion of occluded vessels. For example, it may occur when an embolus causing an 
ischaemic stroke is dislodged. Blood then flows into the softened, infarcted brain tissue.
3
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1.1.4 Symptoms
Stroke causes a variety of clinical presentations. Often a patient may be weak on the 
opposite side of the body to the side of the brain where the stroke has occurred. If this 
weakness involves both arm and leg it is called hemiparesis. The side of the face, mouth 
and tongue may also be affected. Reduced sensation may also be present on the affected 
side, either in addition to weakness or in isolation. Neglect occurs in severe cases where 
the patient is completely unaware of the presence of the affected limbs. Paralysis of the 
face and tongue may result in slurred speech, known as dysarthria. The area of the brain 
containing the nerves which control swallowing may be affected. This inability to 
swallow is known as dysphagia. Loss o f consciousness may also occur at the onset of 
the stroke.
The regions of the brain which deal with the formulation and understanding of speech 
may be damaged by the stroke. Problems may result, ranging from difficulty in finding 
the correct word to having no spoken output or comprehension. The terms dysphasia 
and aphasia are used to refer to language problems. Dysphasia may be classified as 
fluent or non-fluent. Fluent dysphasia types include Wernicke's aphasia (fluently 
articulated speech but impaired auditory comprehension), anomia (word-finding 
difficulty in fluent speech), and conduction aphasia (repetition disproportionately 
impaired). In non-fluent, or Broca’s, dysphasia, comprehension is relatively intact but 
spoken output is impaired. Global aphasia describes the situation where all aspects of 
language are severely impaired.
Problems with vision may also occur. If the stroke has been severe, the patient’s eyes 
may be deviated towards the unaffected side of the body. Double vision or diplopia may 
occur. Patients may lose vision in one half of their visual field (hemianopia).
Other problems which may occur include staggering {ataxia), dizziness {vertigo), loss of 
memory, inability to perform simple tasks such as dressing {apraxia), and bladder or 
bowel incontinence.
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1.1.5 The Oxford classification of acute stroke
The Oxfordshire community stroke project (OCSP) classified ischaemic stroke into four 
categories. (Bamford et al, 1991) This subdivision was based on the patient's clinical 
features at the time of maximum impairment, rather than the underlying 
pathophysiological mechanism. This approach results in a simple classification which can 
be used to identify groups of patients for stroke or secondary prevention therapies, 
without the delay caused by investigations such as cerebral computed tomography (CT). 
If implemented before CT, the classification may also be used on patients who 
subsequently are found to have had a haemorrhagic stroke. The classification also gives 
an indication of the likely prognosis of the patient.
Total anterior circulation infarcts (TACI) are large anterior circulation infarcts with both 
cortical and subcortical involvement. Patients present with a combination of hemiparesis, 
hemianopia, and a new higher cortical dysfunction (for example, dysphasia or neglect). 
Alternatively, if such features are untestable due to the patient being comatose, a 
classification of TACI is also made. Since these strokes involve a large volume of brain 
tissue, the prognosis is poor: 60% of patients with TACI die within one year of the 
stroke.
More restricted and predominantly cortical infarcts are classified as partial anterior 
circulation infarcts (PACl). Patients present with two of the three features required for 
TACI, or with a new higher cortical dysfunction alone. These events lead to a high risk 
of recurrent stroke although survival is much more likely than for TACI.
Posterior circulation infarcts (POCI) are infarcts in the vertebrobasilar arterial territory. 
Patients with POCI present with either hemianopia alone, or with unequivocal brainstem 
signs (for example, ataxia, diplopia, vertigo, disconjugate eye movements or nystagmus). 
M ost POCI have a good prognosis; however, a small proportion deteriorate as a result of 
basilar artery occlusion.
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Infarcts affecting the territory of the deep penetrating arteries alone are classified as 
lacunar infarcts (LACl). Lacunes are small subcortical infarcts. Patients with lacunar 
infarction present with one of five specific syndromes. These are: pure motor stroke 
(hemiparesis only), pure sensory stroke (sensory deficit only), sensorimotor stroke, 
ataxic hemiparesis, and the dysarthria/clumsy hand syndrome. The prognosis is generally 
good as the volume of brain tissue involved is small.
The OCSP classification categories may also be applied to the clinical characteristics of 
patients who suffer haemorrhagic stroke, although not originally developed for this 
purpose. The abbreviations of the four categories become TACH, PACH, POCH and LACH. 
If we are referring to patients with either haemoiThagic or ischaemic stroke, the OCSP 
classification becomes total anterior circulation syndrome (TACS), partial anterior 
circulation syndrome (PACS), posterior circulation syndrome (POCS) and lacunar 
syndrome (LACS).
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1.2 Risk factors for stroke
1.2.1 Ischaemic stroke
Multiple risk factors are associated with ischaemic stroke. Incidence increases with age 
and is slightly higher among males. A previous stroke or transient ischaemic attack 
increases stroke risk as do coronary artery disease (angina, previous myocardial 
infarction), chronic cardiac failure, atherosclerosis, diabetes mellitus, elevated cholesterol 
level and cigarette smoking. Rheumatic heart disease, mitral valve prolapse, mitral 
stenosis and chronic atrial fibrillation are risk factors for cerebral embolism.
Hypertension is the major modifiable risk factor for ischaemic stroke. Artery walls are 
damaged by high blood pressure and this accelerates the accumulation of fatty deposits 
such as cholesterol on the artery wall. Hypertension also increases the number of red 
blood cells present which in turn stimulate platelet aggregation and hence thrombosis. 
Hypertension is also an indirect cause of embolic stroke. High blood pressure is a risk 
factor for myocardial infarction, which may cause the formation of mural thrombus, a 
source of emboli, in the heart. Hypertension and myocardial infarction, alone or in 
combination, may also lead to atrial fibrillation, a further source of emboli. About two- 
thirds of infarctions in the deep penetrating arteries are caused by hypertensive changes: 
microatheroma or fibrin deposits leading to lipohyalinosis weaken the arteriolar wall and 
cause atherosclerosis.
1.2.2 Haemorrhagic stroke
Age and hypertension (via the formation of miliary aneurysms, or Charcot-Bouchard 
lesions) are the main risk factors for intracerebral haemorrhage. Hypertension, 
associated with the formation of berry aneurysms, is also a risk factor for subarachnoid 
haemorrhage. Alcohol intoxication may also be a risk factor. Age is not a risk factor for 
subarachnoid haemorrhage.
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1.3 Acute stroke units and the clinical management of stroke
At present, investigation and treatment of stroke vary, depending on whether the patient 
is admitted to hospital (district general or teaching) or kept at home. One recent 
development has been the introduction of the specialised stroke unit to help co-ordinate 
clinical and paramedical care. Evidence suggests that providing co-ordinated care for 
stroke reduces length of stay in hospital and improves overall outcome. (Stroke Unit 
Trialists Collaboration, 1996)
The acute stroke unit (ASU) of the Western Infirmary, Glasgow, serves a catchment area 
of population 220,000. All patients within this well-defined geographical region who 
suffer an acute neurological deficit of probable vascular origin are admitted, regardless of 
age or severity of deficit. Morris et al. (1993) describe the ASU protocol. Patients with 
known non-vascular disease, recent head trauma, metabolic disturbance, intoxication or 
requiring intensive or coronary care are not admitted. Patients with subarachnoid 
haemorrhage are usually admitted to a specialist neurosurgical unit at the Southern 
General Hospital, Glasgow. Each ASU patient undergoes a standard series of 
investigations, including computed tomography or magnetic resonance (MR) imaging, the 
aim being to complete these within 72 hours of stroke onset.
During the care of a patient in the ASU, a number of important clinical management 
decisions must be made. Firstly, the stroke must be diagnosed as haemorrhagic or 
ischaemic. Evidence regarding the underlying mechanism of the event should be 
gathered. Treatment in a randomised clinical trial may be commenced without delay if 
the patient meets the relevant entry criteria. If the patient survives the first few days 
following the stroke, then it is of interest to make a prediction of the patient's chance of 
making a good recovery. Prevention of further strokes by long-term drug therapy or 
surgery should also be considered.
Quick, accurate diagnosis of stroke type and mechanism is required to enable effective 
patient management and to determine the most appropriate strategy for prevention of
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further strokes. Computed tomography imaging, if performed within 7 days of stroke 
onset, will distinguish between ischaemic and haemorrhagic stroke. Scoring systems, 
(Allen, 1983; Poungvarin et al, 1991) based on the clinical presentation of the patient, 
have also been developed to aid in this differential diagnosis (see chapter 2). Magnetic 
resonance imaging may be performed instead of or in addition to CT, particularly in 
patients with a suspected posterior circulation event.
It is unlikely that the mechanism of cerebral infarction will be identified with certainty. 
The presence of a significant carotid stenosis on the appropriate side is suggestive 
evidence for large artery atherosclerosis; conversely, the presence of a cardiac source for 
embolism is suggestive of cardioembolic stroke. However, in patients with neither or 
both of these findings the mechanism is difficult to determine. The TOAST (Trial of Org 
10172 in Acute Stroke Treatment) classification (Adams et al, 1993) diagnoses each of 
the types of ischaemic stroke as “probable” or “possible” on the basis of the patient’s 
clinical presentation and the results of investigations. Identifying the cause of ischaemic 
stroke is important as it will influence the risks and benefits of therapies for prevention of 
stroke recurrence. Modifiable risk factors can be altered by any of three strategies: 
lifestyle changes (for example, stopping smoking), long-term drug therapy (for example, 
lowering blood pressure), and surgery (for example, repairing carotid artery stenosis).
If the patient survives the initial effects of the stroke, it is useful to have an indication of 
the long-term prognosis. This helps to target rehabilitation resources (physiotherapy, 
occupational therapy, and speech therapy) on the patients with most potential for benefit. 
It gives the patient’s relatives an indication of whether the patient is likely to return to 
independent living. It enables a long-term care plan to be formulated for each patient 
and helps determine placement of the patient after discharge from the ASU. It provides a 
benchmark against which the effects of any treatment interventions can be judged. Short 
and long-term prognosis both influence strategies for prevention of further stroke events. 
Scoring systems have been developed (Fullerton et al, 1988; Allen, 1984; Frithz and 
Wemer, 1976; Wade et al, 1983; Prescott et al, 1982), based on the clinical presentation 
of the patient, which aim to predict the patient’s functional status several months after 
stroke (see chapter 6). Other studies have explored outcome prediction using results of 
radiological or radionuclide investigations alone (Mountz et al, 1990; Giubilei et al,
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1990), or in combination with clinical data (Laloux et al, 1995; Bowler et al, 1996) or 
ultrasound investigation. (Alexandrov et al, 1993) (see chapters 4 and 5) Scales used to 
measure neurological impairment (Brott et al, 1989a; Cote et al, 1986; Hantson et al, 
1994; Orgogozo and Dartigues, 1986; Scandinavian Stroke Study Group, 1985) have 
also been used to predict stroke outcome (see chapter 6).
At present there is increasing interest in the development of pharmacological treatments 
for reducing neurological damage and hence improving functional outcome after acute 
stroke. The thrombolytic agent t-PA has been shown to be efficacious in a phase III 
clinical trial. (The National Institute of Neurological Disorders and Stroke rt-PA Stroke 
Study Group, 1995) Evidence that the neuroprotective compound lubeluzole is 
efficacious was recently presented (Grotta et al, 1997), although another trial did not 
find a positive result (Diener et al, 1997). Agents currently being investigated include 
thrombolytic drugs, antagonists of the excito-toxic neuro-transmitter glutamate, calcium 
entry blockers and free radical scavengers.
Diagnosis of stroke type is essential to assess for which clinical trials a patient is eligible. 
The ASU may be conducting several trials of therapeutic agents at any one time, each 
with its own detailed set of inclusion and exclusion criteria. Trials testing efficacy 
usually take priority over trials investigating safety or tolerability. The priority of each 
trial may also vary depending on the stage which recruitment has reached. A trial must 
be chosen quickly, since any delay is thought to reduce the potential efficacy of the 
intervention. Chapter 8 presents a computer program to assist in clinical trial choice.
If the patient has suffered an ischaemic stroke, long-term anticoagulation (warfarin) or 
antiplatelet therapy will be considered in order to prevent further strokes. Aspirin and 
dipyridamole are the currently licensed antiplatelet therapies; ticlopidine is available in 
the United States and some parts of Europe, and clopidogrel will soon be licensed. 
Haemorrhagic stroke must be excluded before starting any of the above treatments as 
they can be hazardous if given to patients with bleeding lesions. Warfarin dosage must 
also be closely monitored to optimise the benefit of treatment. Over-anticoagulation 
leads to a risk of haemorrhagic stroke or other bleeding complications. Under­
anticoagulation leaves the patient at risk of another ischaemic stroke. Hence other
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factors which affect the control of the clinician over the medication dosage must also be 
taken into account -  for example, the ability of the patient to attend regular clinics for 
monitoring, and to comply with the dose prescribed. Chapters 9 and 10 consider the 
determinants and effects of clinical management decisions relating to secondary 
prevention of stroke. Timing of anticoagulation is also important: if a patient with a 
large infarct is anticoagulated too soon after stroke, there is a risk of haemorrhagic 
transformation of the infarct.
Similarly, if hypertension is present, antihypertensive therapy should be initiated to 
reduce the risk of further strokes. There is debate, however, over the timing of this 
treatment: if blood pressure is lowered too soon or too dramatically after acute stroke, 
this can exacerbate ischaemia and cause an extension of the original stroke.
If Doppler ultrasound or angiography suggests that the stroke was caused by severe 
stenosis of a carotid artery, then carotid endarterectomy may be appropriate. Surgery is 
a high-risk procedure, however, particularly in elderly people who may have cardiac 
problems. Hence it is necessary to select the patients who are at greatest risk of further 
stroke and who are considered to be suitable candidates for surgery -  the patients for 
whom the benefits of surgery outweigh the risks.
The above issues illustrate that management of stroke is a complex task. There is a 
variety of possible underlying causes and a large number of interrelated risk factors. 
Thus, formulating the optimal care plan for an individual patient requires the assimilation 
of many (possibly contradictory) items of evidence. Uncertainty in the diagnosis must be 
incorporated into any decision-making process. For example, in ischaemic stroke, only a 
probable diagnosis of underlying mechanism will be available in the majority of cases. 
New evidence must be accounted for as test results become available. The risks and 
benefits of potential therapeutic strategies must be assessed. The physician is unlikely to 
be able to give each of the many relevant factors the correct weighting when considering 
possible patient management strategies. Hence advisory systems are needed to provide 
the physician with the information required for optimal patient management. Both expert 
systems methodology and long-established statistical techniques such as discriminant 
analysis and log-linear modelling may have a contribution to make in this respect.
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1.4 Expert systems
Lauritzen and Spiegelhalter (1988) give the following definition of an expert system:
“a computer program intended to make reasoned judgements or give assistance in a 
complex area in which human skills are fallible or scarce "
A general characteristic of expert systems is the separation of the “knowledge-base”, 
which contains detailed expert knowledge of the problem of interest, from the 
“inference-engine”, the mechanism by which this knowledge is applied to information on 
a new case.
Expert systems have been considered as a tool to aid human decision making since the 
Second World War. Early unsuccessful expert systems attempted to solve general 
problems, but computational limitations made this infeasible. Greater success was 
achieved when attention was turned to complex but well-defined problems. Advances in 
computer hardware and software in the late 1970s and early 1980s led to the 
development of systems able to deal with real-life problems. These included MYCIN, 
(Buchanan and Shortliffe, 1984) which dealt with the diagnosis and treatment of bacterial 
infections and CASNET, (Weiss, 1977; Weiss and Kulikowski, 1982) which modelled the 
development of glaucoma.
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1.5 Issues in expert system design
There are two main theoretical issues in the development of an expert system. The first 
of these is the means by which the expert knowledge is represented in the knowledge­
base. The second is the method of treating any underlying uncertainty in this knowledge:
expert knowledge may be incomplete, certain rules of thumb may not invariably hold, or 
the data on a particular case may be imprecise or unreliable.
There are several candidate methods of knowledge representation. "Production rules" 
are probably the most widely used. Such rules consist of a premise (a collection of 
statements about the current case) and a conclusion (to be drawn if the premise holds 
true). An example of a production rule from the TOPOSCOUT expert system for stroke 
diagnosis (Spitzer ef a/, 1989a) is:
IF there is weakness in right arm 
AND there is no weakness in left arm 
AND there is weakness in right leg 
AND there is no weakness in left leg 
THEN there is right hemiparesis
An alternative method of knowledge representation is the causal network or directed 
graph. This approach was used in the MUNIN expert system. (Andersen et al, 1986) 
This system aids neurological diagnosis through the analysis of bioelectrical signals from 
muscle and nerve tissue. Such an approach represents associations or causal 
relationships between variables as directed links between nodes of a graph, as illustrated 
in figure 1.1.
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edge
node
Figure 1.1 A causal network. Each node represents one variable. An edge represents 
an association or causal relationship between a pair of nodes, and may be directed or 
undirected. A node is termed a “parent” if a directed link points away from it, and a 
“child” if a directed link leads to it.
Several approaches to handling uncertainty in the knowledge base exist. These include 
the use of certainty factors, fuzzy logic, and Bayesian conditional probability theory. 
MYCIN used certainty factors (CF) to represent the degree of belief in each of its 
production rules (figure 1.2). A CF is a number in the interval [-1 ,1]. A value of 1 
indicates that the conclusion of a rule is certain to be true if all the conditions are 
satisfied, and -1 indicates that the conclusion is definitely false if all the conditions are 
satisfied. A positive CF indicates suggestive evidence for the conclusion, while a 
negative CF implies that the conditions are evidence against the conclusion. Methods for 
combining certainty factors to obtain the certainty factor for a conjunction of rules have 
been developed. (Buchanan and Shortliffe, 1984) Johnson and Keravnou (1985) explore 
the relationship between certainty factors and posterior probabilities in PROSPECTOR, an 
expert system for the evaluation of geological sites for potential ore deposits. There are, 
however, inconsistencies in the theory of certainty factors, and they do not obey all the 
axioms of probability. (Jackson, 1990) This has not prevented the use of the technique 
in several early expert systems, and its subsequent adoption within expert system- 
building tools. For example, the reasoning process embodied in MYCIN was generalised 
in the expert system shell EMYCIN. (van Melle, 1980)
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RULE037
IF: 1) The identity of the organism is not known with
certainty, and
2) The stain of the organism is gram negative, and
3) The morphology of the organism is rod, and
4) The aerobicity of the organism is aerobic
THEN: There is strongly suggestive evidence (CF = 0.8)
that the class of the organism is enterobacteriaceae
Figure 1.2 Use of certainty factors in the rule base of the MYCIN expert system
Fiizzy logic may be used when the questions posed, and the data available, contain 
imprecise concepts. Possibility theory is related to fuzzy logic and is applied when 
precise questions must be answered using uncertain data. Sometimes called the 
‘linguistic approach’, Zahdeh (1986) argues that fuzzy reasoning is the only way to 
interpret expressions of uncertainty in everyday language. An example of this is a 
statement such as “It is very likely that Mary is young”, where “very likely” and “young” 
are both vague concepts. Mamdani and Gaines (1981) apply fuzzy logic to a number of 
real-life problems.
There has been considerable debate in the literature about the validity and practicality of 
implementing probabilistic methods in expert systems. Much of the controversy centres 
round the assignation of probabilities to imprecisely defined events or concepts. Zahdeh 
(1986) argues that in this context, fuzzy reasoning is more appropriate. However, 
Cheeseman (1986) illustrates that a multiplicity of types of uncertainty can be dealt with 
using probability calculus. Spiegelhalter (1986) suggests that probabilistic methods can 
fulfil all the criteria required of an expert system: predictive accuracy, transparency of 
knowledge representation, ability to learn, easy assessment of system performance and 
clear explanation of reasoning.
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These philosophical considerations aside, the remaining criticism of probabilistic methods 
concerns their computational intractability. In a causal network containing n bivariate 
nodes, the number of conditional probabilities which must be summed to calculate the 
marginal distribution on a node is 2n_1. Even in relatively small networks, this number 
will quickly become large. Lauritzen and Spiegelhalter (1988) address this problem by 
exploiting various representations of the network so that the operations of interest in 
expert systems may be carried out in a computationally efficient manner.
Lauritzen and Spiegelhalter assume that the expert knowledge is represented as a causal 
network (figure 1.1), with arrows on the links between nodes to indicate the direction of 
causality. Here, causality is interpreted loosely as an ordering of the nodes in which 
knowledge about a parent node influences opinion about its child node(s). In order to 
form a suitable representation for the probability calculations, they make several changes 
to the network, as shown in figure 1.3. Directions are removed from the edges, edges 
are added between all unconnected parents of a common child, and links are added to 
make the graph triangulated. A triangulated graph contains no cycles of length four or 
more which do not contain a 'chord' or short-cut. The resultant figure is known as the 
triangulated moral graph. Lauritzen and Spiegelhalter then go on to show that this 
representation of the expert knowledge enables the crucial expert system operations to 
be carried out quickly and with relative simplicity.
The first operation which must be carried out is initialisation. Here, the marginal 
distributions for each variable are calculated. In the medical context, this represents the 
average value of each variable in our expert system model before we obtain any data 
about a new case.
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(a) Removing directions
(b) Linking unconnected parents of a common child (the “moral” graph)
(c) Triangulation
Figure 1.3 Alterations to the causal network. In graph (c), a link could have been 
added between nodes A and E instead of between C and D in order to make the graph 
triangulated.
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The next stage is simultaneous absorption of evidence about several variables in the 
expert system model. This is required when data become available on several variables 
for a new patient: perhaps the case history is obtained, risk factors are retrieved from the 
case notes and a routine clinical examination is performed. Evidence absorption involves 
creating a new representation of the expert system knowledge-base. The subsequent 
operation is the propagation of evidence. This assesses the effect of absorbed evidence 
on our beliefs about the remaining variables for which we do not yet have data. 
Hypothesising the value for a single variable in the model allows its effect on all 
unobserved variables in the model to be judged.
Planning enables a decision to be made on which unobserved piece of evidence would 
give most information on a variable of interest. In the clinical management situation, this 
could enable identification of the investigation which would provide most influential 
information about a patient’s diagnosis.
Finally, identification o f influential findings may be performed once all available 
evidence has been absorbed. This highlights which item of data had most influence on 
the expert system output concerning, for example, the diagnosis. This is essentially 
retrospective planning, since it is not performed before the absorption of further 
evidence.
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1.6 Application of an expert system to the management of 
acute stroke
Spitzer and colleagues developed three prototype expert systems designed to aid 
physicians in the diagnosis and localisation of stroke. NERVTRACK (Spitzer et al, 1989a) 
provides the neurologist with detailed, accessible neuroanatomical reference and may 
also be used as a teaching aid. Its knowledge-base contains over 4000 neuroanatomical 
items of information, arranged in a tree-like structure on a directed acyclic graph to 
reflect structural and functional relationships.
TOPOSCOUT (Spitzer et al, 1989b) provides diagnosis of both the anatomic location of 
stroke and the vascular territory involved. It aims to diagnose stroke laterality, to 
distinguish between brainstem and hemispheric stroke, and to recognise established 
vascular and anatomic patterns. The knowledge-base consists of 171 rules regarding 
interpretation of the stroke patient's clinical features. These rules are implemented using 
a backward chaining algorithm. The system is deterministic: it does not use probabilistic 
techniques to deal with uncertainty in the knowledge-base.
MICROSTROKE (Spitzer et al, 1989c), however, uses modified Bayesian methods in a 
system for the categorisation of stroke subtypes based on clinical information. The rules 
used by MICROSTROKE are weighted according to the prior probabilities of various 
symptoms suffered by stroke patients. The expert system aims to identify five subtypes 
of stroke: thrombosis, embolus, lacune, intracerebral haemorrhage, and subarachnoid 
haemorrhage. The system is able to alter its goal according to the clinical situation: if 
intracerebral haemorrhage has already been excluded by CT scan, the program aims to 
distinguish the subtype of ischaemic stroke; if not, the first priority of the program is to 
detect intracerebral or subarachnoid haemorrhage.
Although the above systems address important aspects of stroke diagnosis, they do not 
consider the impact any diagnoses should have on patient management. We aimed to 
implement the methodology of Lauritzen and Spiegelhalter, in addition to standard 
statistical techniques, to address the problem of decision-making in the management of 
acute stroke. The expert system approach is suited to such a medical application because
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it can deal with uncertain knowledge, imprecisely defined terms and missing data, all of 
which are common in the field of medicine. In addition to this, the method also allows 
the propagation of hypotheses. This would be useful, for example, in determining 
whether a particular method of stroke prevention was worthwhile: for instance, to 
predict whether the risk of future adverse events would change substantially if 
anticoagulant therapy was prescribed. As outlined in section 1.3, stroke care involves a 
number of conflicting management decisions which are sufficiently complex to benefit 
from the aid of an expert system.
The aim of the system is to advise clinicians in the following areas of stroke care: 
diagnosis, choice of an appropriate clinical trial, prediction of survival and functional 
outcome, and formulation of the best care plan for the individual patient (with reference 
to placement, rehabilitation, secondary prevention drug therapy, and vascular surgery). 
Evaluation of the system will be in terms of the accuracy of its predictions and its impact 
on clinical practice.
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1.7 Data sources
Two sources provided the majority of the data for the various studies undertaken. The 
ASU database was used to obtain data for each patient on stroke risk factors, presenting 
symptoms, results of investigations and clinical diagnosis. Outcome follow-up for each 
patient admitted to the ASU was obtained by record linkage to hospital discharge 
summaries and to the death certificate. The NHS (Scotland) Information and Statistics 
Division performed the record linkage.
Data are collected on a pro forma for every patient admitted to the ASU, and are 
subsequently entered in a computerised database. Data are collected in several 
categories: stroke risk factors, a list of any medication prescribed prior to the stroke 
event, admission and stroke onset dates and times, presenting complaints, symptoms and 
signs, results of general medical, cranial nerve and neurological assessments, laboratory 
results (biochemistry, haematology, and serology), paramedical assessments (speech 
therapy, physiotherapy, and occupational therapy), list of medications at discharge, 
clinical classification and diagnosis, results of CT and MR imaging, and results of 
additional radionuclide imaging.
Outcome follow-up was by record linkage (Kendrick and Clarke, 1993) to hospital 
discharge records to obtain information on medical events post-stroke and to death 
records from the Registrar General of Scotland. The hospital discharge records (SMRl) 
covered non-psychiatric, non-obstetric specialties. The record linkage is carried out 
using a probability matching algorithm to identify groups of records which refer to the 
same patient. This method avoids minor discrepancies between two records from the 
same patient preventing a link being made between the two records. Items which are 
commonly used to link records include surname, first initial, sex, date of birth and 
postcode.
The technique of record linkage has been validated previously in an epidemiological 
study of hypertension (Isles et al, 1986) and has also been used for endpoint monitoring 
in a large clinical trial. (The West of Scotland Coronary Prevention Study Group, 1995)
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The method of record linkage is a reliable one: the false positive link and false negative 
link rates are both estimated at around 1%. (Kendrick and Clarke, 1993) However, 
admissions to private hospitals or institutions outside Scotland are not detected.
Follow-up of patients using record linkage does not allow direct measurement of 
handicap or disability of individuals. However, it does permit several aspects of patient 
outcome to be explored. Placement at specific time intervals after the initial stroke may 
be categorised as dead, alive in hospital care, or alive at home. This may be used as a 
marker for functional outcome. Survival analysis may be performed and lengths of stay 
in hospital may be measured.
Diagnoses from all hospital discharge records and causes of death are coded according to 
the World Health Organization classification of diseases revision 9 (ICD9) (World Health 
Organization, 1977). Revision 10 (ICD10) of the classification has recently been 
introduced. ICD codes allow the occurrence of specific events to be monitored and the 
length of time to these events from the index stroke to be measured. Table 1.1 shows 
the ICD9 codes which relate to acute stroke.
Table 1.1 ICD9 codes for acute stroke
ICD9code Diagnosis
336.1 infarction or thrombosis of spinal cord
362.8 retinal haemorrhage or ischaemia
430 subarachnoid haemorrhage
431 intracerebral haemorrhage
432 extradural or subdural haemorrhage
433 occlusion or stenosis of precerebral arteries 
(basilar, carotid or vertebral)
434 occlusion or stenosis of cerebral arteries 
(cerebral thrombosis or- cerebral embolism)
435 transient cerebral ischaemia
436 acute, but ill-defined, cerebrovascular disease
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Chapter Two 
Discrimination between ischaemic and 
haemorrhagic stroke using scoring 
systems based on clinical features
2.1 Introduction
As indicated in chapter 1.3, a prerequisite to effective clinical management of stroke is an 
accurate diagnosis of whether the stroke is ischaemic or haemorrhagic. It is essential to 
exclude haemorrhagic stroke before commencing anticoagulation in patients with atrial 
fibrillation; conversely, selected patients with haemorrhage may be considered for 
surgical intervention. Computed tomography scanning, if performed within 7 days of 
stroke onset, will differentiate between ischaemic and haemorrhagic stroke. However, 
many cases of stroke are not admitted to hospital, particularly in developing countries. 
In addition, CT scanning is not available in some hospitals and funding for such
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investigations is severely limited in others. Attempts have therefore been made to 
differentiate between ischaemic and haemorrhagic stroke on the basis of the clinical 
presentation of the patient. To this end, scoring systems have been produced, based on 
clinical features. Linear discriminant analysis was used to obtain the relative importance 
of the variables in making the differential diagnosis.
The Allen Score (Allen, 1983) (also known as the Guy’s Hospital Score) was developed 
between 1979 and 1982. This score was derived from a group of 165 patients (136 with 
ischaemic and 29 with haemorrhagic stroke) using stepwise linear discriminant analysis. 
The Siriraj Stroke Score, (Poungvarin et al> 1991) first presented in 1991, was derived 
from 164 patients with stroke (99 ischaemic, 75 haemorrhagic) in the Siriraj Hospital in 
Bangkok, Thailand. This score was also developed using stepwise linear discriminant 
analysis. In both these scores a higher score indicated a higher likelihood of 
haemorrhage. The Allen and Siriraj Scores were originally designed to produce relative 
probabilities of haemorrhage and infarction for a given patient. The Siriraj score defined 
a ‘grey area’ between scores of -1 and +1 within which a diagnosis was not made. For 
the purpose of comparing the performance of the Allen and Siriraj scores with other 
validations and diagnostic methods, cut-off points were identified subjectively above 
which a diagnosis of haemorrhage was made. In 1995, Besson et al presented a score 
which was derived using stepwise logistic discrimination. The approach used with this 
score was different: the aim was to make a diagnosis of non-haemorrhagic infarct. This 
was done if a patient scored less than 1. If this was not the case, no diagnosis was made 
and CT scanning was recommended. The score was based on data from 368 patients 
admitted to a stroke unit in Grenoble, France. Sixty-three of these patients had primary 
intracerebral haemorrhage or haemorrhagic infarction. Table 2.1 shows the clinical 
variables and weights from which these three scores are calculated. If information on 
any clinical variable was not available for a particular patient, then this variable was 
scored as absent.
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Table 2.1(a) Allen (Guv's Hospital) Score
S = 21.9 x Apoplectic onset 
+ 7.3 x Level of consciousness 
+ 7.1 x Plantar responses 
+ 0.17 x Diastolic blood pressure in mm Hg 
“  3.7 x Atheroma markers
— 4.1 x History of hypertension 
~  6.7 x Previous TIA or stroke 
“  4.3 x Cardiac murmurs
~  4.3 x Cardiac failure 
“  4.3 x Cardiomyopathy 
~  4.3 x Atrial fibrillation 
“  4.3 x Cardiomegaly
— 4.3 x Myocardial infarction within previous 6 months 
”  12.6
Variables coded as follows:
Apoplectic onset (0 if one or none of, 1 if two or more of:
loss of consciousness 
headache within 2hr 
vomiting within 6hr 
neck stiffness )
Level of consciousness 24hr after admission
(0 alert, 1 drowsy, 2 unconscious)
Plantar responses (0 both flexor/single extensor, 1 both extensor)
Atheroma markers: diabetes, angina, intermittent claudication
(0 none, 1 one or more)
Previous TIA or stroke (0 none, 1 one or more)
Other variables (0 if absent, 1 if present)
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Table 2.1(b) Sirirai Score
2.5 x Level of consciousness
+ 2 x Vomiting
+ 2 x Headache
+ 0.1 x Diastolic blood pressure in mm Hg
— 3 x Atheroma markers
12
Variables coded as follows:
Level of consciousness (0 alert, 1 drowsy or stupor, 2 semicoma or coma)
Vomiting (0 no, 1 yes)
Headache within 2hrs of onset (0 no, 1 yes)
Atheroma markers: diabetes, angina, intermittent claudication
(0 none, 1 one or more)
Table 2.1(c) Besson Score
Z 2 x Alcohol consumption
+ 1.5 x Plantar responses
+ 3 x Headache
+ 3 x History of hypertension
— 5 x History of TIA
— 2 x Peripheral vascular disease
— 1.5 x History of hyperlipidaemia
2.5 x Atrial fibrillation on admission
Variables coded as follows:
Alcohol consumption (0 not every day, 1 every day)
Plantar responses (0 absent, 1 extensor ispilaterally, 2 extensor
Headache
contralaterally, 3 both extensor)
(1 if within 2 hours before onset, otherwise 0)
Other variables (0 if absent, 1 if present)
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The Allen score has already been evaluated (Sandercock et al, 1985a) using data from 
the Oxfordshire community stroke project (Bamford et al, 1988) and the National 
Hospital for Nervous Diseases in London, and using data from both a community based 
study and a mixed series of hospital admissions in Italy. (Celani et al, 1992) The Siriraj 
score has been evaluated (Poungvarin et al, 1991) in Siriraj Hospital, Bangkok on a 
separate group of patients from those on whom the score was originally developed. It is 
in widespread use in the form of a score card used at the bedside in rural Thai hospitals. 
Two comparisons of the Allen and Siriraj scores have been presented, one based on data 
from an epidemiological study in Auckland (Hawkins et al, 1995) and the other on a 
series of patients screened for the International Stroke Trial in three Italian hospitals. 
(Celani et al, 1994) The Besson score was validated (Besson et al, 1995) in a series of 
200 consecutive admissions to the stroke unit in which the score was developed.
These validation studies of the diagnostic scores were based on relatively small numbers 
(between 130 and 475 patients) and were performed in populations with varying 
characteristics. Some used patients from community-based studies. (Bamford et al, 
1988; Hawkins et al, 1995; Celani et al, 1992) The OCSP scanned a lower proportion of 
patients (80%) than our ASU (96%), and there is potential bias in a validation which 
excludes such a substantial proportion of patients. Other evaluations were hospital- 
based. (Besson et al, 1995; Poungvarin et al, 1991; Celani et al, 1992; Celani et al, 
1994) The Siriraj score was developed and validated in Thailand, where the prevalence 
of primary intracerebral haemorrhage is 40-50%, compared with 10-15% in developed 
world countries.
Such differences in validation populations may have contributed to the discrepancies in 
the conclusions drawn by these studies. Some studies concluded that the Allen score 
was useful for epidemiological studies, (Sandercock et al, 1985a; Celani et al, 1992) and 
as a screening test to exclude haemorrhage before giving antithrombotic therapy 
(Sandercock et al, 1985a; Celani et al, 1994). Another study concluded that the Siriraj 
score was also useful as such a screening test. (Celani et al, 1994) In contrast, Hawkins 
et al. (1995) concluded that neither the Allen nor the Siriraj score was useful in an 
epidemiological context or as an aid to clinical decision-making. The evaluation of the
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Besson score in the hospital where it was developed achieved a 100% positive predictive 
value for non-haemorrhagic infarction. The evaluation of the Siriraj score in Bangkok 
confirmed a high predictive accuracy of around 90% but recommended its evaluation, 
and comparison with the Allen score, in developed world populations.
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2.2 Evaluation of scoring systems
We aimed to evaluate the three scoring systems described in section 2.1 using data from 
1059 consecutive admissions to the ASU. Table 2.2 shows the diagnoses obtained in our 
patient cohort. A definite CT or post mortem diagnosis was unavailable for 30 patients. 
This occurred either because an alternative explanation for the presenting symptoms was 
thought likely or because the patient died soon after admission and permission for post 
mortem was refused.
Table 2.2 Diagnoses for the evaluation cohort
Diagnosis Number 
(% of strokes)
No CT 30
CT or post mortem 1029
Non-haemorrhagic infarct 857 (86)
Haemorrhagic infarct 6 (1)
Primary intracerebral haemorrhage 128 (13)
Tumour 17
Other non-vascular 20
1059
Patients with haemorrhagic infarct were grouped with the non-haemorrhagic infarcts in 
our evaluation of the Allen and Siriraj scores; for the evaluation of the Besson score the 
haemorrhagic infarcts were grouped with the intracerebral haemorrhages.
The data required to calculate each score were extracted from the ASU clinical database. 
Where information was unavailable in the database, the case notes were consulted. Since 
there were a number of patients for whom complete information was not available even
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after this process, we decided to carry out two phases of analysis. First, the Allen, Siriraj 
and Besson scores were calculated for all 991 patients according to the convention used 
in the development of the scores: if information on any variable was missing, that 
symptom was assumed to be absent. Secondly, the Allen score was calculated for the 
subset of 322 patients with complete data on all of the variables required for the Allen 
score (with the exception of cardiac failure, cardiomyopathy, cardiomegaly and neck 
stiffness), the Siriraj score was calculated for the subset of 482 patients with complete 
information on all of the variables required and the Besson score was calculated for the 
570 patients with complete information on all variables required. This enabled the 
impact of missing data to be assessed.
Receiver operating characteristic (ROC) curves (Altman, 1991) were plotted to illustrate 
the sensitivity and specificity of the Allen and Siriraj scores over a range of cut-off points 
and to compare the results with previous evaluations of the scores. We did this for both 
the whole study group and the subgroups with complete data. In each case, the curves 
were compared according to how closely they approached the point of total diagnostic 
accuracy in the top left comer of the plot (that is, sensitivity = specificity = 100%). The 
Besson score was evaluated, as follows, according to the criteria defined by its 
developers. We calculated the proportion of patients to whom it was applicable (that is, 
the proportion scoring less than 1), and the positive predictive value of the score for non- 
haemorrhagic infarction in those patients.
Figures 2.1, 2.2, and 2.3 show the distributions of the Allen, Siriraj and Besson scores 
respectively, both in the whole cohort of 991 stroke patients (A) and in the subgroups 
with more complete data (B).
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A: All patients
Patients with haemorrhage (n=128) Patients with infarction (n=863)
30%  25
-20
0
20
40
B: Patients with almost complete data
Patients with haemorrhage (n=33) Patients with infarction (n=289)
o30% 25 20 1015 5 30 %
-20
0
20
40
Figure 2.1 Allen scores for patients with haemorrhage or infarction
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A: All patients
Patients with haemorrhage (n= 128) Patients with infarction (n=863)
30 % 25 30%
-10
-5
0
5
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B: Patients with complete data
Patients with haemorrhage (n=51) Patients with infarction (n=431)
30% 25
-10
-5
o
5
10
Figure 2.2 Siriraj scores for patients with haemorrhage or infarction
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A: All patients
Patients with haemorrhage (n=134) Patients with infarction (n=857)
35 % 2S 1530 20 10 5 0
B: Patients with complete data
Patients with haemorrhage (n=76) Patients with infarction (n=494)
35 % 30 25 20 15 10 5 0 0 5 10 15 20 25 30 35 %
- ■ )
Figure 2.3 Besson scores for patients with haemorrhage or infarction
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The considerable vertical overlap in the histograms for haemorrhagic and ischaemic 
stroke for each of the scores, regardless of whether or not more complete data were 
used, suggests that none of the scores will provide good discrimination between the two 
groups. The ROC curves in figure 2.4 confirm that our results for the Allen and Siriraj 
scores give lower sensitivity and specificity than previous evaluations of these scores. 
Table 2.3 gives the sensitivity, specificity and positive predictive value for haemorrhage 
at subjectively chosen ‘optimal’ cut-off points. The proportion of patients with scores 
less than 1 in figure 2.3 shows that the Besson score does not apply to a large proportion 
of our patients. Table 2.4 compares the success of the Besson score in our evaluation to 
its effectiveness in its original setting.
Table 2.3 Allen and Sirirai score evaluation
Cut-ofF
point
Sensitivity to 
haemorrhage (%) 
(95% Cl)
Specificity (%) 
(95% Cl)
Positive 
predictive 
value (%) 
(95% Cl)
Allen score
All 991 patients 1 70 64 22
(67 , 73) (61 , 67) (18 , 26)
322 with near 1 79 66 21
complete data (75 , 83) (61 , 67) (14 , 28)
Siriraj score
All 991 patients -2.5 68 64 22
(65 ,71) (61 , 67) (18 , 26)
482 with -1.5 67 71 22
complete data (63 ,71) (67,75) (15 , 29)
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Figure 2.4 ROC curves for various evaluations of Allen and Siriraj scores
Numbers on curves are cut-off points at which sensitivity and specificity were calculated
(a) Allen, original development; OCSP, Oxfordshire community stroke project; NHND, 
National hospital for nervous diseases; Glasgow, our evaluation (all patients)
(b) Allen score evaluation: all Glasgow patients and selected patients with complete data
(c) Siriraj (1), original development; (2), original evaluation; Glasgow, our evaluation
(d) Siriraj score evaluation: all Glasgow patients and patients with complete data
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Table 2.4 Besson score evaluation
Study Percentage of 
patients scoring < 1 
(95% Cl)
Positive predictive value 
(%) in these patients 
(95% Cl)
Original validation 
(Besson et al, 1995) 
(n=200)
36 (29 to 43) 100 (93 to 100)
This evaluation 
(n=991, all patients) 27 (24 to 30) 91 (88 to 95)
This evaluation 
(n=570, complete data only) 23 (20 to 26) 93 (89 to 97)
The Allen score was first presented in 1983 and was later evaluated prospectively on 
patient data from the OCSP and retrospectively using case notes of patients from the 
National Hospital for Nervous Diseases (NHND) in London. This score was derived from 
a small training set which contained only 29 haemorrhages. Hence it is not surprising 
that when it was validated prospectively in different populations, sensitivity and 
specificity were reduced. This clinical score contains thirteen variables which suggests 
that overfitting may have occurred: more variables than are appropriate may have been 
included in the model with a resulting increase in the standard errors of the linear 
discriminant coefficients. Since this also gives a score which involves more clinical 
variables than is essential, unnecessary time and effort are spent collecting data and 
calculating the score. Indeed, even with staff dedicated to research data collection in our 
ASU, several of the variables required to calculate the score were only occasionally 
available at the time when management decisions were required. It is unlikely that data 
collection would be as good in district general hospitals where scoring systems may be 
necessary. In the model development, certain variables were also pre-judged to be 
equally relevant. For example, table 2.1 (a) shows that each of the variables relating to 
cardiac problems (cardiac murmurs, cardiac failure, cardiomyopathy, atrial fibrillation,
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cardiomegaly and myocardial infarction in the 6 months prior to stroke) contributes -4.3 
to the overall score. It is unlikely that this equal weighting reflects the true underlying 
risk of ischaemic stroke relative to haemorrhage.
The ROC curves in figure 2.4(b) for all patients and for the subgroup with almost 
complete data are similar. As might be expected, the curve for the subgroup of patients 
with accurately known histories shows slightly better sensitivity and specificity than that 
for our whole patient group. The results confirm that the Allen score is insufficiently 
sensitive to haemorrhage to be used as a diagnostic screening tool to exclude 
haemorrhage before anticoagulants are started. Its usefulness as “a screening tool for 
low-risk treatments for the secondary prevention of stroke” (Sandercock et al, 1985a) is 
also doubtful. The score does not give a substantially more accurate diagnosis of 
haemorrhage on the basis of clinical features than do physicians. In a study based in a 
Swedish stroke unit (Von Arbin et al, 1981), physicians correctly identified 39% of 
haemorrhages and 83% of infarctions. This level of accuracy does not lie far below the 
ROC curves in figure 2.4 (b).
The Siriraj score was developed in Bangkok, Thailand, and subsequently validated in the 
same population. Data collection is easier than for the Allen score and calculation is 
simpler since fewer clinical variables are required. As with the Allen score it was 
developed and validated on a small number of patients (75 patients in the development 
study had haemorrhage). The validation study group contained a higher proportion of 
haemorrhage patients (69% as opposed to 43% in the original study). The low 
sensitivity and specificity to haemorrhage achieved were not surprising. The populations 
of stroke patients in Thailand and Glasgow are not directly comparable since a higher 
proportion of strokes in Thailand is caused by haemorrhage (40-50% as opposed to 10- 
15% in the UK). Since haemorrhage caused by poorly controlled hypertension is the 
cause of many strokes in Thailand, one might speculate that there are more large, easily 
detectable haemorrhages. There are also other demographic and ethnic differences. The 
low positive predictive values achieved in our evaluation using Glasgow patients were 
unsurprising since positive predictive value depends on prevalence of haemorrhage, and 
haemorrhage is less prevalent in developed countries. As in the case of the Allen score, 
the Siriraj score was designed to give an indication of the relative plausibility of
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haemorrhage and infarction and not to make a definite diagnosis. Originally, a score 
between -1 and 1 was treated as an equivocal result. This is desirable since it 
acknowledges the inevitable overlap (Harrison, 1980) in clinical presentations of patients 
with haemorrhages and infarctions, particularly in the case of patients with small deep 
haemorrhages.
As with the Allen score the ROC curves were calculated both for all patients and for the 
subset of patients with complete information available on all the scoring variables. Again 
it can be seen that the ROC curves in figure 2.4(d) for patients with complete data show a 
slight improvement over those based on all patients. The ROC curves for the Siriraj score 
do not show much lower sensitivity and specificity than those for the Allen score, even 
though the Siriraj score is based on fewer variables. However, the Siriraj score appears 
to be of limited use in discriminating between haemorrhagic and ischaemic stroke.
One study of the Allen and Siriraj scores concluded that their positive predictive value 
was good (Celani et al, 1992); however, that study was based on a small number of pre­
selected patients. Our results reflect actual clinical practice. The low positive predictive 
values in table 2.3 emphasise that a large proportion of those patients classified as 
haemorrhages will in fact have infarction. This is true for both the Allen and Siriraj 
scores and is a result of the low prevalence of haemorrhage in this developed world 
population.
Table 2.5 shows the various clinical groupings included in the development and some of 
the validation studies carried out on the Allen and Siriraj scores. The scores have not 
been developed and validated in exactly comparable populations, even before location is 
considered. This may go some way towards explaining the differences in results between 
the various evaluation studies.
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Table 2.5 Clinical groupings included in validation studies
Study First stroke 
only
Intracerebral
haemorrhage
Subarachnoid
haemorrhage
Tumour Infarction
This study No Yes Some* No Yes
Allen No Yes Yes Yes** Yes
OCSP Yes Yes Yes No Yes
NHND No Yes No No Yes
Siriraj No Yes No No Yes
* Most cases of subarachnoid haemorrhage are referred directly to neurosurgeons 
** Clinical features of patients with tumour were described separately
Besson et al used an alternative approach in the development of their score. Instead of 
attempting to classify all patients as ischaemic or haemorrhagic stroke on the basis of 
clinical features, they acknowledged the inevitable overlap in clinical presentation 
between infarction and haemorrhage. (Harrison, 1980) They attempted to identify those 
patients whose presentation was typical of non-haemorrhagic infarction with a high 
positive predictive value. In their validation study, based in the hospital where the score 
had been developed, they found that the score was applicable to 36% of stroke patients. 
They demonstrated an empirical positive predictive value of 100%. In our evaluation we 
discovered that the score applied to a smaller proportion of our patients and failed to 
achieve a positive predictive value of 100%. This difference in results may be due to a 
different distribution of stroke risk factors in our population, since these contribute a 
large proportion of the Besson score: indeed, five of the eight variables which make up 
the Besson score are based on the medical history of the patient.
In our subgroup of patients with complete data, the Besson score was slightly more 
accurate. However, in this subgroup a smaller proportion of patients scored below 1 and 
so the score was less widely applicable.
The Besson score aims to discriminate between non-haemorrhagic infarction and 
haemorrhagic infarction or primary intracerebral haemorrhage. In our study, if the
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patients with haemorrhagic infarction were included in the group with ischaemic stroke, 
the positive predictive value of the score improved slightly (from 91% to 92% in the 
whole patient group, and from 93% to 94% in the subgroup with complete data). This is 
unsurprising as an infarct with a haemorrhagic component has more in common with 
pure ischaemic stroke than with primary intracerebral haemorrhage.
There were two phases in the development of the Besson score. An initial stepwise 
logistic regression was performed and from this were selected the patients with non- 
haemorrhagic infarction who scored less than a threshold value, below which no patient 
with haemorrhage scored. These ‘typical’ non-haemorrhagic infarctions were then 
selected along with all the patients with haemorrhage and a second stepwise logistic 
regression was then performed. The final clinical score was derived from this second 
logistic regression. This two-stage process may not have been the most efficient way of 
utilising the data available.
In conclusion, we have applied the Allen, Siriraj and Besson scores to a large number of 
patients from a specialist ASU. The sensitivity and specificity of the Allen and Siriraj 
scores were lower than those published in previous evaluations and suggest that, outwith 
the context of their development, these scoring systems are not useful in excluding 
intracerebral haemorrhage. However, they give at least as accurate a diagnosis on the 
basis of clinical features as do physicians. While the Besson score achieved a high 
positive predictive value for non-haemorrhagic infarction, it was not applicable to a large 
proportion of patients. Computed tomography therefore remains essential for the early 
detection of intracranial blood (Sandercock et al, 1985b), for the rational use of 
antihaemostatic drugs and for valid epidemiological studies.
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2.3 Improving discrimination
2.3.1 Introduction
We sought to obtain improved discrimination between haemorrhagic and ischaemic 
stroke on the basis of clinical features using two methods. Of greatest relevance to the 
ASU in Glasgow would be to adjust the weights of the Allen, Siriraj or Besson scores in 
order to tailor them more closely to the particular characteristics of the Glasgow 
population. Of wider relevance would be the construction of a new discriminant score 
based on our data, since a scoring system developed on a large data set may give more 
reproducible results.
2.3.2 Adjustment of established discriminant scores
It would be difficult to repeat the methods used by Besson et al in the development of 
their score. They chose a cut-off point which gave an empirical positive predictive value 
for non-haemorrhagic infarction of 100%. This would be difficult to emulate in our data 
set as the large number of patients means that a cut-off giving a positive predictive value 
of 100% would apply only to a few patients. We did not attempt to adjust the 
weightings of the Allen score variables because information on some of these is not 
routinely recorded in the ASU.
We therefore attempted to re-weight the variables involved in the Siriraj score to obtain 
the weights which were most appropriate to our population. We used data from the 
same 991 patients on whom the discriminant scores were evaluated in section 2.1. 
Variables were coded as in the original Siriraj score. Patients were allocated at random 
to the training set or test set with probability 0.5. Two training sets were produced. 
One was derived from the whole patient group, missing data on any variable being 
scored as symptom absent. This training set contained 414 ischaemic and 66 
haemorrhagic strokes. The other was derived from the 482 patients with complete data
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on all five variables. This training set contained 200 ischaemic strokes and 29 
haemorrhagic strokes. Linear discrimination was used to derive new weightings for the 
five variables. The constant term was ignored as the scores were to be evaluated using 
cut-off points at various values. Table 2.6 gives the original Siriraj score weights and the 
re-weighted Siriraj scores based on the 50% training sets derived from all patients and 
patients with complete data respectively.
Table 2,6 Sirirai score weights and weights adjusted using ASU data
Siriraj score 
original weights
Adjusted weights, 
based on all patients
Adjusted weights, 
based on patients 
with complete data
vomiting + 2 + 3.23 + 4.21
diastolic BP 24 hours 
after stroke + 0.1
+ 0.02 + 0.03
level of consciousness + 2.5 + 1.16 + 1.58
atheroma markers - 3 -1 .36 -0 .92
headache + 2 + 0.78 + 0.24
The signs of all the variables in the adjusted scores are the same as in the original Siriraj 
score. Presence of vomiting is weighted more highly in our adjusted score. The other 
variables, particularly diastolic blood pressure, are less influential. Headache is not a 
significant discriminant variable in our patients when considered simultaneously with the 
other four variables.
Figure 2.5 shows ROC curves for the 50% test set samples. The curves are plotted for a 
range of cut-off points on the scores, above which a diagnosis of haemorrhage was 
made. The adjusted score based on our whole patient group did not perform better on 
the test set than did the Siriraj score in our original evaluation. The adjusted score 
developed on patients with complete data gave a slightly higher diagnostic accuracy on 
the test set than when the Siriraj score was evaluated in its original form on our data. 
This is not surprising as we have adjusted the score to fit our data more closely; the
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score is still not sufficiently accurate to be of use in clinical practice. Choosing a 
different set of discriminant variables may well lead to improved accuracy since the re­
weighted Siriraj scores included one variable (headache) which was not statistically 
significant in either training set.
ROC curves : adjusted Siriraj score
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Figure 2.5 ROC curves for adjusted Siriraj score, for test sets drawn from all patients 
and from patients with complete data only.
2.3.3 Development of scores based on Glasgow data
The second method of producing an improved discriminant score was to derive an 
entirely new score from our data. The method of linear discrimination was chosen as it is
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robust to deviations from multivariate Normality and produces a score which is easily 
calculated. A linear discriminant score is also easily interpreted in terms of the relative 
probabilities of haemorrhage and infarction.
Data on 37 potentially useful clinical variables were retrieved from the ASU clinical 
database for 990 patients with ischaemic or haemorrhagic stroke confirmed either by CT 
or post mortem. Patients have their pulse and blood pressure measured either when 
admitted to the accident and emergency department, or on admission to the stroke unit, 
or at both times. Data from these two occasions were combined to minimise the amount 
of missing data. The accident and emergency data were used if stroke unit data were 
unavailable. The univariate relationship of each variable with stroke type was explored 
using %2 tests of association for categorical variables and two-sample /-tests for 
continuous variables. Table 2.7 gives the distributions of the variables and the univariate 
test results. If information was unavailable on any categorical variable, then that 
symptom was coded as being absent (as is the convention in other discriminant scoring 
systems for acute stroke diagnosis). An abridged version of the Glasgow coma scale 
(GCS) was recorded, using only the eye opening and motor components and excluding 
the verbal component. This avoids a spuriously low GCS in patients with speech 
disorders and results in a score in the range 2 to 10. Patients with no GCS recorded were 
assumed to be alert.
Cardiomegaly was excluded from the variable selection procedure as its presence must 
be confirmed by a chest X-ray. This information is therefore not routinely available soon 
after the stroke admission when a diagnosis must be made. All other variables with a 
univariate test /7-value of 0.1 or less were considered in the stepwise linear discriminant 
analysis. Impaired consciousness was considered as a binary variable (abridged GCS < 8, 
impaired consciousness = 1 or abridged GCS > 8, impaired consciousness = 0) rather than 
the full GCS. Thus 22 variables were made available for the stepwise linear discriminant 
analysis.
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Table 2.7 Distribution of clinical features with stroke type
Clinical variable Infarction (n=862) Haemorrhage
(n=128)
df p-value
atrial fibrillation 126 (15%) 10 (8%) 1 0.037
hypertension 336 (39%) 50 (39%) 1 1.000
diabetes 75 (9%) 4  (3%) 1 0.030
previous MI 18 (2%) 1 (1%) 1 0.315
angina 158 (18%) 10 (8%) 1 0.003
claudication 76 (9%) 1 (1%) 1 0.002
headache 151 (18%) 37 (29%) 1 0.002
loss of consciousness 65 (8%) 41 (32%) 1 <0.0001
cardiac murmur 150 (17%) 23 (19%) 1 0.874
vomiting 38 (4%) 25 (20%) 1 <0.0001
congestive cardiac failure 6 (1%) 0 (0%) 1 0.344
cardiomegaly 61 (7%) 2 (2%) 1 0.017
age mean 68 (sd 13) mean 71 (sd 13) 981 0.049
pulse rate mean 80 (sd 15) mean 82 (sd 17) 896 0.260
systolic BP mean 160 (sd 30) mean 179 (sd 34) 908 <0.0001
diastolic BP mean 91 (sd 17) mean 96 (sd 20) 904 0.002
smoking 379 (44%) 42 (33%) 1 0.017
previous TIA 123 (14%) 6 (5%) 1 0.003
previous CVA 151 (18%) 13 (10%) 1 0.037
hyperlipidaemia 33 (4%) 1 (1%) 1 0.077
alcohol 229 (27%) 23 (18%) 1 0.037
excess alcohol before CVA 37 (4%) 5 (4%) 1 0.840
diplopia 24 (3%) 2 (2%) 1 0.420
seizure activity 27 (3%) 9 (7%) 1 0.028
vertigo 51 (6%) 9 (7%) 1 0.622
ataxia 67 (8%) 5 (4%) 1 0.116
brainstem signs 17 (2%) 12 (9%) 1 <0.0001
brainstem sensory signs 1 (0%) 1 (1%) 1 0.118
cerebellar signs 34 (4%) 1 (1%) 1 0.071
pulses absent 294 (34%) 54 (42%) 1 0.074
bruits 109 (13%) 9 (7%) 1 0.067
GCS (scale 2 to 10) — — 8 <0.0001
impaired consciousness 
(GCS < 8)
51 (6%) 28 (22%) 1 <0.0001
Unless otherwise stated, figures are number of patients (percentage of diagnostic group). 
/7-values less than 0.01 are in bold. GCS stands for Glasgow coma scale.
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When stepwise discriminant analysis was carried out using training sets consisting of 
50% of patients selected at random, the variables selected varied amongst training sets. 
Sets of between three and ten variables were chosen by the stepwise procedure. In order 
to investigate this instability, all subset linear regression was used to identify the ten 
“best” /7-variable subsets, for every p  in the range two to nine. Even forp  equal to two 
or three, many different subsets were selected when different training sets were used. In 
subsets with three or more variables, {vomiting, impaired consciousness, systolic 
blood pressure} and {vomiting, loss of consciousness at onset, systolic blood 
pressure} were the most commonly appearing combinations of variables in the better 
fitting regressions. It was decided to produce one score based on each of these three- 
variable sets, the weights being calculated from our entire data set. Scores 2A and 2B 
are shown in equations (2.1) and (2.2) respectively. A score was also produced using 
variables freely selected by the stepwise discriminant analysis, again based on all our 
data. Score 2C is shown in equation (2.3).
Score 2A
2.60 x vomiting + 2.25 x impaired consciousness + 0.022 x systolic BP
(2 .1)
Score 2B
2.45 x vomiting + 2.37 x loss of consciousness at onset + 0.019 x systolic BP
(2.2)
Score 2C
2.41 x vomiting + 0.65 x headache + 1.88 x loss of consciousness at onset 
-  0.76 x angina -  1.10 x claudication + 1.45 x brainstem signs 
-  1.52 x cerebellar signs + 0.52 x pulses + 1.38 x impaired consciousness
+ 0.022 x systolic BP
(2.3)
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In each of these linear functions, a higher score indicates a greater probability of 
haemorrhagic stroke. In general, vomiting, loss of consciousness at onset, impaired 
conscious level, elevated blood pressure, brainstem signs and absent pulses are 
suggestive of haemorrhagic stroke. The other scoring items increase the predicted 
probability that the stroke is ischaemic.
Figure 2.6 shows the ROC curves for scores 2A, 2B and 2C. The three scores showed 
similar diagnostic accuracy. The weights for these scores were then recalculated using 
only patients with complete data (487, 588, and 320 patients respectively). Figure 2.7 
gives the ROC curves for these re-weighted scores. The three scores based on complete 
data were more accurate than the corresponding scores based on all patients. For most 
variables the magnitudes of the weights were greater in the scores derived from patients 
with complete data. Scores 2A and 2C showed similar effectiveness and appeared to be 
slightly superior to score 2B in these patients with complete data. Although data on all 
ten variables included in score 2C are routinely collected, only 320 of our 990 patients 
had complete data on all ten variables. This suggests that score 2A may have an 
advantage in terms of easier data collection and score calculation. Scores 2A and 2C 
performed slightly better than did the Allen score when tested on our patients with 
complete data. The ROC curves for scores 2A, 2B and 2C are likely to be over- 
optimistic as they have been calculated on the data which were used to develop the 
scores.
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Figure 2.6 ROC curves for scores 2A, 
2B, 2C (all patients)
Figure 2.7 ROC curves for scores 2A, 2B, 2C 
(patients with complete data)
Figure 2.8 shows histograms of score 2C for haemorrhagic and ischaemic strokes 
separately, (A) for all 990 patients and (B) for scores re-weighted using patients with 
complete data only. The vertical overlap between the histograms for different stroke 
types suggests that an accurate differential diagnosis is not possible even using score 2C.
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A: All patients
Patients with haemorrhage (n=117) Patients with infarction (n=794)
B: Patients with complete data
Patients with haemorrhage (n=23) Patients with infarction (n-297)
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- l i0
- l i
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Figure 2.8 Score 2C for patients with haemorrhage or infarction
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2.3.4 Investigating incorrect diagnoses
To explore whether there exists a subset of patients which cannot be diagnosed by any 
clinical score, or whether the various diagnostic scores incorrectly classify different 
patients, we studied the patients given a false negative diagnosis for haemorrhage by the 
complete data version of score 2C. The ‘optimal’ cut-off point used here was that which 
maximised the sum of sensitivity and specificity. Using this criterion, five haemorrhagic 
stroke patients were wrongly diagnosed as ischaemic stroke. The CT scans for four of 
these patients showed subcortical haemorrhage; the fifth showed a hyperintense lesion in 
the cortex which may have been haemorrhage or tumour. Table 2.8 shows how several 
diagnostic scores performed on these five patients.
Table 2.8 Comparison of performance of diagnostic scores on ‘difficult* cases
Patient CT Score
2A
Score 2A 
(comp)
Score
2B
Score 2B 
(comp)
Allen Siriraj
1 SC haemorrhage X X X X S V
2 SC haemorrhage X X X X X X
3 SC haemorrhage X X X X S X
4 C hyperintensity X X X X X X
5 SC haemorrhage X X X X X X
C, cortical; SC, subcortical
(comp) indicates that score weights were calculated using patients with complete data
None of the scores derived from Glasgow data diagnosed any of these five patients 
correctly. The Allen and Siriraj scores fared slightly better. However, it appears that 
clinical scoring systems do not reliably diagnose patients with subcortical lesions, 
perhaps because these do not have the dramatic features of larger haemorrhagic strokes.
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2.4 Conclusions
We evaluated several methods for differentiating between ischaemic and haemorrhagic 
stroke on the basis of clinical features. None of the methods we used gave sufficiently 
accurate diagnoses to be useful in clinical practice, unless CT scanning is impossible. 
Diagnostic problems arise in patients with haemorrhagic stroke who present with mild 
strokes due to small, deeply placed lesions. These are the patients in whom the Besson 
score is likely to be less reliable, and whose clinical presentations do not have sufficiently 
striking features to identify them as haemorrhages in any other discriminant score. 
Scoring systems may have a role to play in rural hospitals in developing countries where 
CT is not an option. However, for optimal patient management, or for scientific 
purposes in epidemiological studies or clinical trials, CT remains an essential diagnostic 
tool.
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Chapter Three 
Angiotensin converting enzyme (ACE) 
genotype: a risk factor for stroke?
3.1 Genetic factors and stroke development
It is well-established that there exists a familial predisposition to stroke (Gifford, 1966; 
Paffenbarger, Jr. and Williams, 1967), and to risk factors for stroke such as hypertension 
and coronary artery disease. There is some evidence that this predisposition is due to 
genetic factors. Several studies have reported an association between genetic factors and 
the development of stroke (Welin et al, 1987; Brass et al, 1992; Kiely et al, 1993), 
although the strength of the association may be weaker than for ischaemic heart disease. 
(Marenberg et al, 1994)
One candidate genetic site for stroke is a mutation in the gene for factor V. This 
mutation confers resistance to activated protein C (APC), a serine protease which limits
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clot formation during normal haemostasis. The abnormal factor V, also called factor V 
Leiden, is present in 2% to 4% of the UK population and is a risk factor for venous 
thrombosis. (Beauchamp et al, 1994) Its influence on the risk of myocardial infarction 
and stroke through arterial thrombosis is more controversial. Two small studies drew 
different conclusions on the significance of APC resistance as a risk factor for stroke. 
(Halbmayer et al, 1994; Cushman et al, 1994)
Angiotensin converting enzyme (ACE) gene insertion (i) or deletion (d ) polymorphism is 
a candidate genetic locus for stroke because experimental and clinical evidence suggests 
an important role of the renin angiotensin system in the development of atherosclerosis. 
(Laragh and Sealy, 1990; Meyer, 1990) Several case-control studies suggesting that 
patients with DD genotype are more likely to suffer myocardial infarction (Cambien et al, 
1992; Tiret et al, 1993; Evans et al, 1994) encouraged us to investigate ACE gene 
polymorphism in stroke, since stroke and myocardial infarction share several common 
risk factors. It should however be noted that a recent large prospective study failed to 
show any association between ACE gene polymorphism and ischaemic heart disease. 
(Lindpaintner et al, 1995) Many stroke patients are hypertensive and so ACE inhibition 
may be a candidate antihypertensive therapy. If ACE gene deletion polymorphism proved 
to be associated with stroke, the resultant elevated plasma ACE levels in patients with the 
DD genotype could be reduced by ACE inhibition. This would offer an attractive clinical 
strategy for primary or secondary prevention of stroke, particularly in hypertensive 
patients.
Stroke is a heterogeneous condition, and hence careful documentation of clinical features 
and investigations by trained staff and a large number of patients within any subgroup are 
required if an association study in stroke is to be valid. The selection of a suitable 
control population also deserves careful attention.
We tested the association between ACE gene polymorphism and the presence or absence 
of ischaemic stroke. We also tested associations between ACE gene polymorphism and 
certain clinical and radiological subgroups of stroke.
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3.2 Methods
Blood samples for DNA were taken from unselected patients admitted to the acute stroke 
unit, and from a control population with comparable age and sex distributions. Detailed 
medical histories and data on risk factors for stroke were obtained from stroke patients 
and their families and from the control population. Control patients were attending an 
ophthalmology out-patient clinic for routine review: patients with vascular or 
inflammatory conditions were excluded. Routine investigation of stroke patients 
included CT scanning of the brain within 72 hours of symptom onset, unless the patient 
died before scanning could be performed.
Genotyping by polymerase chain reaction (PCR) was carried out by a single investigator 
unaware of patients’ clinical data. ACE gene insertion or deletion polymorphism was first 
identified according to the standard method. (Rigat et al, 1992) Subsequently, samples 
typed as DD were confirmed by the modified method using 5% dimethylsulphoxide and 
the hot start procedure. Here, template DNA was incubated at 93° centigrade for 2 
minutes immediately followed by adding the reaction mixture and starting PCR. The 
quality of PCR amplification was checked by the presence of a third band for the DI 
genotype. DD genotype was also confirmed by the triple primer method described by 
Evans et al. (1994).
A possible association between ACE genotype and presence or absence of ischaemic 
stroke was investigated using a %2 test on the 3x2 table of ACE genotype (DD, DI or II) 
against presence or absence of stroke. This test was carried out for all patients and for 
two subgroups: patients aged 60 or under, and those with hypertension.
Within stroke patients, the association of ACE genotype with stroke type was 
investigated by x test, stroke being categorised as ischaemic or haemorrhagic using the 
CT scan.
The stroke patients were then classified according to their clinical presentation using the 
OCSP categories. (Bamford et al, 1991) Patients were grouped either as having clinical
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signs of large vessel disease (TACS or PACS), or of small vessel disease (LACS). 
Significance of the association of ACE genotype with these two clinical groups was 
measured by x 2 test. Patients with an OCSP classification of posterior circulation 
syndrome were excluded from this analysis.
The patients who presented with total or partial anterior circulation syndromes were 
grouped according to the size of the stroke on CT. A normal CT or one showing a 
subcortical lesion only was considered to represent a small stroke volume, while those 
scans showing large cortical, cortical and subcortical, or transhemispheric lesions were 
defined as showing a large stroke volume. CT performed soon after the onset of 
ischaemic stroke often does not show the full extent of the evolving infarct. The 
assessment of stroke size was therefore only possible in a subset of cases where CT was 
performed sufficiently late. Association between ACE genotype and this grade of stroke 
size was investigated using a x2 test.
Following each %2 test for association, the table rows corresponding to patients with DI 
or II genotype were combined to give a 2x2 table. The odds ratio for DD genotype 
versus other genotype was calculated along with the corresponding approximate 95% 
confidence interval.
The number of patients per group which would be required to detect, with 95% 
confidence, a true odds ratio substantially different from one was determined using 
published tables. (Lemeshow et al, 1990) This figure depends on the proportion of 
controls who have DD genotype and the value of the true odds ratio.
The Bonferroni correction was not used to adjust the /7-values for the tests performed 
because the results are presented as a main analysis (association between genotype and 
ischaemic stroke or control) and analysis of pre-defined subgroups.
Finally, differences in the distributions of vascular risk factors across ACE genotype were 
assessed using x 2 tests for discrete variables and a Kruskal-Wallis ANOVA for the only 
continuous variable, age. These tests were performed separately in both stroke patients 
and in controls.
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3.3 Results
Blood samples were collected from 585 patients with suspected acute stroke. Adequate 
CT scans were available for 549 patients (94%). Of these, 12 (2%) were diagnosed as 
having non-vascular disease (9 having brain tumours), 326 (59%) had evidence of recent 
infarction on CT, 49 (9%) had primary intracerebral haemorrhage, 41 (7%) had cerebral 
atrophy only, 7 (1%) had haemorrhagic infarction and 114 (21%) were normal. Patients 
with non-vascular disease were excluded from the analysis. Samples were also collected 
from 188 control subjects. 99% of patients were Caucasian.
The mean age was 65 years (standard deviation 13) in controls and 68 years (sd 13) in 
ischaemic stroke patients. The corresponding figures for hypertensive patients were 65 
years (sd 14) in controls, and 67 years (sd 12) in ischaemic stroke patients. The mean 
age was 72 years (sd 13) in patients with haemorrhagic stroke. 44% of controls were 
male, as were 51% of ischaemic stroke patients and 41% of haemorrhagic stroke 
patients.
Table 3.1 shows the results of the tests for association between ACE genotype and 
presence or absence of ischaemic stroke, for all subjects and for the two subgroups of 
interest. There was no evidence of association between ACE genotype and ischaemic 
stroke, in all subjects or in the young or hypertensive subgroups. However, within the 
hypertensive subgroup, there was a borderline significant increase in the proportion of 
DD homozygotes having ischaemic stroke when compared to controls.
There were no significant associations between ACE genotype and any of the subgroups 
of stroke investigated (table 3.2).
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Table 3.1 Frequency of ACE genotype in ischaemic stroke patients and controls
All Under 60 years Hypertensive
Control Case Control Case Control Case
DD 41 (22) 127 (26) 17 (24) 28 (23) 7 (16) 61 (32)
DI 105 (56) 271 (56) 45 (58) 68 (56) 30 (67) 93 (48)
II 42 (22) 90 (18) 14 (18) 26 (21) 8 (17) 39 (20)
Allele
Frequency
(D/I)
0.50/0.50 0.54/0.46 0.52/0.48 0.51/0.49 0.49/0.51 0.56/0.44
X2 test (2 df) 2.03 1.58 5.81
/7-value 0.36 0.45 0.05
Odds ratio 
DD vs DI and II
1.26 0.94 2.51
95% Cl [0.84, 1.88] [0.45, 1.95] [1.06, 5.94]
Figures in the top section of the table are number of patients (percentage o f patients) 
with each genotype
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Table 3.2 ACE genotype in subgroups of stroke
Haemorrhagic or 
ischaemic
OCSP classification Stroke size 
(by CT scan)
ICH IS PT L S L
DD 13 (27) 127 (26) 66 (26) 41 (25) 22 (29) 18 (26)
DI 23 (47) 271 (56) 139 (55) 91 (56) 36 (47) 41 (60)
II 13 (27) 90 (18) 48 (19) 31 (19) 18 (24) 9 (13)
Allele frequency 
(D/I)
0.50/0.50 0.54/0.56 0.54/0.56 0.53/0.47 0.53/0.47 0.57/0.43
X2 test (2 df) 2.11 0.05 3.29
p -value 0.35 0.99 0.19
Odds ratio 
DD vs DI and II
1.03 1.05 0.94
95% Cl [0.53, 2.00] [0.67, 1.65] [0.42,1.84]
ICH, intracerebral haemorrhage; IS, ischaemic stroke
PT, partial or total anterior circulation syndrome; L, lacunar syndrome
S, small; L, large
Figures in the top section of the table are number of patients (percentage of patients) 
with each genotype
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Table 3.3 shows results of the tests for association between ACE genotype and stroke 
risk factors. The apparent significant association between ACE genotype and myocardial 
infarction in control subjects should be treated with caution as only thirteen control 
patients had myocardial infarction. The significant association of ACE genotype with 
hypertension in stroke patients is unlikely to be due to a genetic influence as there was no 
trend from DD to II genotype in the proportion of hypertensive patients. With these 
exceptions, there were no significant associations between ACE gene and stroke risk 
factors.
Table 3.3 Tests for association between vascular risk factors and ACE genotype
Risk factor Test of association with ACE genotype
Controls Stroke patients
%z test /7-value %2 test /7-value
Age* H=0.95 0.62 H=4.09 0.13
Myocardial infarction 8.90 0.01 1.60 0.55
Angina pectoris 2.98 0.23 0.91 0.65
Hypertension 2.85 0.24 6.86 0.03
Diabetes m ell it us 2.92 0.24 0.91 0.64
All %2 tests with 2 degrees of freedom, except for (*), which was a Kruskal-Wallis 
ANOVA with 2 degrees of freedom. Results of tests significant at the 5% significance 
level are in bold type.
The proportion of controls with DD genotype was 0.22. The required sample size to be 
able to differentiate, with 95% confidence, a true odds ratio of 2 from ‘no effect’ is 
approximately 82 patients and 82 controls. The required sample size to be 95% 
confident of differentiating a true odds ratio of 1.33 from 1 is approximately 510 patients 
per group. Our results for the association between ACE genotype and ischaemic stroke 
or control patients therefore exclude a large effect of DD genotype.
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3.4 Discussion
We demonstrated no significant association between ACE gene insertion or deletion 
polymorphism and stroke. Recent reports have suggested that high ACE activity or the 
DD genotype may be a risk factor for increased wall thickness in the carotid artery 
(Bonithon-Kopp et al, 1994) and for left ventricular hypertrophy (LVH) independent of 
blood pressure. (Schunkert et al, 1994) More recently, there is a report suggesting that 
the ACE DD genotype reflects not only higher in vitro ACE activity and ACE 
concentration, but also greater conversion of angiotensin I to angiotensin II. (Ueda et al, 
1995b) However, this is not confirmed in another report using a slightly different 
method. (Lachurie et al, 1995) Possible long term effects of the DD genotype through 
these phenotypes on the incidence of stroke in the elderly population cannot be entirely 
discounted but our results exclude a strong effect of the gene. Our results are in 
agreement with a preliminary report by Sharma et al. (1994) in a small number of 
patients. The D allele frequency in our control population, particularly in hypertensive 
controls and patients aged over 60, was lower than expected but consistent with other 
UK studies. (Cambien et al, 1992; Sharma et al, 1994) Although it has not been 
confirmed, age-dependent decrease in DD genotype may partly account for this low 
frequency of the D allele.
Our additional analysis showed a borderline significant association between the ACE gene 
and ischaemic stroke in the hypertensive population. The odds ratio for ischaemic stroke 
was significantly greater than one when comparing patients of DD genotype with other 
patients, suggesting a higher risk of ischaemic stroke in DD homozygotes. There is 
evidence suggesting a relationship between an activated renin-angiotensin system and 
complications in hypertension. (Brunner et al, 1972; Alderman et al, 1991) More 
recently, Morris et al. (1994) suggested that the DD genotype may carry an increased risk 
for poor prognosis in the hypertensive population in Australia. Our results are consistent 
with these reports but should not be emphasised because our study was aimed principally 
at the comparison between ischaemic stroke and control subjects in the whole 
population, and amongst subgroups of stroke patients. The Bonferroni correction was 
not used to adjust the /7-values quoted in the analysis because the results are presented as
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a main analysis (association of genotype with ischaemic stroke/control) and analysis of 
pre-defined subgroups. We recommend caution in interpreting the results of the 
subgroup analyses.
In contrast to myocardial infarction, stroke is a multifactorial disease and it is unlikely 
that the influence of a single genetic factor on stroke would be detectable in a group of 
several hundred heterogeneous patients. Distinct genetic and non-genetic 
pathophysiological mechanisms may contribute to the development of different types of 
stroke which, for example, may originate from large or small vessels or which affect 
outcome after stroke. We therefore repeated the main analysis for sub-groups aged 
under 60 in whom many of the non-genetic factors causing stroke would not have fully 
developed. Although this subgroup was fairly small (76 controls and 122 ischaemic 
strokes), the non-significant result excludes a strong association between ACE gene and 
ischaemic stroke in this subgroup.
Although there is no evidence to suggest association between ACE genotype and 
hypertension, there is a potential relation between the renin-angiotensin system and high 
blood pressure. Hypertension typically predisposes towards small vessel disease and 
sub-cortical (that is, lacunar) strokes, whereas cortical strokes may more often be 
embolic in origin. Thus, we chose to compare a group of patients who had presumed 
lacunar infarcts with patients whose presenting symptoms were consistent with larger 
cortical events: partial anterior or total anterior circulation syndromes. However, we 
found no association between ACE genotype and stroke subtype thus categorised.
Haemorrhagic and ischaemic stroke arise from different pathological mechanisms. 
However, they do share some risk factors, including age and hypertension. This may 
explain the lack of association between ACE genotype and ischaemic versus 
haemorrhagic stroke.
In preclinical studies, middle cerebral artery occlusion causes larger ischaemic lesions and 
several glutamate antagonists are less neuroprotective in genetically hypertensive rats 
than in normotensive animals. (Coyle and Jokelainen, 1983; Roussel et al, 1992) In 
addition, modification of the renin-angiotensin system results in improved prognosis in
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the stroke prone spontaneously hypertensive rat. (Volpe et al, 1990; Vacher et al, 1993) 
Although these experiments are confounded by the effects of blood pressure, it is 
possible that the eventual size of the stroke may be affected by genetic factors. There is 
evidence that angiotensin is involved in the growth of collateral blood vessels, 
(Fernandez et al, 1982) and thus ACE activity or genotype may also have a relation with 
collateral blood supply. Although the time course of collateralisation is unknown, it is 
probable that, following the onset of acute ischaemia, the initial symptoms will reflect the 
volume of tissue at risk, but the final volume of infarction may be influenced by the 
presence or opening of collateral vessels. Thus, we selected a group of patients whose 
clinical presentation suggested larger cortical strokes (TACS or PACS) and divided these 
into two sub-groups according to the volume of infarction on subsequent CT scan. The 
underlying assumption here is that patients who present with extensive symptoms, but 
whose CT scan reveals only a small volume of infarction, may have a better collateral 
blood supply to the area than patients whose final infarct is extensive. However, our 
analysis based upon these speculations did not show any association of stroke size with 
genotype.
We also tested the above stroke subtype hypotheses in subgroups of patients at low risk 
of vascular events. The influence of ACE genotype may be greater in these patients, as 
demonstrated in a previous study of myocardial infarction and ACE gene. (Cambien et al, 
1992) We considered patients who had none of the following vascular risk factors: 
family history of cerebrovascular or ischaemic heart disease, hyperlipidaemia, diabetes, 
hypertension, and history of smoking. There were relatively few patients in these low- 
risk subgroups, and so it was unsurprising that no significant associations were detected. 
It was not possible to explore this subgroup for the ischaemic stroke and control 
comparison, since data were not collected on all the vascular risk factors in the control 
patients.
There was no clinically significant association between ACE gene polymorphism and 
vascular risk factors in our study. As yet no report has suggested any such association, 
except between ACE gene polymorphism and LVH, which was not recorded in our study 
population. It is therefore unlikely that the DD genotype indirectly affects the 
development of stroke. ACE gene insertion or deletion polymorphism is supposedly only
62
Chapter Three: ACE gene and stroke
in linkage disequilibrium with a putative functional variant. Once this new polymorphism 
is identified, it may be worth testing again a possible association with stroke.
In conclusion, our study suggested that the DD genotype in the human ACE gene is not a 
strong risk factor for stroke in the Caucasian population and particularly in the 
normotensive population aged under 60 years. The possibility of an increased risk for 
stroke in DD homozygotes with hypertension merits further investigation in an 
appropriate, strictly controlled population.
63
Chapter Four: Brain imaging and stroke outcome
Chapter Four 
Prediction of ischaemic stroke outcome 
using brain imaging techniques
4.1 Introduction
As described in chapter 1.3, predicting stroke outcome is important for several reasons. 
The inherent variability in functional outcome following stroke is a major difficulty in 
conducting clinical trials of pharmacological treatments of acute stroke. As a result, 
trials which are likely to demonstrate a treatment benefit must be large and are expensive 
to co-ordinate. Surrogate markers, such as biochemical or radiological parameters, are 
often unacceptable to regulatory authorities. An accurate and objective method for 
predicting functional outcome at the time of drug treatment would aid drug development 
programmes by reducing the number of patients needed to detect a treatment effect of a 
given size. We explore the value of three brain imaging techniques in the estimation of 
functional outcome.
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4.2 Imaging in acute stroke
4.2.1 Computed tomography
A  CT image is obtained by taking X-rays from a linear horizontal scan at pre-set angles 
around the patient’s head. Differential absorption of the radiation due to the photo­
electric effect provides contrast between anatomical structures of different electron 
density. Data from the X-ray detectors are then reconstructed into several axial images, 
conventionally spaced at 5 mm or 10 mm vertical intervals.
Cerebral CT was introduced to clinical practice in 1973 (Ambrose, 1973) and is now the 
primary diagnostic tool in acute stroke. It gives accurate information about central 
nervous system anatomy and pathology. It can detect intracranial bleeding if performed 
within one, or even two, weeks of stroke onset and is also used to exclude neoplasm or 
subdural haematoma as the cause of the patient’s symptoms. CT can detect changes in 
tissue density, abnormal positioning of anatomical structures, and, if iodinated contrast is 
infused, blood vessels. However, its usefulness as a prognostic tool if performed soon 
after stroke onset is less well established. It has been suggested that extended 
hypodensity and local brain swelling on CT may be strong indicators of fatal clinical 
outcome. (Von Kummer et al, 1994) Figure 4.1 gives an example of CT images 
performed at two intervals after acute ischaemic stroke.
4.2.2 Single-photon emission computed tomography
Single photon emission computed tomography (SPECT) uses the photons emitted from a 
radionuclide to produce an image which corresponds to the distribution of the labelled 
radiopharmaceutical in the brain. It allows semi-quantitative tomographic mapping of 
cerebral perfusion. Figure 4.1 gives an example of a cerebral perfusion image obtained 
using SPECT. The patient is injected with hexamethylpropylene amine oxime (HMPAO) 
labelled with the radioisotope " m technetium. In experimental conditions the distribution
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of the radiopharmaceutical correlates well with 14C iodo-antipyrine derived cerebral 
blood flow measurements from 0.5-72 hours after middle cerebral artery occlusion in 
rats. (Bullock et al, 1991)
The imaging device used to perform SPECT studies can take two forms (Holman and 
Devous, 1992): a rotating gamma camera or a dedicated brain SPECT imaging system. 
Most hospitals have rotating gamma cameras but the dedicated systems are usually sited 
in specialist neurological or neurosurgical units. The specialised systems cannot be used 
for general nuclear medicine imaging and are relatively expensive. However, they are 
more sensitive, permitting either superior quality imaging or reduced acquisition times. 
A  SPECT study performed using a rotating gamma camera takes 30 to 40 minutes.
4.2.3 Mean cerebral transit time
Merrick and colleagues (Merrick et al, 1991; Naylor et al, 1991) first described the 
production of parametric images of cerebrovascular reserve using mean cerebral transit 
time (MCTT). The patient is injected with a radioisotope (for example, " m technetium- 
labelled human albumin). A mobile gamma camera is used to perform the imaging, 
which takes around two minutes.
A theoretical advantage of measuring the MCTT is that it is approximately proportional to 
the reciprocal of the cerebral vascular reserve (CVR). The CVR is the most sensitive 
indicator of the degree to which a patient with cerebrovascular disease is maintaining 
perfusion by vasodilatation. It also indicates whether the limits of this natural reflex 
mechanism are in danger of being exceeded.
The result that MCTT is the ratio of regional cerebral blood volume (rCBV) to regional 
cerebral blood flow (rCBF) follows from the basic flow equation:
Flow = Volume / Transit time (4.1)
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It is well-established that this relationship applies to the cerebral circulation. (Meier and 
Zierler, 1954) Gibbs et al. (1984) showed using positron emission tomography that the 
most accurate indicator of CVR at any point is the ratio of rCBF to rCBV. Hence MCTT is 
approximately proportional to the reciprocal of the CVR.
A parametric image of CVR may be produced, based on the mean residence time of the 
injected radioisotope bolus in the gamma camera’s field of view. Figure 4.1 gives an 
example of such an image. The major disadvantage of MCTT imaging is that it does not 
provide tomographic information.
Figure 4.1 Brain images obtained using HMPAO SPECT, MCTT and CT scanning in a 
patient with a large infarction caused by left middle cerebral artery occlusion. Top left: 
HMPAO SPECT axial slice. Top right: MCTT scan. Bottom left: axial slice from a CT 
scan 5 hours after stroke onset. Bottom right: axial slice from a CT scan 4 days after 
stroke onset.
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4.2.4 Other imaging techniques
Magnetic resonance imaging exploits the property of certain nuclei that, when a magnetic 
field is applied, they absorb and then re-emit radio waves of a characteristic frequency. 
Hydrogen nuclei (*H) are among the most sensitive to magnetic fields. Since they are 
also abundant in biological tissue, they are the most commonly targeted nuclei in MR 
studies. The time interval between absorption and re-emission of the radiation (Ti) and 
the rate of decay of the signal after the initial radiation emission pulse (T2) vary 
depending on the composition of the tissue within which the nuclei are situated. Hence 
MR produces a chemical image which also shows anatomy. Although MR is less reliable 
than CT for the detection of intracranial haemorrhage, it boasts several advantages. The 
patient is not exposed to X-ray radiation, although the magnetic field naturally attracts 
ferromagnetic objects such as prostheses or metal clips and adversely affects the function 
of cardiac pacemakers. Cerebral infarction may be identified more quickly after onset 
and is delineated more clearly. The MR image shows improved contrast between 
anatomical structures. Adjacent bone matter does not cause an artefact on the image as 
occurs in CT. This allows superior imaging of lesions in the brainstem. The image may 
be reconstructed in any plane after data have been collected. Blood flow in intracranial 
vessels may also be apparent.
Doppler ultrasound is a non-invasive diagnostic test commonly used in cerebrovascular 
disease. An electric current is supplied to a piezoelectric crystal, which converts the 
electrical energy to sound waves in the frequency 2-10MHz. The Doppler probe, which 
both emits and receives these ultrasound waves, is passed along the surface of the skin 
above the common and internal carotid arteries. It detects both velocity of red blood 
cells and changes in tissue density. Real time, or B-mode, ultrasound detects echoes 
caused by the variation in the acoustical impedance of the tissues being scanned. This 
allows imaging of the arterial wall. Duplex ultrasound combines both Doppler and B- 
mode imaging. Flow velocity is usually represented in colour on the image. Colour-flow 
duplex Doppler ultrasound is now standard in most departments. It provides a two- 
dimensional image of the arterial wall and blood flow information. Doppler ultrasound 
can be used to detect the degree of internal carotid artery stenosis and any turbulence
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beyond the stenosis. It also gives information on the haemodynamic significance of 
extracranial arterial lesions. However, Doppler cannot adequately distinguish between 
sub-total and complete occlusion. Since the test is non-invasive and safe, it may be used 
as a screening test to decide which patients require cerebral angiography, a procedure 
with an appreciable risk of neurological complication or death. Doppler may be used as 
a follow-up for monitoring improvement in haemodynamics after carotid 
endarterectomy.
Transcranial Doppler (TCD) is a non-invasive method of measuring blood flow velocity in 
the large intracranial arteries. Three pathways are used: transtemporal, transforamen 
magnum, and transorbital. This is because the sound waves will not penetrate the full 
thickness of the skull. TCD allows continuous monitoring of the cerebral circulation and 
may be used to detect emboli entering the brain.
Cerebral angiography is the definitive method for the complete study of extracranial and 
intracranial vasculature. An iodinated contrast material is injected, either directly into the 
artery, or indirectly through a femoral artery catheter. If performed soon after stroke 
onset it differentiates between embolism and large artery thrombosis. However, it is not 
considered as a routine procedure as it carries a risk of between 0.5% and 1.2% of 
permanent injury or death. (Toole, 1990) Angiography used to be considered essential 
before carotid endarterectomy to visualise accurately the grade and site of the carotid 
lesion. Many surgeons now accept the use of duplex Doppler ultrasound for this 
purpose.
Magnetic resonance angiography (MRA) is an alternative, non-invasive, safe, procedure 
for imaging arterial blood flow. However, when compared to cerebral angiography, it 
does not give such good delineation of the grade of stenosis. It is also difficult to see 
arteries which curve in and out of the plane of the image and where the arterial blood 
flow is not laminar. Laminar flow is lost, particularly around high-grade stenosis: thus, 
MRA may give false positive results for arterial occlusion. More sophisticated MRA 
techniques are currently being developed and promise to replace traditional angiography 
in many clinical applications.
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We now go on to compare the usefulness of CT, SPECT and MCTT scanning and clinical 
assessment in the prediction of functional outcome three months after acute ischaemic 
stroke.
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4.3 Outcome study
4.3.1 Introduction
There is increasing interest in the pharmacological treatment of acute ischaemic stroke. 
Treatment is more likely to be effective if started within 12, 6 or even 3 hours of the 
onset of symptoms. Clones et al, 1981; Barsan et al, 1989) Computed tomography 
scanning, described in section 4.2.1, differentiates between ischaemic stroke and 
haemorrhage if performed soon after stroke onset. Unfortunately, the earlier the CT scan 
is performed, the less likely it is to demonstrate the location and extent of the evolving 
infarct. In contrast, early cerebral blood flow studies often show perfusion deficits. 
Such studies may help to define groups of patients for treatment with investigational 
drugs, or to provide an objective baseline by which the subsequent effects of treatment 
could be judged.
The technique of SPECT, described in section 4.2.2, is widely used in medical imaging. It 
is primarily used for diagnostic purposes. However, early SPECT studies may predict 
outcome better than clinical assessment and may thus be useful in stratifying patients 
during the acute phase of ischaemic stroke. (Giubilei et al, 1990; Limburg et al, 1991) 
Mountz et al. (1990) suggest that relating the structural defect on CT to the volume of 
blood flow deficit seen using SPECT may improve prognostication. Other studies (Defer 
et al, 1987; Shimosegawa et al, 1994) suggest that SPECT can be used to distinguish 
between infarcted and morphologically viable brain, even within 6 hours of onset. SPECT 
studies may also be useful in identifying patients at risk of haemorrhagic transformation 
during thrombolytic therapy. (Ueda et al, 1994)
There are logistical difficulties associated with utilising SPECT in the acute phase of 
stroke. The imaging devices are generally fixed in the nuclear medicine department and 
patients must be transported there for the imaging to be performed. If a porter service is 
unavailable, it may be difficult to provide a 24-hour service. In addition to this, the 
HMPAO must be labelled with the " mTc in the 20 minute period before administration to 
the patient.
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MCTT, described in section 4.2.3, has not been adopted widely in medical imaging. It has 
practical advantages over SPECT imaging for the assessment of stroke in the early phase 
of onset. It does not require sophisticated imaging equipment. A small mobile gamma 
camera can be used. This can be stored on the ward and the measurements made at the 
patient’s bedside. The imaging takes only around two minutes to perform. A theoretical 
advantage of measuring the MCTT is that it is approximately proportional to the 
reciprocal of the cerebral vascular reserve (CVR), a parameter which is claimed to be of 
more physiological relevance than cerebral blood flow (CBF) alone. A parametric image 
of CVR may therefore be produced. The major disadvantage of MCTT imaging is that it 
does not provide tomographic information.
In the ASU we ran these two radionuclide techniques for assessing cerebral perfusion in 
tandem for one year. We compare the value of these two techniques, CT, and clinical 
assessment in predicting functional outcome following acute stroke.
4.3.2 Subjects and methods
Sixty three patients (mean age 72 years, standard deviation 10 years) were investigated 
by MCTT, SPECT and conventional CT brain scanning. Other patients, who will not be 
described, were investigated by CT alone or in combination with one of the radionuclide 
methods over the same time period. Staff and equipment were available to perform the 
radionuclide methods during working hours for five days per week. Delayed scans were 
discouraged. The radionuclide investigations were also subject to patient consent. 
Patients with intracerebral haemorrhage on CT were excluded. Comatose patients were 
avoided, as were those with uncontrolled cardiac failure or poor venous access. These 
latter factors influence the rate at which a rapidly injected bolus of isotope travels to the 
heart, and the extent to which it becomes diluted by blood within the venous and 
pulmonary vessels and the cardiac chambers. Retention of a discrete bolus is a 
prerequisite to adequate transit time scanning. Agitated patients who would have had 
difficulty remaining still during scanning were excluded. Hence the reported patients
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represent under 20% of admissions to the ASU over the study period. However, patients 
with posterior circulation strokes were included in the study in addition to those with 
cortical and subcortical strokes. All patients had their stroke subtype categorised on the 
basis of clinical presentation according to the OCSP classification. (Bamford et al, 1991)
Patients underwent CT scanning (Philips Tomoscan 310) to establish a diagnosis of 
haemorrhagic or ischaemic stroke. Nine mm axial slices were used, with 6 mm slices for 
the posterior fossa. The volume of any ischaemic lesion present was measured by visual 
assessment by a single observer.
SPECT (Siemens Orbiter) was performed in the Nuclear Medicine Department of the 
Western Infirmary, using " mTc-labelled hexamethylpropyleneamine oxime (99mTc- 
HMPAO) 500 MBq Ceretec, provided by Amersham pic. The radionuclide for SPECT 
scans was injected with the patient lying supine in a quiet and darkened room. The scan 
was also performed with the patient supine. Four to 5 million counts were recorded for 
a 360° rotation around the head with 64 angular views. The rotation time was 30 to 45 
minutes. After reconstruction and correction for attenuation and patient movement, a set 
of axial tomographic slices was obtained, at 12 mm intervals, from the posterior fossa to 
the vertex. The SPECT slice showing the greatest asymmetry of perfusion was chosen for 
analysis. Regions of interest were placed symmetrically and the percentage difference in 
activity in comparison to the contralateral hemisphere was automatically recorded. A 
difference of more than 15% was regarded as significant. This choice of threshold has 
been reported in a previous study of epilepsy (Duncan et al, 1992) and corresponds 
approximately to those used in other SPECT studies of stroke. (Giubilei et al, 1990; 
Mountz et al, 1990) The area of such asymmetry was estimated by visual measurement 
of the antero-posterior and lateral dimensions, and this was multiplied by the total depth 
of the lesion in order to estimate volume. This measurement was performed by a single 
observer experienced in SPECT, blind to each patient’s clinical details and CT scan.
The same gamma camera system was also used for the MCTT scans. A second detector 
was placed over the aortic arch. (Merrick et al, 1991; Naylor et al, 1991) MCTT scans 
were performed with the patient lying supine and the neck extended. Patients received 
an antecubital venous injection of 0.3-0.5 ml of 99mTc pertechnetate labelled human
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serum albumin 500 MBq via a 21 gauge cannula (Venflon R). This was rapidly flushed 
with 20ml 0.9% saline and total time for the entire injection was approximately 1 to 1.5 
seconds. Data were collected for up to two minutes and analysed according to the 
method described by Merrick et al. (1991). In particular, the scans were interpreted and 
reported by visual inspection, looking for evidence of asymmetry, and with reference to 
the normal ranges for arrival time and transit time in each standard region of interest 
published by Merrick et al. (1991). A further objective measure of the abnormality of 
each scan was obtained by computing the mean transit time for each hemisphere and then 
forming the ratio of the mean for the affected hemisphere to that for the unaffected 
hemisphere (hereafter called MCTT ratio).
A trained occupational therapist assessed patient outcome after three months. The 
assessment was based on mortality and on the Barthel Index (Mahoney and Barthel, 
1965) for survivors. This outcome measure is widely used in therapeutic intervention 
studies in stroke. The assessments were undertaken by telephone conversation with the 
patient, a carer, or ward nursing staff as appropriate. The validity of outcome 
assessment by telephone has been demonstrated previously. (Shinar et al, 1987)
Associations between clinical classification and mortality, and CT, MCTT and SPECT scan 
results and mortality were investigated using %2 tests. Mann-Whitney tests were used to 
compare CT lesion volume, SPECT deficit volume, and MCTT ratio in survivors and 
patients who died. An alternative set of normal ranges of mean cerebral transit times, 
based on the data from the unaffected hemispheres of our elderly stroke patients, was 
derived and compared with the normal ranges published by Merrick et al. (1991). A 
Kruskal-Wallis test was used to test for differences in median functional outcome scores 
among clinical groupings. Follow-up multiple comparisons were used to identify any 
significant pairwise differences. Spearman rank correlation coefficients (rs) were 
calculated to assess the strength of the relationship between functional outcome in 
survivors (as measured by three-month Barthel Index) and each of CT lesion volume, 
SPECT lesion volume and MCTT scan ratio. These non-parametric methods were used 
since Barthel scores do not follow a Normal distribution. A cut-off point of 70 was then 
defined on the Barthel score, with scores above this point being considered to represent a 
good functional outcome. This represents a compromise between the levels of assisted
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independence (Barthel Index > 60) and near independent, that is, able to live alone 
(Barthel Index > 85). Forward stepwise logistic regression was performed to test 
whether any subset of CT lesion volume, SPECT lesion volume and MCTT scan ratio was 
useful in predicting good functional outcome thus defined. This analysis was then 
repeated to include in the “poor functional outcome” group those patients who died.
4.3.3 Results
Sixty-three patients underwent all three imaging investigations. The delay between 
stroke onset and scanning was similar for all three methods. MCTT scans were 
undertaken at a median of 2 days (interquartile range [IQR] 1 to 3 days), SPECT scans at 
a median of 3 days (IQR 2 to 4 days) and CT scans at a median of 1 day (IQR 1 to 4 days) 
after stroke onset. Only one SPECT scan showed post-ischaemic hyperperfusion.
The mean cerebral transit times for our patients, with few exceptions, exceeded the 
upper end of the normal ranges given by Merrick et al. (1991). This was the case for the 
unaffected hemisphere as well as for the hemisphere affected by the stroke and may be 
due to our patients being drawn from an elderly population with cardiac and 
cerebrovascular disease. Table 4.1 gives sets of normal ranges based on the unaffected 
hemispheres of our patients, for (a) mean cerebral transit time and (b) fractional 
turnover, or reciprocal MCTT. The estimates of the 95th and 5th centiles, based on our 
relatively small sample, may be unreliable.
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Table 4.1(a) Normal ranges of mean cerebral transit time in seconds
Region Median Range 95th centile
Anterior 6.7 3.3 -16.6 13.6
Pre-central 6.5 3.6 -15.8 12.0
Post-central 6.9 3.8 -15.5 11.8
Posterior 7.8 3.8 -15.3 12.3
Hemisphere 7.0 3.85 -15.6 12.1
Table 4.1(b) Normal ranges of fractional turnover (reciprocal MCTT) in (seconds)'1
Region Median Range 5th centile
Anterior 0.15 0.06 - 0.30 0.07
Pre-central 0.15 0.06 - 0.28 0.08
Post-central 0.14 0.06 - 0.26 0.07
Posterior 0.13 0.07 - 0.26 0.08
Hemisphere 0.14 0.06 - 0.26 0.08
Figure 4.2 shows the mean (over all patients) ratio of hemisphere mean transit times 
(affected : unaffected hemisphere) and its associated standard deviation for each of the 
four regions of measurement. These mean ratios are presented separately for the four 
clinical subtypes of cerebral infarction and demonstrate the ability of MCTT to relate 
perfusion deficit to clinical presentation. The high inter-patient variability may limit the 
use of this relationship for prognostication, however.
The distribution of patients across the OCSP clinical categories is shown with mortality 
data in table 4.2. There was no evidence of an association of mortality with OCSP
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category or with normality or abnormality of CT, SPECT, or MCTT scans (table 4.2). CT 
lesion volume and SPECT blood flow deficit volume did not show significant differences 
between survivors and non-survivors (95% Cl for difference in medians [-6ml, 9ml], 
^>=0.847 and 95% Cl [-29ml, 68ml], /?=0.575 respectively). Surprisingly, patients who 
died had significantly lower MCTT ratios than survivors (95% Cl for difference in medians 
[-0.24, -0.05],/7=0.011).
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Figure 4.2 Mean MCTT ratio for each brain region (1 = anterior, 2 = pre-central, 3 = 
post-central, 4 = posterior) within each clinical grouping (TACI = total anterior 
circulation infarct, PACI = partial anterior circulation infarct, LACI = lacunar infarct, POCI 
= posterior circulation infarct). Solid line indicates mean, dotted line indicates ± 
standard deviation.
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Table 4.2 Three month outcome bv clinical. CT. SPECT and MCTT findings
Alive (n=51) Dead (n=12) X2 test WO p-value
OCSP classificationt
TACI 13 (25) 5 (42)
PACI 14 (27) 3 (25)
POCI 8 (16) 0 (0)
LACI 16 (31) 4  (33) 2.805 (3) 0.422
A bnorm al CT 28 (54) 7 (58) 0.429 (1) 0.513
Abnormal SPECT 43 (84) 11 (92) 0.046 (1) 0.830
A bnorm al MCTT* 43 (84) 10 (83) 0.055 (1) 0.815
* TACI indicates total anterior circulation infarct; PACI, partial anterior circulation infarct; 
LACI, lacunar infarct; POCI, posterior circulation infarct.
* The interpretation of one scan was regarded as equivocal.
Figures in brackets are percentages within each outcome group.
Functional outcome varied with clinical grouping in survivors (Kruskal-Wallis %2 =10.79, 
df = 3, p  = 0.013). This was attributable to higher Barthel scores in patients with 
posterior circulation infarcts (table 4.3). Figures 4.3, 4.4 and 4.5 show the relationship 
between 3-month functional outcome in survivors (as measured by Barthel Index) and 
SPECT blood flow deficit volume, CT lesion volume and MCTT ratio respectively. The 
plots are labelled according to the OCSP classification. Functional outcome in survivors 
was significantly correlated with SPECT lesion volume (Spearman rs = -0.425, /?=0.002) 
and with MCTT ratio of mean transit times (rs = -0.356, p=0.010) but not with CT lesion 
volume (rs = -0.175,/7=0.110). The atypical MCTT scan result for one patient had a large 
influence on the correlation observed: with the results of this patient removed the 
Spearman rank correlation was -0.400 (p=0.004). Correlations were also calculated 
between scan data and Barthel Index within the subgroups defined by the OCSP clinical
79
Chapter Four: Brain imaging and stroke outcome
classification. There was a suggestion that both SPECT and MCTT showed a stronger 
relationship with outcome in patients presenting with lacunar syndromes (rs = -0.682, 
/?<0.005 and rs = -0.456,/?<0.05 respectively). However, the number of patients in the 
lacunar subgroup was small (16 survivors).
Table 4.3 Comparison of functional outcome among clinical groups
OCSP classification Median 3-month 
Barthel Index
Significantly higher than
TACI 72 -
PACI 73 -
LACI 84.5 -
POCI 100 TACI, PACI
TACI indicates total anterior circulation infarct; PACI, partial anterior circulation infarct; 
LACI, lacunar infarct; POCI, posterior circulation infarct.
Forward stepwise logistic regression on data from all three imaging methods identified 
SPECT blood flow deficit volume as the only significant predictor of good functional 
outcome in survivors. A SPECT deficit of 80ml was the optimum cut-off point for 
discriminating between poor and good functional outcome. Twenty-seven of the 34 
patients (79%) with good functional outcome had SPECT deficits of less than 80ml. Ten 
out of 17 (59%) with poor functional outcome had deficits greater than 80ml. This gave 
an overall predictive accuracy of 73%. Including patients who died in this analysis did 
not give substantially different results. Again, SPECT deficit volume was the only 
significant predictor of outcome, and the overall predictive accuracy was 66%.
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Figure 4.3 Relationship between 3-month Barthel score and, SPECT deficit volume (ml) 
in survivors. ( □  = total anterior circulation infarct, A = partial anterior circulation 
infarct, ■ = posterior circulation infarct, A = lacunar infarct)
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4.3.4 Discussion
Neurological damage following acute cerebral ischaemia continues for an undetermined 
time after the onset of ischaemia. (McCulloch, 1992) Several mechanisms are involved, 
but in particular excito-toxic damage from the neuro-transmitters, glutamate and 
aspartate, coupled with calcium entry and activation of energy-dependent processes 
appear to be implicated. There is considerable interest in developing pharmacological 
treatments to reduce neurological damage and thus to improve functional outcome. 
(Lees, 1992) Several agents are now undergoing phase III clinical trials and there is the 
prospect of many more compounds reaching clinical trials in the near future. The wide 
variability in outcome following acute stroke is a major difficulty in conducting such 
trials. In order to detect any treatment benefit with high power, large numbers of 
patients require to be enrolled. Hence stroke trials are expensive to co-ordinate and 
patient recruitment may take a long time. Surrogate markers which do not directly 
measure the patient’s outcome are often unacceptable to regulatory authorities. An 
objective method for predicting functional outcome at the time of acute treatment would 
aid in drug development programmes and possibly in triage for rehabilitation care.
The OCSP clinical classification alone clearly cannot predict functional outcome, and CT, 
although essential to confirm the diagnosis and to establish presence or absence of 
haemorrhage, does not predict outcome when performed within early hours of an 
ischaemic stroke. The proportion of patients with normal CT in this study (44%) reflects 
the fact that a substantial proportion of infarcts are small and situated subcortically or in 
the brainstem. The OCSP (Bamford et al, 1990) also reported a high normal CT rate in an 
epidemiological study of patients presenting with first-ever acute stroke.
The suggestion that MCTT scanning may help predict outcome is attractive since this 
technique is rapid and can be established in departments with only simple gamma-camera 
facilities. Unfortunately, our results suggest that the information obtained from MCTT 
scanning is inadequate for the prediction of functional outcome. We surmise that the
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lack of tomographic information makes the technique insensitive to small vessel 
occlusion and areas of focal ischaemia. Other factors which influence sensitivity may 
include bilateral carotid artery stenosis or raised intracranial pressure which would 
increase transit times, and post-ischaemic hyperaemia which would cause reversal of the 
increase in transit time.
With the additional tomographic information provided by SPECT, we found a similar level 
of predictive accuracy to that obtained in a previous study. (Giubilei et al, 1990) 
However, our patient group was a heterogeneous one and the delay from onset to SPECT 
for some patients was outside the time window recommended by Limburg et al. (1991). 
This may have weakened the observed relationship between SPECT deficit and functional 
outcome. We actively excluded patients with significant cardiac disease, in whom 
cardioembolism is more common, but we did not prospectively collect data on the 
incidence of cardioembolic stroke. We excluded patients who were agitated and thus 
unable to remain still for an examination, who had poor venous access which prevented 
retention of an adequate bolus of isotope reaching the aorta or who refused consent to 
undergo scanning, as a practical necessity. However, these factors may also have an 
influence on outcome. Finally, the scans in this study were conducted relatively late, by 
the criteria now used for acute treatment trials. Thus, we may have underestimated the 
predictive value of SPECT. However, estimating the predictive value of SPECT was not 
the aim of our study: the comparison between MCTT and SPECT remains valid since the 
time of the two scans was similar and since we confirmed the predictive value of SPECT 
even at the later time of scanning.
Stronger correlations of SPECT deficit volume and MCTT ratio with functional outcome 
were seen in patients presenting with lacunar syndromes. Both scanning techniques may 
be detecting additional cortical areas of reduced blood flow which are at risk of 
ischaemia, although the clinical presentation is of subcortical infarction. However, there 
were only 16 patients with LACI in this study: this apparent increased correlation should 
be investigated in a larger group of patients.
Since mortality after stroke is often due to factors other than neurological damage (for 
example, ischaemic heart disease or deep vein thrombosis), it is not surprising that none
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of the methods enabled accurate prediction of death. However, there was a small but 
significant difference in the median MCTT ratios between survivors and non-survivors.
The relationship between SPECT results and outcome deserves to be assessed in a larger 
patient cohort and using a more objective measurement of SPECT deficit than in this 
study. The potential use of combinations of clinical, radiological and radionuclide 
methods should be pursued. The use of MCTT scanning for the prediction of functional 
outcome in patients with acute ischaemic stroke is not recommended.
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Chapter Five 
Prognostic value of SPECT in acute 
ischaemic stroke
5.1 Introduction
Accurate outcome prediction is essential in acute stroke, and chapter 1.3 described 
several reasons for this. One such reason is that outcome predictions may provide a 
benchmark by which therapeutic or clinical interventions may be judged. Early CT is 
essential for differentiating between ischaemic and haemorrhagic stroke. It often fails to 
demonstrate the location and extent of an evolving infarct, (Bryan et al, 1991) although 
one study has suggested that CT may still have prognostic value within six hours of 
middle cerebral artery stroke. (Von Kummer et al, 1994) In contrast, early cerebral 
blood flow studies often show perfusion deficits and thus may be useful in predicting
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patient outcome, or in defining groups of patients for treatment with investigational 
drugs.
Single-photon emission computed tomography allows semi-quantitative tomographic 
mapping of cerebral perfusion. It is widely used in the investigation of acute stroke, 
(Holman and Devous, 1992; Fayad and Brass, 1991) both for diagnostic and prognostic 
purposes. In experimental conditions the distribution of the radiopharmaceutical used, 
" mTc-HMPAO, correlates well with 14C iodo-antipyrine derived cerebral blood flow 
measurements from 0.5-72 hours after middle cerebral artery occlusion in rats. (Bullock 
et al, 1991) Many studies have explored the relationship between regional cerebral 
blood flow (rCBF) and clinical outcome of stroke. (Heiss et al, 1977; Kushner et al, 
1987; Lee et al, 1984; Mountz et al, 1990; Limburg et al, 1991; Giubilei et al, 1990; 
Hanson et al, 1993; Davis et al, 1993; Alexandrov et al, 1993; Limburg et al, 1990; 
Laloux et al, 1995) The clinical usefulness of this correlation remains controversial, 
however. Mountz et al. (1990) obtained improved prognostication by relating the blood 
flow deficit on SPECT to the anatomical defect found by CT. One study considered the 
severity of the flow deficit alone (Giubilei et al, 1990) while others combined the volume 
and severity of the flow deficit. (Limburg et al, 1990; Limburg et al, 1991) Infeld et al. 
(1995) considered cross cerebellar diaschisis as measured by SPECT in 47 patients but 
found it to have no prognostic value. However, they suggested it may represent the 
degree of nutritional perfusion at the infarct site.
Luxury perfusion is caused by the spontaneous recanalization of occluded vessels. It was 
first described by Lassen (1966). It has been suggested that the presence of luxury 
perfusion is an indicator of improved prognosis (Heilman and Tikofsky, 1990) and of 
poor prognosis. (Irino et al, 1977) Jorgensen et al. (1994b) undertook a large study in 
acute stroke patients to determine the clinical importance of spontaneous reperfusion and 
showed that its presence was associated with improved clinical outcome at a few weeks. 
Its influence on long-term functional outcome has yet to be tested in a large group of 
acute stroke patients.
Our study aimed to model the effects on functional outcome of several parameters 
(volume of flow deficit, severity of flow deficit, and presence of increased HMPAO
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counting rate) obtained from SPECT studies performed soon after acute stroke. We 
report our findings from a cohort of patients admitted to the ASU of the Western 
Infirmary, Glasgow.
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5.2 Subjects and methods
Computed tomography or MR imaging is performed routinely in all patients admitted to 
the ASU. SPECT scans were performed in patients according to the following criteria. 
Patients whose symptoms were found to be non-vascular in origin were excluded from 
the study, as were those whose CT scans showed evidence of primary intracerebral 
haemorrhage or tumour. Comatose patients and uncooperative or agitated patients who 
would have had difficulty in remaining still during SPECT scanning were also excluded. 
We retrieved 287 SPECT images stored in our nuclear medicine department. Of these, 
180 were found to be from ischaemic stroke patients (mean age 67.7 years, sd 12.5 
years). These patients had one year of functional outcome and mortality follow-up. The 
clinical presentation of patients was reviewed by a small group of experienced clinicians, 
including a stroke physician and a neurologist. Patients were then classified according to 
the OCSP classification.
SPECT using " mTc-HMPAO (500 MBq Ceretec, provided by Amersham pic) was carried 
out on a single-head rotating gamma camera (Siemens Orbiter) using a 128 x 128 matrix 
and 64 projections for 30 seconds per angle over 360°. The attenuation was corrected 
using Chang’s algorithm and an attenuation coefficient of 0.15cm'1. Data were 
reconstructed to obtain 16 axial slices 6mm thick parallel to the orbitomeatal line. The 
SPECT resolution of the camera was 14mm. The lower four slices were used to provide 
information on the cerebellum, with two regions of interest being placed over each lobe 
of the cerebellum. This allowed a measure of cross-cerebellar diaschisis to be made. 
The semi-automatic analysis was performed blind to the clinical and CT details. A set of 
templates was chosen from a series of standard sizes, according to the size of the 
patient's head. Once the size had been selected, templates were placed over each of the 
twelve axial slices. These templates contained 16 symmetrical non-anatomic cortical 
segments and 8 subcortical segments. The subcortical segments were not used in the 
subsequent analysis. Each segment has a volume of between 3 and 6ml. An 
interhemispheric segment count difference of at least 15% was considered to be a 
significant deficit, based on confidence intervals constructed previously from normal 
scans. The volume of lesion was calculated by summing the volumes of all such
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segments (provided that a deficit appeared on at least two neighbouring segments on 
more than one consecutive slice: this allowed for partial volume effect).
To estimate the presence of increased HMPAO counting rate on the affected side, the 
slices were normalised to the unaffected side of the cerebellum. In patients with an 
elevated count rate, the CT and clinical data were also considered. Three experienced 
observers then viewed this information and made a decision on the presence of 
hyperaemia. Increased HMPAO counting rate does not necessarily imply that luxury 
perfusion is present, since HMPAO hyperfixation may lead to spuriously high estimates of 
cerebral blood flow. (Sperling and Lassen, 1993; Steinling et al, 1994)
Trained research nurses assessed patient outcome one year after onset of stroke. The 
assessment was based on mortality and on the Barthel Index (Mahoney and Barthel, 
1965) for survivors. Patients who died scored zero on the Barthel Index. Mortality 
follow up was validated by record linkage (Kendrick and Clarke, 1993) with the Scottish 
Deaths Register. Record linkage with hospital discharge data was used to obtain 
information on hospital admissions for recurrent stroke and carotid surgery. The 
functional outcome assessments were obtained by telephone interview with the patient, a 
carer, or ward nursing staff as appropriate. The validity of telephone assessment has 
been confirmed by ourselves and others previously. (Shinar et al, 1987)
The Spearman rank correlation coefficient was calculated to assess the relationship 
between functional outcome (as measured by Barthel Index at one year) and SPECT 
parameters (total volume of CBF deficit, maximum percentage CBF deficit relative to 
contralateral reading). This was repeated in subgroups of patients categorised according 
to timing of SPECT scan (<40 hours from onset, >40 hours from onset, and <16 hours 
from onset) and according to clinical presentation using the OCSP classification. Non- 
parametric methods were used since Barthel scores are not Normally distributed. A cut­
off point of 60 was then defined on the Barthel Index: scores of 60 or more were 
considered to represent a good functional outcome. It is widely accepted that this cut­
off corresponds to the functional ability required for supervised independence. (Hanson 
et al, 1993; Trust Study Group, 1990) Patients who died were included in the poor 
functional outcome group. Mann-Whitney tests were used to assess whether the median
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ages, deficit volumes or maximum percentage deficits were different for the two 
outcome groups. Univariate %z tests were used to assess whether the presence of luxury 
perfusion or the OCSP clinical classification was associated with functional outcome as 
categorised above. Forward stepwise logistic regression was used to assess which 
combination of SPECT parameters and clinical variables gave the best prediction of 
outcome.
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5.3 Results
On admission, 36 patients (20%) presented with total anterior circulation infarcts (TACI), 
67 (37%) with partial anterior circulation infarcts (PACl), 13 (7%) with posterior 
circulation infarcts (POCl), and 49 (27%) with lacunar infarcts (LACl). Fifteen patients 
(8%) did not have their stroke subtype classified into one of these groups. At one year 
after stroke, 49 patients (27%) had died, and 107 (59%) had a Barthel score > 60. 
SPECT was performed at a median of 1 day after onset (range, 0 to 11 days). Figure 5.1 
shows the relationship between volume of CBF deficit and functional outcome. The 
Spearman rank correlation coefficient was significantly negative. (rs = -0.310, p  < 
0.0001) Figure 5.2 shows the relationship between the maximum percentage deficit and 
functional outcome. Again the Spearman rank correlation coefficient was significantly 
negative. (rs = -0.316, p  < 0.0001)
Barthel 
Index at 
1 year
100 i — j -  • ;i  •  • •
50
0
200 300 4000 100
Volume of CBF deficit (ml)
Figure 5.1 Relationship between volume of CBF deficit and functional outcome
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Figure 5.2 Relationship between severity of CBF deficit and functional outcome
Table 5.1 gives the correlations between these SPECT parameters and functional outcome 
for several subgroups of patients. In general, correlations were more strongly negative 
for patients scanned a shorter time after stroke onset, and for patients with anterior 
circulation events or lacunar syndromes. The patients in the good functional outcome 
group were significantly younger (poor outcome median 71 years; good outcome median 
65 years; p  = 0.016). The median deficit volume was higher in the poor outcome group 
(poor outcome median 54ml; good outcome median 27ml; p  < 0.001). The median of 
the maximum percentage deficits was higher in the poor outcome group (poor outcome 
median 37%; good outcome median 27%;p < 0.001).
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Table 5.1 Spearman rank correlation between SPECT parameters and 1-vear 
Barthel score
Patient group SPECT deficit volume 
<rs)
SPECT deficit severity 
(r.)
All patients (n=180) -0.310 (p< 0.0001) -0.316 (p< 0.0001)
SPECT within 40 hours (n=97) -0.403 ip< 0.0001) -0.341 ip< 0.001)
SPECT > 40 hours (n=83) -0.187 ip < 0.05) -0.291 (p < 0.01)
SPECT within 16 hours (n=28) -0.606 (p< 0.001) -0.492 (p< 0.005)
anterior * (n=103) -0.202 (p < 0.05) -0.216 ip < 0.05)
posterior (n=13) 0.071 ip > 0.1) -0.058 ip > 0.1)
lacunar (n—49) -0.511 ip< 0.001) -0.447 ip< 0.001)
within 40 hours, 
not posterior (n=81) -0.465 (p< 0.0001) -0.419 ^  < 0.0001)
within 16 hours, 
not posterior (n=26)
-0.592 (p< 0.001) -0.507 ip< 0.005)
* Patient presented with total or partial anterior circulation syndrome according to the 
OCSP classification of acute stroke.
Table 5.2 shows the distribution of OCSP classification of stroke with functional 
outcome. Excluding the 15 patients with an uncertain classification, there was significant 
evidence of an association between OCSP classification and functional outcome (y2 = 
23.91, df = 3,/? < 0.0001). The presence of luxury perfusion was not associated with 
functional outcome grouping (16% of poor outcome patients had luxury perfusion; 15% 
of good outcome patients had luxury perfusion; y2 = 0.073, df = l ,p  = 0.79).
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Table 5.2 Clinical classification of stroke and functional outcome
Poor
functional
outcome
Good
functional
outcome
TACI 26 (72%) 10 (28%)
OCSP
classification PACI 26 (39%) 41 (61%)
POCI 4 (31%) 9 (69%)
LACI 10 (20%) 39 (80%)
uncertain 7 (47%) 8 (53%)
TACI, total anterior circulation infarct; PACI, partial anterior circulation infarct; POCI, 
posterior circulation infarct; LACI, lacunar infarct. Percentages are calculated separately 
within each clinical subgroup.
When both SPECT data (total deficit volume, maximum percentage deficit, presence of 
luxury perfusion) and clinical information (age, OCSP classification) were considered 
(model 5.1), the stepwise logistic regression algorithm included OCSP classification (p = 
0.007), total deficit volume ip = 0.023), and age ip = 0.039) as significant predictors of 
good functional outcome. Only data from the 165 patients with a definite OCSP 
classification were considered for this model.
When SPECT data alone were considered (model 5.2), the only significant predictor of 
good functional outcome was total deficit volume ip = 0.0001). When data from the 28 
patients scanned within 16 hours of onset were analysed (model 5.3), total deficit volume 
ip = 0.003) was the only significant predictor. Table 5.3 shows the relative risks and 
associated 95% confidence intervals for the variables included in models 5.1, 5.2 and 5.3. 
Table 5.4 describes the accuracy of the three models when the cut-off point on the 
logistic regression predicted probability was fixed as the prior probability of a poor 
outcome. That is, cases for which the logistic regression predicted a higher probability 
of a poor outcome than the proportion of poor outcomes in the sample were given a 
prediction of ‘poor outcome’. For model 5.2, this is equivalent to choosing a cut-off
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deficit volume on SPECT of 80ml, above which cases are predicted to have a ‘poor 
outcome’. Model 5.1 achieved 72% accuracy overall, while model 5.2 achieved 66%. 
The stronger correlation between SPECT data and outcome in patients scanned within 16 
hours of onset was reflected in the higher accuracy of model 5.3 (75%).
Table 5.3 Relative risks and associated 95% confidence intervals for variables 
included in models 5.1. 5.2 and 5,3
Variable Relative risk of 
poor outcome
95% Cl
Model 5.1 OCSP classification* (1) 0.35 (0.14,0.88)
(2) 0.27 (0.06 , 1.19)
(3) 0.14 (0.05 , 0.42)
volume of deficit on SPECT 1.20 (per 25ml) (1.03 , 1.40)
age 1.39 (per decade) (1.02, 1.88)
Model 5.2 volume of deficit on SPECT 1.31 (per 25ml) (1.14, 1.49)
Model 5.3 volume of deficit on SPECT 1.65 (per 25ml) (1.09 , 2.50)
* (1) refers to relative risk of poor outcome for PACI compared to TACI, (2) refers to 
POCI compared to TACI, and (3) refers to LACI compared to TACI. Cl, confidence 
interval.
Table 5.4 Sensitivity to poor outcome, specificity, positive predictive value, 
and overall accuracy for models 5.1. 5.2 and 5.3
Model Sensitivity Specificity Positive predictive 
value
Overall
accuracy
5.1 (n=165) 0.64 0.77 0.65 0.72
5.2 (n=180) 0.47 0.79 0.60 0.66
5.3 (n=28) 0.46 0.94 0.83 0.75
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5.4 Discussion
It is now widely accepted that a relationship exists between rCBF on SPECT and 
functional outcome of acute stroke. Our model predictions indicate that SPECT gives 
useful prognostic information, particularly if performed within 16 hours of stroke onset. 
Our results suggest a lower predictive value of SPECT for stroke outcome than reported 
in previous studies based on smaller groups of patients. (Giubilei et al, 1990; Mountz et 
al, 1990) The endpoint we used, functional outcome one year after stroke, may have 
contributed to this lower predictive value when comparing our study to those which 
considered outcome at, for example, one month. (Laloux et al, 1995) Our longer delays 
in SPECT scanning from stroke onset, combined with the presence of luxury perfusion, 
may have reduced the apparent blood flow deficit size. This may have weakened the 
relationship between deficit volume and functional outcome, as suggested by the stronger 
correlation between deficit volume and outcome in patients scanned within 40 hours or 
16 hours of onset. Moretti et al. (1990) showed that HMPAO SPECT images in the 
subacute phase (48 hours to 4 weeks after onset) were less sensitive for volume of lesion 
measures because hyperaemia masks underlying tissue ischaemia. Other studies (Mountz 
et al, 1990; Davis et al, 1993) restricted the type of stroke included, for example 
investigating cortical strokes only. Mountz et al. (1990) investigated recovery from 
stroke rather than measuring absolute outcome. This reduced the variability in the 
outcome measure by correcting for the initial severity of the stroke. In our study, despite 
stronger correlations between SPECT parameters and functional outcome, outcome 
prediction within some homogeneous subgroups of patients was no more accurate than 
in all 180 patients. This was true for the patients scanned within 40 hours of onset and 
for the subgroups defined by the OCSP clinical classification. However, in patients 
scanned within 16 hours of onset, outcome prediction was substantially better.
Other factors which may influence spontaneous outcome at one year include stroke 
recurrence, surgical intervention, recruitment into clinical trials and availability of 
rehabilitation resources. Six of the 171 patients in our cohort with detailed follow up 
information on hospital admissions were admitted to hospital with a further ischaemic 
stroke. Of these six, one patient died and the other five attained one year Barthel scores
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of 60 or more. Two patients underwent carotid endarterectomy and had good functional 
outcome at one year. Sixteen percent of the patients in this cohort were enrolled in trials 
of neuroprotective or antihaemostatic agents, roughly two-thirds of whom received 
active treatment. However, none of the agents tested in these trials has yet been shown 
to influence functional outcome. All patients were afforded the same access to 
physiotherapy, speech therapy and occupational therapy.
It should be noted that the estimates of the accuracy of the logistic regression predictions 
are likely to be over-optimistic. This is because the accuracy of the model has been 
assessed on the data from which it was derived. Testing of the model predictions on an 
independent sample of patients from the same population would give a more realistic 
assessment of the predictive value of the SPECT and clinical data.
The presence of an increased HMPAO count rate was not a prognostic factor, the 
observed proportions of poor outcomes in patients with and without signs of luxury 
perfusion being almost identical. However, our study was not designed specifically to 
detect luxury perfusion, and patients were scanned soon after stroke onset. Patients 
were scanned only once with each of SPECT and CT, and in many cases not long enough 
after onset for luxury perfusion to have occurred. The presence of luxury perfusion is 
most common 11-13 days after onset. CJorgensen et al, 1994b) Our study reflects the 
use of SPECT in actual clinical practice where serial scanning of patients is not 
practicable.
A recent study (Gompertz et al, 1994) which prospectively evaluated a prognostic score 
(Allen, 1984) based on clinical features alone, found that the score predicted outcome 
correctly in 69% of cases. When tested against predictions obtained from volumetric 
analysis of SPECT images (Davis et al, 1993), this clinical score was found to be a better 
prognostic method. Alexandrov et al. (1993) derived a “cerebral perfusion index” by 
combining SPECT data with information from transcranial Doppler studies. This cerebral 
perfusion index performed better than the Canadian neurological scale (CNS) in 
predicting outcome at two weeks after stroke. However, a study by Bowler et al. 
(1996) suggested that CNS assessment at the acute stage predicts outcome better than 
does SPECT. Our results agree with those obtained by Bowler et al.: infarct volume on
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SPECT predicts outcome, while luxury perfusion does not. The /7-values for variables 
entering model 5.1 also indicate that clinical data may have a stronger relationship with 
outcome than SPECT data, if SPECT is not performed soon after stroke onset.
In conclusion, SPECT studies afford prognostic information in acute stroke. The 
accuracy of outcome prediction using SPECT data depends on the time interval between 
stroke onset and SPECT. Our data suggest that clinically useful predictions are obtained 
when SPECT is performed within 16 hours of stroke onset. However, scanning patients 
within this time limit may prove difficult in actual clinical practice. Combinations of 
radionuclide, ultrasound, and clinical methods may also be considered in order to obtain 
improved prognostication.
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Chapter Six 
Clinical and neurological scales for 
prediction of acute stroke outcome
6.1 Introduction
A recent study has shown that providing predictions of outcome for head injury patients 
alters some aspects of patient management. (Murray et al, 1993) The prognosis of acute 
stroke is also clearly an influential factor on patient management decisions. Choice of 
rehabilitation methods and arrangement of placement for the patient after acute stroke 
unit discharge are strongly dependent on short-term prognosis. As will be explored in 
chapters 9 and 10, both short and long-term prognosis influence strategies for prevention 
of further stroke events.
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Chapters 4 and 5 investigated prediction of stroke outcome using radionuclide and 
radiological methods. In this chapter we look at the use of clinical and neurological 
assessments for outcome prediction.
Several multivariate scoring systems have been developed with the sole aim of predicting 
outcome. Some of these were designed to be used a few days after stroke onset, (Frithz 
and Wemer, 1976; Wade et al, 1983; Allen, 1984) while others were intended for use 
several weeks after stroke. (Prescott et al, 1982; Fullerton et al, 1988) A recent 
evaluation (Gladman et al, 1992) compared five multivariate prognostic scoring systems 
with simple univariate predictors of outcome such as level of consciousness, and 
concluded that multivariate scoring systems, when applied outwith the context of their 
development, fare no better than simple predictors.
The OCSP classification (Bamford et al, 1991) categorised patients into four groups on 
the basis of clinical presentation. Although not expressly designed for prediction of 
outcome, the four categories have widely varying survival and rehabilitation prospects. 
(Bamford et al, 1991)
Stroke scales were developed for a variety of reasons, including monitoring neurological 
status for deterioration (Cote et al, 1986) and adjusting final outcome for initial severity 
of stroke in clinical trials. (Brott et al, 1989a) Whilst the purpose of many of these 
scales has not been explicit, their primary uses have been (1) to compare the baseline 
stroke severity of patient groups and (2) to quantify neurological recovery over time. In 
effect, impairment scales have thus often been used to predict outcome despite not 
having been designed for this purpose.
In this chapter, section 6.2 evaluates the ability of the Guy’s prognostic score (Allen, 
1984) to predict acute stroke outcome in a setting outwith the context of its 
development. Following this evaluation, a comparison is made in section 6.3 of outcome 
prediction using the National Institutes of Health Stroke Scale (Brott et al, 1989a) 
(NIHSS), the Canadian Neurological Scale (Cote et al, 1986) (CNS), the middle cerebral 
artery neurological scale (Orgogozo et al, 1983; Orgogozo and Dartigues, 1986) 
(MCANS), the Guy’s prognostic score and the OCSP classification. Finally, in section 6.4,
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an attempt is made to develop a new prognostic score of greater local relevance using a 
combination of these established scales and information from the ASU database.
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6.2 Evaluation of the Guy’s prognostic score
6.2.1 Introduction
The Guy’s prognostic score was derived from and evaluated in a group of 137 patients 
who survived the first 24 hours after an acute stroke. The score performed well in these 
patients, partly because it was evaluated in the patients whose data were used to derive 
the score. The score was further evaluated in a new sample of 361 patients from several 
hospitals in a different geographical location, where a simplified version of the score was 
also developed. (Gompertz et al, 1994) As one would expect, the score did not perform 
as well in this independent set of patients. We aimed to evaluate the Guy’s prognostic 
score in a large sample of acute stroke patients to determine its applicability to the 
population of ASU patients.
6.2.2 Subjects and methods
Chapter 1.3 describes the admission criteria and protocol of the ASU of the Western 
Infirmary, Glasgow. The patients in this evaluation were a series of consecutive 
admissions to the ASU. Patients with TLA, RIND or stroke were included. Patients with 
subarachnoid haemorrhage or diagnoses other than stroke were excluded from the study.
Table 6.1 gives the clinical features which are combined to form the Guy’s prognostic 
score. The Guy’s score was calculated for each patient using information from the ASU 
clinical database. Two methods of dealing with missing data were used. The first was to 
exclude from the analysis the patients in whom any of the required data was missing. 
The second was to assume that if information on a symptom was unavailable, then the 
symptom itself was absent. This second method of dealing with missing data was 
employed in the original development of the Guy’s prognostic score. The analysis was 
performed on both data sets.
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Table 6.1 Components of the Guv’s prognostic score
Clinical feature Guy’s score
complete paralysis of worst limb (Medical -12
Research Council grade 0 or 1)
hemiparesis + hemianopia + higher cerebral -11
dysfunction*
drowsy or comatose after 24 hours -10
loss of consciousness at onset -9
age (years) - (age x 0.4)
uncomplicated hemiparesis + 8
constant + 40
1 higher cerebral dysfunction: dysphasia, perceptual or cognitive impairment
Outcome follow-up was by record linkage (Kendrick and Clarke, 1993) to death records 
from the Registrar General of Scotland, and to hospital discharge records to obtain 
information on medical events post-stroke. Outcome was categorised as alive at home, 
alive in care, or dead, at each of two, three, six and twelve months after stroke.
The main analysis used ROC curves (Altman, 1991) to depict the sensitivity and 
specificity to poor outcome (alive in care, or dead) at several cut-off points on the Guy’s 
score. Confidence intervals were calculated for the sensitivity, specificity and overall 
predictive accuracy of the prognostic score.
6.2.3 Results
1517 consecutive admissions to the ASU with diagnosis of TIA, RIND or stroke were 
included in this study. The Guy’s score could be calculated from the ASU database for 
1388 patients, using the convention that if data were missing for a clinical feature, it was
105
Chapter Six: Predicting acute stroke outcome
assumed to be absent. Outcome data were unavailable on 463 of these, largely because 
the time required for obtaining follow-up information had not elapsed, and so 925 
patients were included in the analysis. CT was performed on 888 patients: 815 (91.8%) 
were diagnosed as ischaemic stroke, 64 (7.2%) as intracerebral haemorrhage and 9 
(1.0%) as haemorrhagic infarction. If cases with any missing data on clinical features 
were excluded from the analysis, Guy’s score could be calculated on 1145 patients. 763 
of these had outcome data available.
Table 6.2 shows the distribution of patient outcome at each of two, three, six and twelve 
months after stroke. Figure 6.1 shows the ROC curves for prediction of poor outcome at 
these four time points, for the 925 patients in whom missing data was coded as symptom 
absent. The ROC curves for the patients with complete data were almost identical to 
these. A cut-off point on the Guy’s score, predicting patients scoring below five to have 
a poor outcome, appeared to give the best performance in discriminating between good 
and poor outcome. Table 6.3 gives the sensitivity to poor outcome, specificity and 
overall predictive accuracy, at each of the follow-up times, when the cut-off point of five 
was used, for the group of 925 patients with complete or near-complete data.
Table 6.2 Changes in patient status over time
2 months 3 months 6 months 12 months
Alive at home 508 (55) 554 (60) 570 (62) 555 (60)
Alive in care 219 (24) 157 (17) 108 (12) 79 (9)
Dead 197 (21) 213 (23) 246 (27) 291 (31)
Figures are the number of patients (percentage of patients) in each category at a given 
time
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Figure 6.1 ROC curves for prediction of poor outcome at each follow up time point 
using the Guy’s prognostic score.
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Table 6.3 Sensitivity, specificity and overall predictive accuracy of Guv’s 
prognostic score
sensitivity 
(95% Cl)
specificity 
(95% Cl)
overall accuracy 
(95% Cl)
2 months 0.64 (0.59,0.68) 0.81 (0.78,0.85) 0.73 (0.71,0.76)
3 months 0.66 (0.61,0.71) 0.79 (0.76 , 0.83) 0.74 (0.71,0.77)
6 months 0.66 (0.61,0.70) 0.78 (0.74 , 0.81) 0.73 (0.70,0.76)
12 months 0.63 (0.58,0.68) 0.77 (0.73 , 0.80) 0.71 (0.68,0.74)
Sensitivity, specificity and predictive accuracy are calculated using the cut-off point of 5 
on the Guy’s prognostic score at each time point.
6.2.4 Discussion
Seventy four percent of three-month outcomes were correctly predicted at the chosen 
cut-off point on the Guy’s score in this evaluation. The results of this study are generally 
in agreement with those from a previous evaluation (Gompertz et al, 1994), despite large 
differences in case-mix between the patient populations. 62% of patients from the ASU 
had a good outcome six months after stroke, while only 31% of patients from the 
evaluation study by Gompertz had such an outcome. Some of this difference may be 
accounted for by the different outcome measurements used. It does appear that the 
Guy’s score gives consistent performance in these two differing populations.
Although the performance of the Guy’s score was adequate, there remained a substantial 
proportion of patients in whom the outcome was not correctly predicted. In some cases 
this may be due to differences in characteristics of the ASU patients and those in whom 
the score was developed. For example, the derivation cohort consisted of patients aged 
under 76 and surviving for 24 hours following the stroke. Neither of these restrictions 
was in place in the ASU patient cohort.
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We now go on to investigate methods for improving acute stroke outcome prediction. 
Section 6.3 compares the prediction of acute stroke outcome using the Guy’s score, 
neurological scales and the OCSP classification, and section 6.4 derives a new prognostic 
score from these established scales and information available in the ASU database.
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6.3 Comparison of neurological scales and clinical scoring 
systems for acute stroke prognosis
6.3.1 Introduction
Stroke scales exist principally as a result of clinical trials, and their existence reflects the 
heterogeneity of stroke patients and attendant difficulties in reliably assessing outcome 
with respect to disability or neurological deficit. Scales seek to quantify different aspects 
of function within the framework of the World Health Organization hierarchy of 
impairment, disability and handicap. (World Health Organization, 1980) Since the 
introduction of the Mathew scale (Mathew et al, 1972), there has been a steadily 
increasing number of scales which seek to quantify neurological impairment. These 
impairment scales involve scoring various modalities of neurological function for an 
individual and then summing the scores to provide an index of neurological status. 
Baseline measurements on the CNS predict functional outcome six months after stroke. 
(Cote et al, 1989) Acute scores on the NIHSS correlate with both CT infarct volume 
(Brott et al, 1989b) at 7-10 days after stroke and functional outcome (Brott et al, 1989a) 
at three months. Stroke assessment scales should not, however, be used as a measure of 
functional outcome itself, since impairment scales only partly explain functional health. 
(De Haan et al, 1993)
Although neurological scales were not designed specifically for the prediction of 
outcome, they have often been used for this purpose. We sought to determine the best 
statistical model for predicting outcome at three months after stroke using baseline 
measures on three stroke scales [MCANS, (Orgogozo et al, 1983; Orgogozo and 
Dartigues, 1986) CNS (Cote et al, 1986) and NIHSS (Brott et al, 1989a)], a specifically 
designed prognostic score [the Guy’s prognostic score (Allen, 1984)], and a clinical 
classification of stroke type [the OCSP classification (Bamford et al, 1991)].
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6.3.2 Subjects and methods
Chapter 1.3 describes the admission criteria and protocol of the ASU of the Western 
Infirmary, Glasgow. The patients included in this study represent a series of consecutive 
admissions to the ASU. Patients whose symptoms were found to be caused by a 
condition other than stroke were excluded from the analysis.
A single experienced observer assessed each of the patients within 72 hours of admission 
according to the NIHSS, CNS, and MCANS and the OCSP classification. The originally 
described version of the NIHSS was used for all patients. The Guy’s prognostic score 
was derived for each patient using information from the ASU clinical database.
Outcome follow-up was by record linkage (Kendrick and Clarke, 1993) to death records 
from the Registrar General of Scotland, and to hospital discharge records to obtain 
information on medical events post-stroke. Outcome was categorised as alive at home, 
alive in care, or dead at each of two, three, six and twelve months after stroke. Outcome 
at three months was chosen as the outcome measure for the subsequent multivariate 
analysis. This practical outcome measure is a marker for three month functional 
outcome, an endpoint commonly used in trials of therapeutic agents in acute stroke. (The 
European Co-operative Acute Stroke Study, 1995)
Throughout the analysis, non-parametric methods were used, since stroke scales provide 
ordinal level data which are not Normally distributed. Correlations between the stroke 
scales and the Guy’s score were expressed using the Spearman rank correlation 
coefficient. Kruskal-Wallis tests were used to investigate differences in median scores 
between patients in the alive at home, alive in care, and dead outcome groups. A %2 test 
was used to detect any association between OCSP classification and placement. 
Receiver-operating characteristic (ROC) curves were used to assess the usefulness of the 
individual scores in predicting whether outcome was poor (alive in care or dead) or good 
(alive at home).
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Stepwise logistic regression (Engelman, 1990) was used to assess which subset of the 
variables best predicted good or poor outcome at three months as defined above. This 
sequential procedure first includes the best predictor variable, then the next best 
predictor variable, and so on until no significant variables remain outside the model. 
Logistic regression estimates the probability of poor outcome for each patient and by 
choosing a cut-off probability the patients may then be predicted as having a good or 
poor outcome. These predictions may be compared with the true outcomes to obtain the 
sensitivity and specificity of the procedure for identifying patients who will have a poor 
outcome. A cut-off probability of 0.5 was chosen. The logistic regression analysis was 
repeated after the exclusion of patients with clinical signs of posterior circulation stroke, 
since the CNS was designed for use in carotid territory stroke with motor signs and the 
MCANS for use in middle cerebral artery strokes. This avoids a biased comparison of the 
stroke assessment scales since the NIH is the only one to include signs indicative of 
vertebrobasilar stroke such as ataxia.
6.3.3 Results
Four hundred and eight patients were included in this study. A non-stroke diagnosis was 
reached in 29 patients (6 old stroke, 6 seizure activity, 5 tumour, 4 non-organic, 8 
others), who were therefore excluded from the analysis. Primary intracerebral 
haemorrhage was diagnosed in 43 patients (11.4% of strokes), and haemorrhagic infarct 
in 2 patients (0.5%). The remaining 334 patients (88.1%) were diagnosed as having 
ischaemic stroke. The low proportion of haemorrhagic infarction may be due to early CT 
scanning of patients in our ASU, often within 24 hours of onset. At this stage 
haemorrhagic transformation is less likely to be observed. Outcome data were 
unavailable in 6 patients due to no matching records being identified by record linkage. 
Data on 373 patients were therefore available for analysis. The median age was 69 
(range 22-96, interquartile range 59-77). There were 191 male patients (51.2%).
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Table 6.4 shows the placement of patients at each of two, three, six and twelve months 
after admission to the ASU. Table 6.5 shows pairwise Spearman rank correlation 
coefficients among the four scores being tested. Table 6.6 shows the median of each of 
the scores at each level of the OCSP classification. Table 6.7 gives the median of each 
score according to the three month outcome grouping. For each score, a Kruskal-Wallis 
ANOVA showed highly significant differences in median baseline score betwieen outcome 
groups ip < 0.001 in each case). Table 6.8 shows the relationship between OCSP 
classification and outcome group. A x2 test identified a highly significant association 
between OCSP classification and outcome group ip < 0.0001). Figure 6.2 gives ROC 
curves for prediction of three month ‘poor outcome’ for each of the numerical scores 
and the OCSP classification. A comparison of the predictive power of variables can be 
made by assessing which curve approaches the top-left comer of the plot most closely. 
The Guy’s prognostic score and the OCSP classification appear to be weaker predictors 
of outcome than the neurological scales, of which the NIHSS seems narrowly to be the 
best.
Table 6.4 Changes in patient status over time
2 months 3 months 6 months 12 months
Alive at Home 220 (59) 229 (61) 237 (64) 231 (62)
Alive in Care 77 (21) 62 (17) 41 (11) 34(9)
Dead 76 (20) 82 (22) 95 (25) 108 (29)
Figures are the number of patients (percentage of patients) in each category at a given 
time
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Table 6.5 Correlations between neurological and Guv’s prognostic scores
MCANS NIHSS Guy’s
CNS 0.977 -0.948 0.397
MCANS — -0.950 0.386
NIHSS — — -0.380
Correlations given are Spearman rank correlation coefficients
Table 6.6 Median neurological and Guv’s prognostic scores for each level of 
the OCSP classification
CNS MCANS NIHSS Guy’s
TACS 30 20 18 -4.9
OCSP
classification
PACS 90 75 6 1.0
POCS 95 77.5 5 1.8
LACS 90 75 4.5 0.1
other 115 100 0 1.8
TACS, total anterior circulation syndrome; PACS, partial anterior circulation syndrome; 
POCS, posterior circulation syndrome; LACS, lacunar syndrome; other, none of the above.
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Table 6.7 Median baseline neurological and Guv’s prognostic scores according 
to outcome group at three months
CNSf MCANSt NIHSSf Guy’s*
Alive at Home 95 80 4 1.6
Alive in Care 50 35 14 -1.8
Dead 25 20 18 -8.5
f Kruskal-Wallis ANOVA comparison of median scores across outcome groups: /?<0.001.
Table 6 .8 RelationshiD between OCSP classification and outcome c x o u d  at
three months
Alive at Home Alive in Care Dead Total
TACS 21 (25) 24 (29) 38 (46) 83
PACS 116 (73) 21 (13) 23 (14) 160
POCS 35 (67) 3(6) 14 (27) 52
LACS 51 (78) 11 (17) 3(5) 65
Figures are number of patients (percentage of patients) in each outcome group, for each 
level of the OCSP classification. y£ test of association: X2 = 72.14, df = 6,p < 0.0001
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Figure 6.2 ROC curves for prediction of three month outcome using neurological 
scales and Guy’s prognostic score.
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Figure 6.2 (continued) ROC curves to assess prediction of three month outcome using 
neurological and Guy’s prognostic scores and the OCSP classification.
Figures on curves correspond to the cut-off point above which (for NIHSS) or below 
which (for CNS, MCANS and Guy’s score) poor outcome was predicted.
For the OCSP classification, categories were ordered by increasing likelihood of good  
outcome: TACS, POCS, PACS, LACS. The figures on the curves represent the following  
cut-off points: (1) N o patients predicted to have poor outcome, (2) TACS patients only 
predicted to have poor outcome, (3) TACS and POCS patients predicted to have poor 
outcome, (4) TACS, POCS and PACS patients predicted to have poor outcome, (5) All 
patients predicted to have poor outcome.
Results are presented in terms of sensitivity (proportion of poor outcomes correctly 
predicted) and specificity (proportion of good outcomes correctly predicted).
In the stepwise logistic regression model, the NIHSS ip < 0.0001) was the first variable to 
be included. The model using the NIHSS only gave a sensitivity to poor three-month 
outcome of 0.71 (95% confidence interval [0.64 , 0.79]), a specificity of 0.90 [0.86 , 
0.94], a positive predictive value of 0.82 [0.75 , 0.89], and an overall predictive accuracy 
of 0.83 [0.79 , 0.87]. Guy’s prognostic score was the next variable to be added to the 
model. However, although this variable was statistically significant ip = 0.0016), the 
number of correct predictions decreased slightly (sensitivity 0.70 [0.62 , 0.77], specificity
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0.89 [0.85 , 0.93], positive predictive value 0.80 [0.73 , 0.87], overall predictive 
accuracy 0.82 [0.78 , 0.86]). None of the other variables (CNS, MCANS, OCSP 
classification) was significant Prediction using the model based on NIHSS score alone is 
equivalent to choosing a cut-off point of 13 on the baseline NIHSS, and predicting all 
patients scoring 13 or more as having a poor outcome. Despite its statistical 
significance, the model using NIHSS alone did not give substantially greater accuracy than 
those using the CNS or MCANS alone.
To investigate further the apparent superiority of the NIHSS over the CNS, MCANS, Guy’s 
prognostic score and OCSP classification, each variable in turn was forced into the model. 
Stepwise logistic regression was then used to test if any of the other variables 
significantly improved the fit of the model. Table 6.9 gives the results of this additional 
modelling. In each case the NIHSS was found to add extra predictive information to the 
variable which was initially forced into the model. However, these more complex models 
did not give better predictive accuracy than the model using the NIHSS only.
Table 6.9 Additional logistic regression modelling
Variable 
forced into 
model
Other
significant
variables
Sensitivity 
(95%  Cl)
Specificity 
(95% Cl)
Positive 
predictive 
value 
(95%  Cl)
Overall 
accuracy 
(95% Cl)
CNS NIHSS, Guy’s 0.71
(0.64,0.79)
0.89
(0.85,0.93)
0.81
(0.74,0.88)
0.82
(0.78,0.86)
MCANS NIHSS, Guy’s 0.71
(0.64,0.79)
0.89
(0.85,0.93)
0.80
(0.73,0.87)
0.82
(0.78,0.86)
OCSP
classification
NIHSS, Guy’s 0.69
(0.61,0.77)
0.90
(0.86,0.94)
0.81
(0.74,0.88)
0.82
(0.78,0.86)
Guy’s NIHSS 0.70
(0.62,0.77)
0.89
(0.85,0.93)
0.80
(0.73,0.87)
0.82
(0.78,0.86)
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After excluding patients with posterior circulation events, the results of the stepwise 
logistic regression modelling were identical to those when all patients were considered. 
The NIHSS was the best predictor of outcome, providing extra predictive information 
over the other scores. Table 6.10 shows that the overall accuracy of each scale, except 
for the Guy’s score, was slightly lower than in the whole patient group.
Table 6.10 Comparison of predictive accuracy in all patients and in 304 patients 
without signs of posterior circulation stroke
Model All patients: Non-posterior strokes:
Overall accuracy Overall accuracy
(95% Cl) (95% Cl)
NIH alone 0.83 (0.79 ,0.87) 0.82 (0.77, 0.86)
CNS alone 0.79 (0.76 ,0.85) 0.77 (0.73, 0.82)
MCANS alone 0.79 (0.76 ,0.85) 0.77 (0.72 , 0.81)
Guy’s score alone 0.76 (0.72,0.80) 0.76 (0.72. 0.81)
6.3.4 Discussion
Outcome at three months as assessed by simple and clinically relevant criteria is best 
predicted by the baseline NIHSS score. A score of 13 discriminates, with good predictive 
value, patients likely to be independent from those likely to be dependent. This score 
represents approximately 50% of the practical maximum score on this version of the 
NIHSS. Little additional information is added by Guy’s prognostic score, the OCSP 
classification, or the other acute impairment scales, although all baseline measures 
correlate well with outcome.
None of the acute impairment scales has sought to assess disability, and none was 
designed to provide any indication of prognosis. The use of stroke scales in clinical trials
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to measure either baseline severity or progress has therefore hitherto been based on the 
assumption that the features assessed by a scale are of relevance to disability. In 
contrast, scales designed to predict outcome have not been used widely in clinical trials. 
The OCSP classification is robust and ease of use by clinicians represents a significant 
advantage over numerical systems. However, the lack of a numerically analysable 
component has led to limited uptake for clinical trials.
Most impairment scales, including the MCANS, CNS, the Scandinavian Stroke Scale 
(Scandinavian Stroke Study Group, 1985) and the European Stroke Scale (Hantson et 
al, 1994) (ESS), are weighted very heavily towards motor function in the hemiparetic 
limbs, with minor additional scores for language function, conscious level or hemianopia. 
There has if anything been a tendency to increase the relative importance of the motor 
score and to specify more complex assessments with each new scale. The NIHSS is 
constructed differently, in that each test item is graded, but no significant weighting is 
given to limb function, and many additional items such as ataxia, sensory loss or 
visuospatial perception are also included. However, scoring these additional aspects of 
neurological function may be a mixed blessing since they are often untestable in aphasic 
or comatose patients. Total scores cannot be reliably compared between the NIHSS and 
other scales (Muir et al, 1994), and in clinical use the NIHSS total score has a practical 
ceiling well below its theoretical upper limit due to non-scoring of untestable items. 
Patients with language disorders are particularly likely to produce scores of poor 
comparability between the NIHSS and MCANS or CNS.
Given these differences between stroke scales, why should the NIHSS provide a better 
prediction of three month outcome than either the MCANS or CNS? Unlike the MCANS or 
CNS, the NIHSS is not weighted in an arbitrary fashion towards motor function of limbs, 
but since all tested items are graded more or less equally, rather reflects the overall 
degree of neurological deficit. Whilst limb strength is certainly an important determinant 
of functional recovery from stroke, our results suggest that the MCANS and CNS perhaps 
place unnecessary emphasis on assessment of the degree of weakness over other 
neurological features. An even more heavily motor-weighted scale such as the ESS is 
clearly open to similar criticism. These differences will also be determined by the chosen 
outcome measure since many of the disability scales in current use are similarly heavily
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weighted towards motor function (notably the Barthel Index (Mahoney and Barthel, 
1965)). Simple and robust outcome criteria were chosen for this study since these are of 
greater importance to patients and carers than minor differences in the abstract numbers 
of a rating scale. Our inclusion of patients ‘alive in care’ in the poor outcome group 
reflects the situation in Scotland, where more severely disabled patients are cared for in 
hospital rather than at home.
Where several rating scales for prediction of outcome are available, sensitivity and 
specificity to poor outcome are only two criteria for comparing scales. If there is no 
substantial difference in the predictive accuracy of a number of rating scales, then 
simplicity of use becomes important. The NIHSS requires scoring of a greater number of 
aspects of neurological function than the CNS or MCANS. However, video training in the 
use of the NIHSS is available, which provides a standard for the use of the scale and 
improves interobserver reliability. (Lyden etal, 1994)
Our results suggest that where baseline comparison of treatment groups in a clinical trial 
is required, the NIHSS is sufficiently accurate, and for many trials should be routine. The 
CNS, MCANS and specialised predictive scores offer no useful additional information. 
The NIHSS remains accurate even when patients with vertebrobasilar stroke are not 
considered, a fact which is relevant to the many clinical trials which limit inclusions to 
hemispheric strokes only. For large clinical trials involving centres unfamiliar with stroke 
scales, it may be preferable to ensure baseline homogeneity of groups by the proportions 
of patients in different OCSP categories, since this clinical classification requires no prior 
training and has a well-established relationship with outcome.
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6.4 Development of an alternative prognostic scoring system
6.4.1 Introduction
Section 6.3 has shown that neurological impairment scales such as the NIHSS provide an 
accurate means of predicting outcome after acute stroke. However, it is desirable to 
consider other simple pieces of clinical evidence in addition to, or instead of, established 
neurological scales for three reasons. Some clinical variables, such as history of 
ischaemic heart disease, may provide information on aspects of prognosis which are not 
dealt with by neurological scales. Use of such clinical variables in combination with a 
neurological scale may improve outcome prediction. Alternatively, a combination of a 
small number of simple clinical variables alone may provide outcome prediction which 
approaches the level of accuracy achieved by neurological scales. Using such variables 
for outcome prediction may save time in clinical practice by avoiding the need for 
training in and measurement of complex impairment scales. Finally, developing methods 
for predicting outcome from locally collected data may result in improved prognostic 
accuracy due to the closer relationship between the data and the target population.
6.4.2 Subjects and methods
The data for this analysis of potential prognostic factors in stroke were obtained from the 
group of patients studied for the comparison of neurological and clinical scales in section 
6.3. The outcome data gathered for that comparison were used in this study. The 
outcome measure used in this analysis was three month placement, categorised as good 
(living at home) or poor (living in care or dead).
Clinical, radiological and biochemical variables were studied. Measurements on 
established stroke scales were included: NIHSS, MCANS, CNS, OCSP classification and the
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separate components of the Guy's prognostic score given in table 6.1. Data on other 
variables were drawn from the ASU database. These covered the patient’s medical 
history, results of clinical and radiological investigations, and results of biochemistry 
analysis. In addition, transformations of some clinical variables were made if these were 
thought likely to be more clinically relevant. For example, a measurement of the total 
MRC power grading on the limbs on the side affected by the stroke was included, as well 
as the grading on each limb separately. The verbal component of the Glasgow coma 
scale was excluded to avoid spuriously low scores in patients with language disorders. 
The score therefore ranged from 2 to 10 rather than from 3 to 15.
Univariate analysis was performed to identify which of the 53 variables were most likely 
to be useful in acute stroke prognosis. Associations between categorical variables and 
three month outcome group were investigated by x2 tests. Median values of continuous 
variables, or ordered categorical variables with a large number of categories, were 
compared between the two outcome groups by Mann-Whitney test.
The variables for which the univariate testp -value was less than 0.1 then were entered in 
multivariate analysis to determine which set of variables best predicted outcome. 
Stepwise linear discriminant analysis was performed in order to obtain a prognostic score 
which was easy to calculate. All subset linear regression of the variables was performed 
in order to compare the relative performance of different sets of variables and to identify 
worthwhile sets of variables which may have been missed by the stepwise procedure. 
The accuracy of the score resulting from the discriminant analysis was interpreted using 
ROC curves. The stepwise linear discrimination was repeated after several of the ordered 
categorical variables were dichotomised in an attempt to fulfil the assumptions of the 
discriminant analysis more completely. Linear discriminant analysis was also used to 
identify the best set of prognostic variables obtained when established stroke scales were 
excluded from the analysis. This was done to ascertain whether a valid prognostic score 
could be obtained using a few simple clinical variables. Finally, after each phase of linear 
discriminant analysis stepwise logistic regression was performed in order to confirm the 
results using a method which did not require multivariate Normality.
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6.4.3 Results
Data on 379 patients with a diagnosis of acute stroke were used for this study. Outcome 
data were unavailable in six patients, and so the analysis was performed in 373 patients. 
Table 6.11 shows the results of the univariate screening analysis of 53 variables for 
differences between the good outcome and poor outcome groups. These results were 
used to select a subset of these variables for multivariate analysis. 31 variables with a p- 
value of less than 0.1 were identified for multivariate analysis. Although plasma glucose 
level on admission had a /7-value of 0.017, it was not included in multivariate analysis 
because it was unavailable in 31% of patients. Similarly, the measurement of stroke 
lesion size on CT (p < 0.0001) was not recorded for 10% of patients and was excluded 
from the multivariate analysis.
Some unusual findings arose from the univariate analysis. Patients with a history of 
alcohol consumption were more likely to have a good outcome. Female patients were 
more likely to have a poor outcome than males. In the case of other significant variables, 
any observed effects were consistent with those from previous studies on acute stroke 
outcome. It should be emphasised that the unusual findings are based on univariate 
analysis; multivariate analysis is required to determine which variables are independently 
related to good or poor stroke outcome.
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Table 6,11 Univariate analysis of 53 variables with respect to outcome grouping
Variable Test statistic df p-value
age M l = 67, M2 = 73 < 0.0001
marital status 1.014 1 0.3139
sex 5.219 1 0.0223
previous stroke 1.312 1 0.2520
previous TIA 2.835 1 0.0922
family history of ischaemic heart disease 0.013 1 0.9092
family history of stroke 0.106 1 0.7447
diabetes mellitus 1.974 1 0.1600
hyperlipidaemia 0.222 1 0.6375
history of alcohol consumption 6.024 1 0.0141
previous MI 0.493 1 0.4826
angina 0.728 1 0.3935
intermittent claudication 1.609 1 0.2046
smoking 2.395 1 0.1217
hypertension 1.461 1 0.2268
AF 12.26 1 0.0005
headache 1.67 1 0.1963
vomiting 2.147 1 0.1428
loss of consciousness at stroke onset 59.367 < 0.0001
visual loss 2.456 1 0.1171
dysphasia 4.708 1 0.0300
altered sensation 0.146 1 0.7024
poor co-ordination 1.465 0.4807
neglect 15.782 1 0.0001
hemianopia 16.504 1 <0.0001
facial weakness 18.253 1 < 0.0001
gaze paresis 12.244 1 0.0005
abnormal pupils 1.491 1 0.2221
diplopia 0.639 1 0.4241
clinical diagnosis (stroke vs RIND vs TIA) 23.409 2 < 0.0001
size of lesion on CT 37.92 2 <0.0001
CT diagnosis (normal or atrophy vs infarct vs haemorrhage) 21.445 2 < 0.0001
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Table 6.11 (continued) Univariate analysis of 53 variables with outcome erouDinf
Variable Test statistic df p-value
right arm power (MRC grade 0 to 5) 28.102 5 < 0.0001
right leg power (MRC grade 0 to 5) 31.707 5 < 0.0001
left arm power (MRC grade 0 to 5) 30.401 5 < 0.0001
left leg power (MRC grade 0 to 5) 48.282 5 < 0.0001
minimum power on any limb (MRC grade 0 to 5) 74.709 5 < 0.0001
total limb power (0 to 20) Ml = 19, M2 =: 14.5 < 0.0001
minimum total power on one side of body (0 to 10) Ml = 9, M2 = 6 < 0.0001
total leg power (0 to 10) Ml = 10, M2 = 8 < 0.0001
total arm power (0 to 10) Ml = 9, M2 = 7 < 0.0001
plasma glucose (on admission) Ml = 6.1, M2 = 6.8 0.017
plasma glucose (morning after admission) Ml = 6.6, M2 == 6.75 0.868
creatinine Ml = 95, M2 = 96 0.257
Glasgow coma scale (10 vs 9 or less) 58.828 1 < 0.0001
Glasgow coma scale (score from 2 to 10) 67.458 8 < 0.0001
OCSP classification 63.974 3 < 0.0001
CNS Ml = 95, M2 = 35 <0.0001
MCANS Ml = 80, M2 = 25 <0.0001
NIH Ml =4, M2 == 16 < 0.0001
complete paralysis of any limb 64.573 1 <0.0001
uncomplicated hemiparesis 5.666 1 0.0173
hemiparesis + higher cerebral dysfunction + hemianopia 16.979 1 < 0.0001
df, degrees of freedom. MRC, Medical Research Council. Variables outlined in bold 
type have a p-walue less than 0.1. Test statistic and degrees of freedom data refer to x2 
tests. For Mann-Whitney tests, M l gives the median in the good outcome group and 
M2 gives the median in the poor outcome group.
Stepwise linear discriminant analysis selected a group of four variables which best 
differentiated between patients with good and poor outcome. Equation 6.1 gives the 
discriminant score derived from this analysis (score 6A). LOC stands for loss of
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consciousness at onset of the stroke. Variables other than NIHSS are coded as 1 if 
present and 0 if absent. A higher score indicates a greater probability of poor outcome.
Score 6A
0.22 x NIHSS + 1.22 x LOC + 1.11 x com plete paralysis o f  any lim b + 1.17 x AF
(6 .1)
Figure 6.3 shows the ROC curve for score 6A. Table 6.12 gives the ten best-fitting 
regression models containing four variables which were identified in the all subset linear 
regression. The NIHSS appears in all ten regression models. The other variables selected 
include various measures of limb power, loss of consciousness at onset, atrial fibrillation, 
age and previous TIA. The second best fitting regression was very close in performance 
to the first in terms of the adjusted R2 value.
Prognostic score ROC curve
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Figure 6.3 ROC curve for score 6 A, which was described in equation 6.1.
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Stepwise logistic regression on the 31 potential prognostic variables selected NIHSS, loss 
of consciousness at onset, atrial fibrillation and total leg power as significant variables. 
This set o f variables also formed the second best four-variable model in the all subset 
regression (table 6.12).
Table 6.12 Ten best-fitting linear regression sets of variables
R2 (adjusted) variable 1 variable 2 variable 3 variable 4
0.4211 NIHSS LOC CP AF
0.4200 NIHSS LOC AF TLP
0.4144 age NIHSS LOC CP
0.4136 NIHSS LOC AF MTP
0.4135 age NIHSS AF TLP
0.4135 age NIHSS CP AF
0.4133 age NIHSS LOC TLP
0.4129 NIHSS CP TIA AF
0.4126 NIHSS LOC TIA AF
0.4121 NIHSS TIA AF TLP
CP, complete paralysis o f any limb; TLP, total leg power; LOC, loss of consciousness at 
stroke onset; MTP, minimum total power on one side of the body.
After several o f the ordered categorical variables were dichotomised, stepwise linear 
discriminant analysis selected NIHSS, loss o f consciousness at stroke onset (LOC), atrial 
fibrillation (AF), minimum total power on one side o f the body (MTP), and total arm 
power (TAP) as significant predictors o f outcome. Equation 6.2 gives the discriminant 
score obtained from this analysis (score 6B). AF and LOC are, coded as 1 if present and 0 
if absent, and a code o f 1 is given to higher limb power grades and 0 to lower limb power 
grades. A higher score indicates greater probability of poor outcome.
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Score 6B
0.23 x  NIHSS + 1.15 x  LOC + 1.24 x  AF - 3.10 X MTP + 2.15 x  TAP (6.2)
Stepwise logistic regression selected the same variables, with the exception of total arm 
power which was not statistically significant. Figure 6.4 shows the ROC curve for score 
6B.
ROC curve: using dichotomised power measures
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Figure 6.4 ROC curve for score 6B, which was derived from transformed data.
From the prognostic models obtained by selecting from all 31 potential prognostic 
variables, it appears that a general form of model to predict acute stroke outcome is: 
NIHSS + LOC + AF + some measurement of limb power.
The linear discriminant score achieved by selecting from 28 variables (that is, excluding 
established neurological scales) is given in equation 6.3 (score 6C). HH denotes
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homonymous hemianopia, FW facial weakness, TLP total limb power, and IC impaired 
conscious level (Glasgow coma scale below 10 out of 10). Variables other than TLP are 
coded as 1 if present and 0 if absent, and a higher score indicates greater probability of 
poor outcome. The ROC curve for score 6C is illustrated in figure 6.5. The 
corresponding stepwise logistic regression model included the same variables, with the 
exception that OCSP classification was included and homonymous hemianopia was not.
Score 6C
2.15 x LOC + 0.87 XHH + 0.87 x FW + 1.15 XAF - 0.23 x TLP + 1.38 x IC
(6.3)
ROC curve: excluding established stroke scales
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Figure 6.5 ROC curve for score 6C, which was based on simple clinical features.
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Table 6.13 presents the accuracy of the three linear discriminant scores which have been 
derived from the ASU data. Score 6A performed well, although its accuracy was no 
greater than that found for the NIHSS alone in section 6.3. The corresponding logistic 
regression model had an overall accuracy of 82%. The predictive accuracy of score 6B 
was rather lower. The logistic regression model, which contained one variable fewer, 
had an accuracy of 81%, similar to that of the logistic regression model based on the 
untransformed data. Score 6C had a lower proportion of correct predictions than score 
6A. However, this score would be easier to calculate due to the lower number of items 
to be tested on the patient. The corresponding logistic regression model correctly 
predicted the outcome of 78% of patients.
Table 6.13 Predictive accuracy of linear discriminant prognostic scores
Score Cut-off point Sensitivity 
(95% Cl)
Specificity 
(95% Cl)
Overall accuracy 
(95% Cl)
6A 2.5 0.80 0.80 0.80
(0.74, 0.87) (0.75 , 0.85) (0.76 , 0.84)
6B 10 0.75 0.75 0.75
(0.67, 0.82) (0.69 , 0.80) (0.70 , 0.79)
6C -4 0.74 0.77 0.76
(0.67, 0.81) (0.71 , 0.82) (0.72, 0.80)
6.4.4 Discussion
This extensive analysis into the prognostic influence of a wide range of variables has 
highlighted a number of issues. The absence of the OCSP classification from linear 
discriminant score 6C and its presence in the corresponding logistic regression model 
suggest that its non-ordinal categorical structure makes it inappropriate for linear 
discriminant analysis.
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The logistic regression modelling consistently produced more accurate predictions than 
the corresponding discriminant score. This may be partly due to the different modelling 
procedure: while linear discrimination provides an easily calculable score, logistic 
regression may provide a more accurate method of predicting outcome using prognostic 
variables. Alternatively, the assumptions of the logistic regression may be more likely to 
be fulfilled by the prognostic variables being studied.
Although score 6A produced accurate predictions, they were no more accurate than 
those produced by the logistic regression model using NIHSS alone in section 6.3. This 
may indicate that some information in the NIHSS was not utilised because of the 
restrictions of the linear discriminant analysis, in comparison with the logistic regression 
model in section 6.3. It may also reflect the fact that statistical significance of additional 
variables does not necessarily imply substantial improvement in prognostic accuracy. 
This was illustrated in section 6.3: predictions from the model including the NIHSS and 
the Guy’s prognostic score (both of which were statistically significant) were less 
accurate than those from the model including the NIHSS alone.
Discriminant score 6B had lower predictive accuracy than score 6A. It appears that 
information useful to a linear discriminant model was discarded in the transformation of 
the limb power variables. The total arm power variable in score 6B also had the opposite 
effect from that which one would expect: greater total arm power increased the 
probability of poor outcome. This suggests that the assumptions of the linear 
discriminant model were not satisfied. Score 6B is therefore unlikely to be useful in 
practice.
One essential feature of any prognostic score which is to be used in actual clinical 
practice is simplicity. None of the linear discriminant models examined (Guy’s 
prognostic score, scores 6A, 6B and 6C) is sufficiently simple to be applicable in clinical 
practice. A simplification of the calculations involved in measuring the Guy’s prognostic 
score has been presented. (Gompertz et alt 1994) Similar changes could be made in 
scores 6A and 6C to increase their practical relevance. Revised versions of scores 6A 
and 6C, achieved by multiplying through the original score by a common factor and 
rounding coefficients to the nearest integer, are given in tables 6.14 and 6.15
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respectively. These discriminant scores have the advantage that the NIHSS and total limb 
power stand unchanged.
Table 6.14 Simplified version of discriminant score 6A
Clinical feature Contribution to score
NIHSS add NIHSS to score
loss of consciousness at stroke onset + 5
complete paralysis of any limb + 5
facial weakness + 5
Table 6.15 Simplified version of discriminant score 6C
Clinical feature Contribution to score
loss of consciousness at stroke onset + 9
homonymous hemianopia + 4
facial weakness + 4
atrial fibrillation + 5
total limb power subtract total limb power
impaired consciousness (GCS <10) + 6
The original discriminant function for score 6A  was used to obtain the probability of a 
poor outcome over the entire range of possible scores. This mapping is shown in figure 
6.6. A similar graph for score 6C revealed that the linear discriminant model consistently 
overestimated the probability of poor three month outcome. This implies that the data 
used did not match the assumptions of the linear discriminant model closely enough. The
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highly skewed nature (maximum value = upper quartile value) of total limb power may 
have caused this problem. A point estimate of the probability of poor outcome and its 
corresponding 95% confidence interval is given in table 6.16 for each quartile of the 
revised version of score 6C.
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of poor 
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Discriminant score 6A (simplified version)
Figure 6.6 Predicted probabilities of poor three month outcome using score 6A.
Table 6.16 Observed probabilities in quartiles of revised version of score 6C
Score 6C 
(revised)
Probability of 
poor outcome
95% Cl
<-16 0.13 (0.07, 0.19)
-15 to -13 0.19 (0.10 , 0.28)
-12 to -3 0.44 (0.33 , 0.54)
>-3 0.83 (0.75 , 0.90)
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6.4.5 Future work and implications for clinical practice
Sections 6.3 and 6.4 illustrated the prognostic value of the NIHSS, despite the fact that it 
was not developed for this purpose. One possible extension to the work described in this 
chapter would be to analyse the separate components of the NIHSS in order to re-weight 
them according to their prognostic influence. Components shown not to be related to 
outcome could be removed from the prognostic score. These changes could result in an 
abbreviated score which relates to outcome even more strongly than the original NIHSS.
If staff are already experienced in the use of the NIHSS or can be trained in its use, the 
revised version of score 6A should be used in practice to obtain a probability of poor 
outcome for acute stroke patients. Training in the measurement of the NIHSS should be 
included in protocols for new acute stroke services. If the use of the NIHSS is not 
possible due to time or other constraints, the performance of the revised version of score 
6C indicated that it has potential as a useful and simple prognostic score. Its overall 
predictive accuracy (76%) is close to that of score 6A (80%) which includes the NIHSS.
As will be further discussed in chapters 10 and 11, a prognostic score will be useful when 
clinical management decisions regarding rehabilitation methods and secondary stroke 
prevention are required.
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Chapter Seven 
Hyperglycaemia independently predicts 
poor outcome following acute stroke
7.1 Introduction
Diabetic patients have worse survival and recovery prospects after acute stroke than their 
non-diabetic counterparts. In addition to this, hyperglycaemia in the acute phase of 
stroke has also been established as a predictor of poor outcome in non-diabetics. 
However, there is dispute as to whether an elevated plasma glucose level is 
independently associated with a poor prognosis. Several studies have suggested that 
hyperglycaemia in non-diabetic patients following acute stroke is in fact a stress response 
(O'Neill et al, 1991; Murros et al, 1992; Murros et al, 1993; Woo et al, 1990; Woo et 
al, 1988; Candelise et al, 1985; Melamed, 1976; Toni et al, 1992) reflecting more severe 
neurological damage.
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Others have suggested that hyperglycaemia influences outcome independently of stroke 
severity. (Jorgensen et al, 1994a; van Kooten et al, 1993; Kiers et al, 1992) This being 
the case, it would naturally be of interest to investigate whether reversing 
hyperglycaemia in the acute phase of stroke reduced its adverse effect on survival.
We studied the effect of hyperglycaemia on stroke mortality and morbidity by assessing 
the effect of hyperglycaemia on outcome after adjusting for known prognostic factors. 
We describe our findings in a cohort of unselected patients admitted to the ASU.
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7.2 Subjects and methods
The admission criteria of the ASU are described fully in chapter 1.3. All patients have 
their stroke subtype categorised on the basis of clinical features according to the OCSP 
classification. (Bamford et al, 1991) This clinical classification divides patients into four 
groups: total anterior circulation syndrome (TACS), partial anterior circulation syndrome 
(PACS), posterior circulation syndrome (POCS) or lacunar syndrome (LACS).
Biochemistry is analysed routinely in all patients on the day of admission and early the 
following morning. Plasma glucose is measured on both these occasions, giving one 
random and one fasting glucose measurement. In this study we used the random glucose 
measurement for each patient if it was taken; if not, we used the fasting measurement. 
Glucose level was recorded both as a continuous variable and a binary one (< 8 mmol/L, 
normoglycaemic; > 8 mmol/L, hyperglycaemic). The upper limit of the normal range for 
fasting plasma glucose level is 6.5 mmol/L. Since not all glucose measurements taken in 
our study were fasting, 8 mmol/L was used as the cut-off point for hyperglycaemia. 
Other potential prognostic variables which we considered were: age, stroke type 
(ischaemic or haemorrhagic), admission blood pressure (systolic and diastolic), smoking 
status (non-smoker, ex-smoker or current smoker), resolution time of symptoms (< 72 
hours or > 72 hours), and OCSP category.
The subjects in this study presented to the ASU between June 1990 and December 1993. 
Previously diagnosed diabetics were included in the study but the data from these 
patients were analysed separately since there is evidence that hyperglycaemia affects 
outcome differently in diabetic patients. (Jorgensen et al, 1994a)
Survival and placement follow-up were by record linkage (Kendrick and Clarke, 1993) 
to the Scottish Deaths Register and to a national database of hospital discharge records. 
Outcome placement was coded as: alive at home, alive in care, or dead. This placement 
information was recorded at two, three, six and twelve months after admission.
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Baseline variables in diabetic and non-diabetic patients were compared using x2 tests for 
discrete variables and Mann-Whitney tests for continuous variables. Differences in the 
distributions of potential prognostic variables between placement categories at three 
months were assessed by x2 test for discrete variables and Kruskal-Wallis analysis of 
variance for continuous variables. The main analysis used Cox’s proportional hazards 
regression model (Cox, 1972) to estimate the effect of hyperglycaemia on survival after 
stroke. A separate baseline survival function was fitted for each of the four OCSP 
categories since including OCSP classification as an explanatory variable in the regression 
was unlikely to fulfil the proportional hazards assumption. The effect of plasma glucose 
level was determined after entering other significant prognostic variables (selected from 
age, stroke type, resolution time of symptoms, smoking status, and systolic and diastolic 
blood pressure). The assumption of proportional hazards was checked for all variables 
included in the model. The effect of hyperglycaemia on outcome was further explored 
by coding three-month outcome as good (alive at home) or poor (alive in care, dead) and 
then performing a stepwise logistic regression analysis. (Engelman, 1990) We tested 
whether hyperglycaemia was independently associated with this outcome after adjusting 
as necessary for age, time to resolution of symptoms, stroke subtype, OCSP classification 
category, smoking status, and systolic and diastolic blood pressure. In the proportional 
hazards and logistic regression analysis, a quadratic relationship between blood pressure 
and outcome was permitted.
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7.3 Results
811 patients with computed tomography confirmed acute stroke and plasma glucose data 
were included in the study. 77% of patients had plasma glucose measured on admission; 
in the remaining 23% the measurement was taken early on the morning after admission. 
Plasma glucose was measured at a mean of 3.6 hours after admission to the stroke unit 
and a mean of 14.4 hours after stroke onset. Sixty-one (8%) patients were diabetic, 
seven (1%) being insulin-dependent. The characteristics of these patients are compared 
with those of non-diabetic patients in table 7.1. As expected median plasma glucose 
level and the proportion of patients with hyperglycaemia was higher in the diabetic 
group. The main analysis was restricted to the 750 non-diabetic patients. Fifteen 
patients were lost to follow-up for placement (due to failure of hospital discharge record 
linkage) but not for survival. The mean follow-up time was 1.65 years.
Table 7.2 shows the number of patients in each outcome category over time. Table 7.3 
gives the distributions of patient variables across the three placement categories. Table 
7.4 shows the results of the proportional hazards modelling. Hyperglycaemia led to 
higher mortality, even after adjusting for other prognostic variables. Increased systolic 
and diastolic blood pressure were not significant linear or quadratic predictors of poor 
survival and were not included in the final proportional hazards model. Similarly, 
smoking status did not predict survival and was excluded from the model. The 
assumption of proportional hazards held for all variables except plasma glucose level 
(continuous). This variable was therefore removed from the model and plasma glucose 
was considered as a binary variable.
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Table 7.1 Comparison of characteristics of diabetic and non-diabetic patients
Diabetic
n=61
Non-diabetic
n=750
Median age 69 70
Male sex (%) 34 (56) 371 (49)
Median plasma glucose (mmol/L) * 11.1 6.5
Hyperglycaemia (%)* 42 (69) 162 (22)
Smoker (%)r 11 (18) 326 (43)
Median diastolic blood pressure (mm Hg) 90 90
Median systolic blood pressure (mm Hg) * 170 160
Haemorrhagic stroke (%) 4(7) 105 (14)
Symptoms resolved within 72 hours (%) 7(11) 92 (12)
OCSP classification
Total anterior circulation syndrome 12 (20) 173 (23)
Partial anterior circulation syndrome 22 (36) 259 (35)
Posterior circulation syndrome 4(7) 78 (10)
Lacunar syndrome 21 (34) 217 (29)
Other 2(3) 23 (3)
Figures are numbers of patients (percentage of patients) unless otherwise stated. 
* Mann-Whitney test significant atp  < 0.0001 
t  %2 test significant at/? < 0.0001 
$ Mann-Whitney test significant atp  < 0.05
Table 7.2 Numbers of patients in each outcome category over time
2 months 3 months 6 months 12 months
Alive at home 410 (56) 441 (60) 453 (62) 444(60)
Alive in care 173 (24) 129 (18) 91 (12) 68 (9)
Dead 152 (21) 165 (22) 191 (26) 223 (30)
Figures are number of patients (percentage of patients at each time). Fifteen patients 
were lost to follow-up for placement.
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Table 7.3 Distribution of variables bv three month placement
Variable Alive at home 
(n=441)
Alive in care 
(n=129)
Dead
(n=165)
Median age1 68 75 72
Male sex* (%) 239 (54) 51 (40) 78 (47)
Median plasma glucose1 (mmol/L) 6.2 6.7 7.3
Hyperglycaemia* (%) 68 (15) 27 (21) 66 (40)
Smoker (%) 206 (47) 50 (39) 63 (38)
Median diastolic blood pressure (mm Hg) 90 90 90
Median systolic blood pressure (mm Hg) 160 164 160
Haemorrhagic stroke* (%) 36 (8) 21 (16) 45 (27)
Symptoms resolved within 72 hours* (%) 82 (19) 4(3) 5(3)
OCSP classification*
(% within each outcome group)
Total anterior circulation syndrome 47 (11) 44 (35) 80 (50)
Partial anterior circulation syndrome 167 (39) 38 (31) 46 (29)
Posterior circulation syndrome 60 (14) 2(2) 15 (9)
Lacunar syndrome 154 (36) 40 (32) 19 (12)
* Kruskal-Wallis analysis of variance showed significant differences between outcome 
groups, p  < 0.001
* %2 test showed significant differences between outcome groups,p  < 0.01
* X2 test showed significant differences between outcome groups,/? <0.0001
Table 7.4 Proportional hazards modelling of mortality
Variable Relative hazard 95% Cl p-value
Hyperglycaemia 1.87 1.43 to 2.45 <0.0001
Increasing age (per decade) 1.36 1.21 to 1.53 <0.0001
Symptoms remaining after 72h 2.15 1.15 to 4.05 0.015
Haemorrhagic stroke 1.67 1.22 to 2.28 0.001
Different baseline survival functions were used for each of the OCSP categories.
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Figure 7.1 illustrates the checking of the proportional hazards assumption for the binary 
plasma glucose variable in patients with TACS. The proportional hazards curves match 
the Kaplan-Meier curves fairly accurately. This was also the case for the other OCSP 
categories, although for PACS and LACS the proportional hazards estimate tended to 
overestimate slightly the survival rate in hyperglycaemic patients.
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Figure 7.1 Survival curves assessing validity of proportional hazards assumption for the 
plasma glucose measurement in patients with total anterior circulation syndrome.
1, Kaplan-Meier survival curve for patients with plasma glucose < 8mmol/L;
2, Kaplan-Meier survival curve for patients with plasma glucose > 8mmol/L;
3, proportional hazards survival curve for patients with plasma glucose < 8mmol/L;
4, proportional hazards survival curve for patients with plasma glucose > 8mmol/L.
Figure 7.2 gives the Kaplan-Meier survival curves for patients with and without 
hyperglycaemia, at each level of the OCSP classification.
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Total anterior circulation syndrome (n=173) Partial anterior circulation syndrome (n=259)
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Figure 7.2 Kaplan-Meier survival curves for hyperglycaemic (---------- ) and
normoglycaemic (----------- ) patients, for each of the four OCSP classification categories.
Hyperglycaemia also predicted poor outcome at three months: this variable significantly 
ip = 0.0003) improved prediction of three month outcome (alive at home vs alive in care 
or dead) by logistic regression after adjusting for age, time to resolution of symptoms, 
stroke subtype, and OCSP classification category. Systolic and diastolic blood pressure 
were not included in the logistic regression model since they were neither linear nor 
quadratic predictors of outcome. Smoking status did not predict outcome and was 
excluded from the logistic regression model.
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7.4 Discussion
Hyperglycaemia is a predictor of higher mortality and morbidity after acute stroke, 
independently of other adverse prognostic factors such as older age, type and severity of 
stroke, and non-reversibility of neurological deficit. The effect of hyperglycaemia on 
mortality is large: the estimated relative hazard of 1.87 is greater than that for
haemorrhagic versus ischaemic stroke, and equivalent to adding more than twenty years 
to a patient’s age.
To assess our method of adjustment for stroke severity, we compared the estimate of the 
hyperglycaemia effect in the main analysis with that obtained after adjusting for severity 
using only the NIHSS. Chapter 6 showed the NIHSS to be an excellent predictor of stroke 
outcome. The NIHSS was available in 277 patients from this cohort. In proportional 
hazards analysis adjusting for the NIHSS alone, hyperglycaemia was not a significant 
predictor of outcome; however, its estimated coefficient indicated a negative effect on 
outcome (relative hazard 1.24). Hyperglycaemia may not have been significant due to 
the reduced sample size. An alternative explanation is that additional predictors of 
outcome may not be significant because of the prognostic power of the NIHSS: in chapter 
6 neither the CNS nor the MCANS improved outcome prediction, after adjusting for the 
NIHSS.
Our results suggest that hyperglycaemia is not solely a stress response to neurological 
insult, since it predicts outcome after taking other prognostic factors into account. 
Indeed, the relative risk conferred by hyperglycaemia is greatest in patients with lacunar 
stroke. Previous studies which concluded that hyperglycaemia was a stress response, 
based on a correlation between stroke severity and plasma glucose level, (Melamed, 
1976; Candelise et al, 1985) did not consider whether hyperglycaemia independently 
predicted outcome after adjusting for stroke severity. Van Kooten et al. (1993) 
demonstrated that norepinephrine levels were associated with stroke severity, but could 
not find significant relationships between catecholamine and plasma glucose level or 
between glucose level and stroke severity. They concluded that elevated plasma glucose 
in non-diabetic stroke patients could not be explained by a stress response. Jorgensen et
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al. (1994a) found a correlation between glucose level and stroke severity but found that 
glucose level independently predicted outcome after adjusting for stroke severity.
We sought to correct for admission blood pressure in our modelling of survival, since 
elevated blood pressure after stroke admission may be due to both mental stress of 
hospitalisation (Carlberg et al, 1991a; Carlberg et al, 1991b) and physical stress of 
neurological damage. However, neither systolic nor diastolic blood pressure was 
associated with outcome. In addition, diastolic blood pressure was not significantly 
correlated with plasma glucose level (Spearman rank correlation coefficient r5 = 0.053,/? 
= 0.0819) while systolic blood pressure was only weakly correlated with plasma glucose 
level (rs = 0.131, p  = 0.0003). This further indicates that elevated plasma glucose is not 
due to a stress response after acute stroke.
It is likely that in many of the hyperglycaemic patients in our study, the elevated plasma 
glucose was of a long-standing nature. Other studies (Kiers et al, 1992; van Kooten et 
al, 1993; Murros et al, 1992; Murros et al, 1993; Jorgensen et al, 1994a) investigated 
this by measuring glycosylated haemoglobin HbAic and inferred that elevated HbAic 
levels indicated a long pre-stroke history of hyperglycaemia. HbAic is not routinely 
monitored in the ASU and we were thus unable to estimate the prevalence of previously 
undiagnosed diabetes.
The mechanism by which hyperglycaemia might influence stroke outcome is uncertain. 
Both acute and chronic hyperglycaemia are associated with increased oedema and infarct 
size (Helgason, 1988), and with reduced cerebral blood flow and cerebrovascular 
reserve. (De Chiara et al, 1993) Ischaemia leads to a slowing of the oxidative glucose 
metabolism and an increase in anaerobic glycolysis. The concentration of lactic acid 
increases locally as a result. Hence intracellular pH is lowered and cells die or become 
dysfunctional. (Rehncrona et al, 1981) Hyperglycaemia exacerbates such changes. 
(Chew et al, 1991; Pulsinelli et al, 1982) Experimental evidence suggests 
hyperglycaemia may increase lactate production in two ways: either directly in the 
severely ischaemic brain by increasing available glucose, or indirectly in the case of 
incomplete cerebral ischaemia by inhibiting mitochondrial respiration and glucose 
oxidation. (Pulsinelli et al, 1982) Such increased lactate production in the ischaemic
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penumbra may lead to poorer outcome. The above mechanisms may also cause a worse 
outcome in hyperglycaemic primary intracerebral haemorrhage, the excess lactate 
generation occurring in the area of ischaemia around the site of the haemorrhage.
Our results suggest that a randomised trial of glucose control in hyperglycaemic stroke 
patients is warranted. Randomisation should be sufficiently soon after stroke onset to 
allow treatment during the “window of opportunity” for pharmacological intervention. 
Recently reported studies suggest that this time window lasts for up to three (The 
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, 
1995) or even twelve (Mohr et al, 1994) hours after stroke onset.
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Chapter Eight 
Streamlining patient enrolment into 
clinical trials
8.1 Introduction
As indicated in Chapter 1.3, there is increasing interest in developing pharmacological 
treatments for the neurological consequences of acute stroke. Several compounds have 
reached the stage of phase III clinical trials. Such trials have strict time limits for patient 
entry after stroke onset, following the hypothesis that there exists a “window of 
opportunity” for neuroprotection lasting for a limited number of hours from stroke onset. 
At a given time, an ASU may be conducting several clinical trials. Each trial has a 
specific set of inclusion and exclusion criteria. Criteria for these trials generally cover the 
same issues; however, there are often subtle differences in the criteria between trials. 
These criteria may number twenty or thirty: it is therefore time-consuming to check the
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entry criteria for all possible trials for an individual patient, and unlikely that any member 
of staff would be able to remember all these criteria.
Priorities for recruitment to the various trials will depend on the stage of recruitment 
reached in each trial and may change over time. Normally only one phase III efficacy 
trial will be recruiting at any one time, since recruitment bias due to extensively 
overlapping entry criteria could prejudice the result of a second trial. The other available 
trials would normally therefore have safety, tolerability or pharmacokinetic parameters as 
their primary endpoint. A further complication is that the set of trials available for 
selection will change as new clinical trials commence and existing trials reach the end of 
recruitment.
We aimed to produce a computer program which would streamline clinical trial selection 
and enable patients to be recruited more easily within the strict inclusion time limits. 
This program would ask the duty medical staff questions about the patient. The program 
would then advise the research nurse or doctor of the subset of the active trials for which 
the patient was eligible. The program would store details of the individual trials in a 
database, which could also include information on the current order of priority of trials. 
This arrangement would allow trial recruitment policy to be automated. Extending the 
system to screen patients automatically for trial eligibility as their clinical data are added 
to the ASU database would allow a register of screened patients to be kept. This register 
could contain an objective record of any selection criteria which prevented a given 
patient being recruited to each of the available trials.
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8.2 Methods
The development tool used to produce the trial selection system was Knowledge Pro® 
for Windows (KPWin). KPWin is a flexible, object-oriented, list processing programming 
language. It enables easy design of user-friendly screen layouts. It can also co-ordinate 
dynamic data exchange with other Windows applications. It contains built-in expert 
system features which enable intelligent routines to be incorporated in applications. 
Finally, programs written in KPWin may be used to generate C++ code which in turn may 
be used to produce stand-alone executable files.
The primary aim in the design of the trial selection program is that the program should 
ask the minimum number of questions required to determine for which trials the patient is 
eligible. This suggests the use of backward chaining. Backward chaining is often used in 
rule-based expert systems (Buchanan and Shortliffe, 1984), notably in the TOPOSCOUT 
expert system (Spitzer et al, 1989b) which diagnoses the anatomic location and vascular 
territory involved in an acute stroke.
Backward chaining involves seeking information only as it is required. For example, 
several pieces of information about a patient may be required to determine whether he is 
suitable for clinical trial B. If the first piece of information was already ascertained while 
assessing the suitability of trial A, the question relating to this need not be asked. If this 
item satisfies the criterion for trial B, the procedure will move on to item two. If we 
assume that information on item two has not yet been obtained, a question seeking it 
must be asked. If this item satisfies the criterion for trial B, the procedure will move on 
to item three. If not, the patient is unsuitable for trial B and no further questions will 
have to be asked about trial B criteria.
In this way, backward chaining avoids unnecessary questioning about the patient and 
thus minimises the number of questions asked. One disadvantage is that it may be 
difficult to provide explanations for the conclusions of the algorithm since some of the 
reasoning is performed automatically.
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A secondary aim is that the trial selection program has a flexible structure. There are 
two aspects to this. First, the program must be able to deal with additions to and 
subtractions from the list of available trials. Ideally, this should be possible with few 
alterations to the existing program. The second aspect to this flexibility is that the 
program must allow for changing relative priorities of trials for recruitment.
In order to take this secondary aim of the trial selection program into account, a 
compromise must be made. If the program operated using only a backward chaining 
algorithm, substantial changes would be required each time a new clinical trial was added 
to the set of trials available for selection. The solution proposed is to apply the 
backward chaining procedure on a ‘core’ set of 16 questions. These core questions tend 
to be straightforward, general in nature and likely to be used as criteria for more than one 
clinical trial.
More complex and specific questions would be asked if the answers to all the core 
questions were appropriate for a given trial. It would not be advantageous to include 
such detailed questions within the backward chaining section, since no two trials would 
be likely to possess exactly the same question. Indeed, basic definitions of several terms 
vary from one set of detailed criteria to another.
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8.3 Program development
Seven clinical trials were active in the ASU at the time of the implementation of the trial 
selection program. The agents involved were: (1) selfotel, a competitive NMDA 
antagonist, (2) remacemide, a moderate affinity NMDA antagonist, (3) lubeluzole, 
probably a sodium channel blocker although its mode of action is uncertain, (4) 
streptokinase, a thrombolytic drug, aimed within this trial at treating basilar artery 
thrombosis, (5) perindopril, an ACE inhibitor for patients who are hypertensive after 
stroke, (6) GV150526A, an antagonist at the glycine site of the glutamate NMDA 
receptor-ion channel complex, (7) intravenous magnesium, a physiological NMDA 
receptor blocker.
Appendix Al gives the KPWin source code of the trial selection program. Figure 8.1 
shows the basic program structure, and illustrates the phases of trial selection. The 
program reads the information on the available trials from a text file delimited with the */' 
character. This text file has been extracted from the database of trial information, and 
must therefore be re-created each time the database has been changed.
The text file contains information on the availability of trials for recruitment and the 
order of priority of the available trials. The database is indexed according to the order of 
priority; any trial which is not available is given a priority of zero. An available trial may 
be given one of nine levels of priority. The limitation of nine levels is due to 
incompatibility of numerical database fields with the KPWin program structure. A text 
field is therefore used instead of a numerical field. Nine levels should however be 
sufficient, given the number of trials normally available.
Figure 8.2 shows a typical screen with which the user is faced during the core 
questioning procedure. Figure 8.3 shows the user interface after the questioning on core 
entry criteria has been performed for all available trials.
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to enter another patient’s  
data or exit program
user may check detailed 
criteria for any or all of these 
or restart program to enter 
another patient’s  data or exit 
program
display list of trials whose 
core entry criteria have been 
satisfied
if no trials 
remain 
untested
Figure 8.1 Flow diagram representing the main procedures within the clinical trial 
selection program.
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W hat is the m aximum tim e which 
may have elapsed since onset?
Less than 12 hours 
Less than 24 hours 
Less than 48 hours 
Less than 7 days
Figure 8.2 Example o f the screen layout displayed by the program during the core entry 
criteria questioning.
This patient potentially is eligible for the 
following trials (in order of priority):
Selfotei 
posterior S.K 
GV15P528A
Click on trial name to check further 
criteria for a given trial
Figure 8.3 Example o f the screen displaying the names of trials w hose core entry 
criteria have been fulfilled.
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The storage of questioning information in the database makes alterations to the trial 
selection data straightforward. A new trial may be introduced by adding another record 
to the database. Priorities and availability of trials may be changed by altering the 
priority index in the database. A plain text file contains the detailed questioning data and 
may be altered or augmented as necessary.
Two associated programs have been created to check that the correct inclusion and 
exclusion criteria for a given trial have been entered into the database. One of these 
programs deals with the core questioning procedure; the other assists with the more 
detailed entry criteria. In each case the list of questions and answers associated with a 
trial may be printed out by selecting the trial name with the mouse.
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8.4 Implementation in practice
This trial selection program makes a compromise on minimising the number of questions 
which must be asked to determine which clinical trial is appropriate, in order to maintain 
flexibility in the system. However, six or seven questions are still normally sufficient to 
check the core inclusion criteria for all available trials.
An alternative selection algorithm could have involved choosing the next question about 
a patient in order to minimise the number of trials available after that question was 
answered. This system would lead to fewer questions being asked about the patient. 
However, the program would need to be rewritten as new trials became available or 
others finished recruitment. One advantage of such an algorithm is that it would enable 
explanations for a patient’s exclusion from a particular trial to be given. The screening 
log and study report for a trial often require this information.
The current system enables data on the core question responses for a new trial to be 
acquired simply by adding one record to the trial information database. New data on 
detailed questioning may be entered into the text file containing the information for all 
the trials. These techniques result in a system which can cope with the constantly 
changing set of available trials. The addition of extra core questions may be achieved 
with minor changes to the selection program and its associated database file.
One practical issue which should be considered is the training of ward staff to use the 
program as part of routine patient management. At present the program is available for 
use within the ASU but has not been widely used, most probably due to the absence of 
this training. Use of the program should be encouraged to allow the need for any further 
development of the program to be assessed. In future the interface between the trial 
selection program and the ASU database could be refined to allow the screening of 
patients for clinical trial eligibility as their data are entered into the database.
An addition could be made to the program to enable concurrent recruitment for more 
than one phase III efficacy trial. If a patient was eligible for more than one efficacy
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study, the program could select at random the trial in which he should be enrolled. This 
would not, however, completely avoid recruitment bias. Recruitment bias could be 
removed if a patient was randomised to one of the available efficacy trials before any 
entry criteria were checked, and was not entered in another efficacy trial if he was 
ineligible for the trial to which he had been randomised.
In conclusion, this trial selection program provides a quick method for ASU staff to 
ascertain the trials for which a newly admitted patient is eligible. This saving of time 
could be valuable in order to permit treatment within the period in which limitation of 
neurological damage may be possible.
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Chapter Nine 
An Expert System to Assist Clinical 
Decision-making on Anticoagulation
9.1 Introduction
One major problem which confronts the stroke physician is deciding whether a patient is 
suitable for anticoagulation therapy for the secondary prevention of ischaemic stroke. 
Warfarin is a powerful anticoagulant drug, which at least in theory offers greater 
protection than does aspirin against ischaemic events. However, potential interactions 
with other drugs are associated with warfarin, and it is only effective within a narrow 
therapeutic range. Warfarin carries a greater risk of adverse events such as 
haemorrhagic stroke and other bleeding complications, and the risk of such events is very 
often greater in the patients who would potentially gain most benefit from being 
anticoagulated. The warfarin dosage required must be monitored by regular clinic visits 
in order to maintain the patient’s international normalised ratio (INR), a measure of the 
degree of anticoagulation, within a target range of values. The INR target range is 2.0 to
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3.0 for patients with atrial fibrillation, and 3.0 to 4.5 for patients with mechanical heart 
valves. Therefore many aspects of the patient’s health and suitability for anticoagulation 
must be taken into account in order to arrive at a reasoned conclusion as to whether 
anticoagulation is appropriate.
In this chapter we present the development of a prototype model, using expert system 
methodology, to assist decision-making on whether anticoagulation is appropriate for an 
individual patient. This piece of work is applicable to patients who have acute ischaemic 
stroke confirmed by CT scan. Two primary aims were defined at the outset of this work:
(1) To outline the decision-making procedure by which clinicians arrive at the 
prescription of the long-term anticoagulant warfarin, aspirin, or no therapy in patients 
with acute ischaemic stroke. This should take into account any contraindications to the 
therapy, in addition to the risks and benefits of the treatment.
(2) To provide a comparison of the risks and benefits of no therapeutic 
intervention with those if warfarin, or aspirin were given. The risks and benefits, which 
may not be directly available from the results of clinical trials for many specific groups of 
patients, should be tailored to the individual patient’s clinical data.
This prototype model will not include all potential risks of and contraindications to 
warfarin. Its purpose is to assess the plausibility of using expert system methodology to 
solve this type of clinical problem.
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9.2 Model development
9.2.1 Knowledge acquisition
There were three sources of knowledge for our prototype models on anticoagulation. 
First, literature searching identified published results of relevant clinical trials. Secondly, 
data from the ASU clinical database were used. Finally, a series of detailed interviews on 
the subject with an experienced stroke physician was carried out.
Literature searching identified several reports of clinical trials of either warfarin or 
aspirin. We also used meta-analyses of completed trials which were available. Where 
possible, we also considered the ‘grey’ literature of interim results or local literature 
reviews. Information on several variables in the ASU clinical database was used in order 
to tailor the model to the local population characteristics. This database is also linked to 
future hospital admissions and causes of death, and so may be used to monitor the actual 
rates of adverse events and compare these with the model predictions. Information was 
obtained from discussions with an experienced stroke physician on the clinical decision­
making procedures involved, and on the influence of risk factors and contraindications 
on both the benefits of therapy and the rates of adverse events. This method of 
knowledge acquisition is widely accepted as being the most time-consuming. (Jackson, 
1990) Estimates of risks and benefits of therapy, which could not be calculated for 
particular patient subgroups from clinical trial data or the ASU clinical database, were 
also made during these discussions.
9.2.2 Initial model development
At the outset of this prototype modelling, the factors considered which affect stroke risk 
and decision-making on the prescription of warfarin were:
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• patient’s age (in four categories: 59 and under, 60-69, 70-79, and 80 and over)
• presence or absence of one or more vascular risk factors (hypertension, diabetes 
mellitus, congestive cardiac failure or previous myocardial infarction)
• atrial fibrillation
• presence of any risk factors for haemorrhagic complications of therapy (age 
over 80 years, presence of uncontrolled hypertension, likely poor compliance 
with therapy, or presence of active peptic ulceration).
Other variables included in the model were choice of therapy (warfarin, or no therapeutic 
intervention). In this initial model, aspirin was not considered as a potential drug 
therapy. The three endpoints of interest were: annual risk of recurrent ischaemic stroke, 
haemorrhagic stroke, and other serious bleeding complications requiring hospitalisation 
[for example, the European atrial fibrillation trial (e a f t ) (EAFT Study Group, 1993) 
classified these as anaemia, urogenital, gastrointestinal, or respiratory].
Figure 9.1 summarises the assumptions that are made on the relationships between 
variables included in model 9.1. These local influences among the variables are as 
follows. The prevalence of atrial fibrillation varies with the patient’s age. The decision 
for anticoagulation or no therapeutic intervention depends on the presence of atrial 
fibrillation and/or haemorrhagic risk factors. The annual risk of ischaemic stroke 
recurrence after the initial stroke depends on (a) whether the patient has any of the 
vascular risk factors stated above and (b) which therapeutic intervention is made. The 
annual risk of haemorrhagic complications is influenced by the presence of haemorrhagic 
risk factors and the drug therapy prescribed. Finally, the annual risk of haemorrhagic 
stroke depends on therapy alone. Table 9.1 gives the conditional probabilities relating 
the variables in the model which quantify the relationships described above and shown by 
the graphical representation. Figure 9.1 indicates the assumption, based on our 
knowledge sources, that the joint probability distribution of all the variables in the model 
may be described by the product of the conditional distributions shown in table 9.1.
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HRF
AF
VRF
OH
ICH
Figure 9.1 Graphical representation of model 9.1 in the anticoagulation decision­
making problem. Each node represents one variable in the model. The labelling of the 
nodes is as follows: A, patient’s age; AF, atrial fibrillation; VRF, presence of vascular 
risk factors; HRF, presence of haemorrhagic risk factors; T, therapy (warfarin, or no 
therapy); R, ischaemic stroke recurrence; ICH, intracerebral haemorrhage; OH, other 
haemorrhagic complication. Conditional probability tables quantifying the relationships 
between variables are given in table 9.1.
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Table 9.1 Conditional probabilities between variables in model 9,1
Variable Probability distribution
patient’s age (A) P (A <60) 0.20
P (A € [60 , 6 9 ]) 0.26
P (A <= [70 , 7 9 ] ) 0.33
P (A > 79 ) 0.21
atrial fibrillation (AF) P (AF 1 A <60) 0.14
P (AF 1 A > 60 and A < 69) 0.17
P (AF 1 A > 70 and A < 79) 0.19
P (AF 1 A > 79 ) 0.21
vascular risk factors P (no VRF) 0.45
(VRF) P (one or more VRF) 0.55
haemorrhagic risk factors P (no HRF) 0.66
(HRF) P (one or more HRF) 0.34
therapy (T) P (T = no treatment 1 no AF, no HRF) 0.50
P (T = warfarin 1 no AF, no HRF) 0.50
P (T = no treatment 1 AF, no HRF’) 0.20
P (T = warfarin 1 AF, no HRF) 0.80
P (T = no treatment 1 no AF, HRF') 0.99
P (T = warfarin 1 no AF, HRF) 0.01
P (T = no treatment 1 AF, HRF) 0.98
P (T = warfarin 1 AF, HRF) 0.02
ischaemic stroke P ( R = yes 1 no VRF, T = warfarin) 0.02
recurrence (R) P ( R = yes 1 one or more VRF, T = warfarin) 0.05
P ( R = yes 1 no VRF, T = no treatment) 0.06
P ( R = yes 1 one or more VRF, T = no treatment) 0.15
intracerebral P (ICH 1T = no treatment) 0.001
haemorrhage (ICH) P (ICH 1T = warfarin) 0.003
other haemorrhagic P (OH 1 T = warfarin, no HRF) 0.028
complications (OH) P (OH 1 T = no treatment, no HRF) 0.001
P (OH 1 T = warfarin, 1 or more HRF) 0.300
P (OH 1 T = no treatment, 1 or more HRF) 0.002
Abbreviations used are as in figure 9.1. The vertical bar ( I ) within the conditional 
probability statements should be read as “given that”.
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The knowledge used to obtain the table 9.1 probabilities for model 9.1 came from a 
variety of sources. The age distribution and prevalence of vascular risk factors of 
ischaemic stroke patients were taken from the ASU clinical database. The distribution of 
atrial fibrillation across different age groups was estimated using evidence presented by a 
Greater Glasgow Health Board (GGHB) working party and data from the EAFT. (EAFT 
Study Group, 1993) Information on the prevalence of haemorrhagic risk factors was 
taken from patient selection data for the EAFT. (EAFT Study Group, 1993) My own 
estimates of the probabilities of warfarin or no drug therapy being prescribed in the 
situations described in table 9.1 were inserted. The annual risk of ischaemic stroke 
recurrence was estimated using the EAFT results and a prospective pooled analysis of five 
randomised trials of warfarin in primary stroke prevention. (Laupacis et al, 1994) The 
annual risk of intracerebral haemorrhage, dependent on whether or not warfarin was 
prescribed was also estimated from this pooled analysis. Results from the EAFT were 
used to assess the annual risk of other haemorrhagic complications, although these 
figures were then adjusted according to the presence or absence of haemorrhagic risk 
factors.
An alternative structure to model 9.1 is shown in figure 9.2. Model 9.2 arose through 
the wish to have a direct link between atrial fibrillation (AF) and ischaemic stroke 
recurrence (R). However, the structure of Bayesian inference Using Gibbs Sampling 
(BUGS) (Gilks et al, 1994), the software used to perform calculations on the model, is 
such that a single node may not have more than two other parent nodes. The vascular 
risk factors (VRF) variable was therefore removed from the model to accommodate this. 
Apart from this change, the structure of model 9.2 is the same as model 9.1. The 
probability distributions for ischaemic stroke recurrence (r) were taken from EAFT, with 
an adjustment being made for patients in whom atrial fibrillation is absent. The complete 
set of conditional probabilities for model 9.2 is given in appendix Bl.
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HRF
AF
OH
ICH
Figure 9.2 Graphical representation of model 9.2 in the anticoagulation decision­
making problem. Each node represents one variable in the model. The labelling of the 
nodes is as follows: A, patient’s age; AF, atrial fibrillation; HRF, presence of 
haemorrhagic risk factors; T, therapy (warfarin, or no therapy); R, ischaemic stroke 
recurrence; ICH, intracerebral haemorrhage; OH, other haemorrhagic complication. 
Conditional probability tables quantifying the relationships between variables are given in 
appendix Bl.
The graphs for models 9.1 and 9.2 and the corresponding probability tables were shown 
to an experienced stroke physician. He suggested several changes to the model. The 
number of age categories should be increased from four to five. An extra category for 
those aged 50 to 59 was created, since it was felt that the distribution of atrial fibrillation 
in these patients would be different from those under 50. A revised distribution of atrial 
fibrillation according to age was put forward. The physician suggested that the number 
of categories of the haemorrhagic risk factor variable should be increased to take account 
of minor (age over 80, uncontrolled hypertension, or possible poor compliance with 
therapy) and major (active peptic ulceration present) risk factors. He also suggested that 
the model should include the effects both of vascular risk factors and of atrial fibrillation 
on the risk of ischaemic stroke recurrence. Finally, he suggested that aspirin should be
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included as another possible therapy. Figure 9.3 shows the structure of model 9.3. The 
set of conditional probabilities for model 9.3 is given in appendix B2.
HRFVRF AF
OH
ICH
Figure 9.3 Graphical representation of model 9.3 in the anticoagulation decision­
making problem. Each node represents one variable in the model. The labelling of the 
nodes is as follows: A, patient’s age; AF, atrial fibrillation; VRF, presence of vascular 
risk factors; E, either AF, VRF, neither, or both; HRF, haemorrhagic risk factors (five 
categories); T, therapy (warfarin, aspirin or no therapy); R, ischaemic stroke recurrence; 
ICH, intracerebral haemorrhage; OH, other haemorrhagic complication. Conditional 
probability tables quantifying the relationships between variables are given in appendix 
B2.
The distribution for the age variable was again drawn from the ASU database. The 
haemorrhagic risk factors variable now has five levels: no minor haemorrhagic risk 
factors, one minor risk factor, two minor risk factors, three minor risk factors, presence 
of ulceration. Data on the prevalence of these risk factors was extracted from the ASU 
database where possible, with input from the experienced stroke physician on the 
prevalence of active peptic ulceration. To counter the model structure restrictions 
imposed by the BUGS software, the “either AF or VRF” variable was introduced. This has 
four levels corresponding to (1) neither AF nor VRF present, (2) only AF present, (3) only 
VRF present, and (4) both AF and VRF present. The advice of the stroke physician was
166
Chapter Nine: Prototype expert system development
sought on the likelihood of either warfarin, aspirin or no therapy being prescribed for 
various combinations of the variables atrial fibrillation and haemorrhagic risk factors. 
The effect of aspirin on ischaemic stroke recurrence, haemorrhagic stroke risk, and other 
haemorrhagic complications was taken from the results of EAFT (EAFT Study Group, 
1993) and an overview of randomised trials of antiplatelet therapy. (Altman et al, 1994)
After a review of model 9.3, the stroke physician suggested including further variables 
which influence the decision on whether warfarin or aspirin should be prescribed. 
Variables which indicate that the ischaemic stroke originated from an embolic source 
include absence of carotid stenosis or occlusion on Doppler ultrasound, presence of 
mural thrombus on echocardiography, and presence of mitral stenosis. These variables 
were therefore included in model 9.4. Absence or presence of a carotid lesion was 
included as a binary variable in the model, while another variable was included with the 
two categories “no cardiac source of emboli” and “one or more cardiac sources of 
emboli”. Again, due to the restrictions of the BUGS software, these variables contribute 
to another variable representing the likelihood of an embolic source for the stroke. In 
turn, this variable and the atrial fibrillation variable contribute to the choice of therapy 
node through a variable with the categories “neither”, “AF only”, “other embolic source 
only” and “both AF and other embolic source”. Figure 9.4 illustrates the graphical 
representation of model 9.4. The relevant probability tables may be found in appendix 
B3.
The source of information for some of these revised probability estimates was a 
discussion with the stroke physician on the likelihood of embolic stroke in a variety of 
clinical situations. The classification of ischaemic stroke used in the Trial of Org 10172 
in Acute Stroke Treatment (TOAST) trial (Adams et al, 1993) was used to assist in this 
problem. The prevalence of cardiac sources of emboli and carotid stenosis or occlusion 
in patients with ischaemic stroke were initially provided from my own estimates.
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cs
CA
ES
AF
VRF
E2
HRF
OH
ICH
Figure 9.4 Graphical representation of model 9.4 in the anticoagulation decision­
making problem. Each node represents one variable in the model. The labelling of the 
nodes is as follows: A, patient’s age; AF, atrial fibrillation; VRF, presence of vascular 
risk factors; E l, either AF, or VRF, neither or both; CS, cardiac source of emboli; CA, 
carotid artery (stenosis or occlusion); ES, embolic source responsible for ischaemic 
stroke; E2, either atrial fibrillation or other evidence of embolism; HRF, presence of 
haemorrhagic risk factors; T, therapy (warfarin, aspirin or no therapy); R, ischaemic 
stroke recurrence; ICH, intracerebral haemorrhage; OH, other haemorrhagic 
complication. Conditional probability tables quantifying the relationships between 
variables are given in appendix B3.
In order to achieve a more effective representation of the reasoning on the likelihood of 
an embolic stroke, further changes were made to the layout of the model. Figure 9.5 
shows the graphical representation of model 9.5. The CS variable has been expanded to 
three categories to give the number of cardiac sources of emboli (excluding atrial 
fibrillation). The categories are “no sources”, “one source” and “two sources”. This 
variable is then combined with the AF variable to give NCS, the total number of cardiac 
sources of emboli. NCS then contributes jointly with the arterial lesion variable (CA) to
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the probability of an embolic source of the ischaemic stroke. Collaboration with the 
stroke physician was used to estimate the additional quantities required for this model. 
The structure of model 9.5 is otherwise the same as model 9.4. Table 9.2 gives details 
of the conditional probabilities among linked nodes before assessment of the expert 
system performance was made.
CS
VRF AF
CANCS HRF
ES
OH
ICH
Figure 9.5 Prototype expert system graphical model. Graphical representation of 
model 9.5 in the anticoagulation decision-making problem. Each node represents one 
variable in the model. The labelling of the nodes is as follows: A, patient’s age; AF, 
atrial fibrillation; VRF, presence of vascular risk factors; E l, either AF, or VRF, neither 
or both; CS, number of cardiac sources of emboli, excluding AF; NCS, number of 
cardiac sources of emboli, including AF; CA, carotid artery (stenosis or occlusion); ES, 
embolic source responsible for ischaemic stroke; HRF, presence of haemorrhagic risk 
factors; T, therapy (warfarin, aspirin, or no therapy); R, ischaemic stroke recurrence; 
ICH, intracerebral haemorrhage; OH, other haemorrhagic complication. Conditional 
probability tables quantifying the relationships between variables are given in table 9.2.
The knowledge acquisition procedure illustrates that overall probabilities were often 
obtainable from published results or indeed meta-analyses of clinical trials. However, 
estimation of risk in various patient subgroups often had to be drawn from the
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discussions with the stroke physician, either because the clinical trials results were not 
presented in an appropriate format or the numbers of patients recruited in the subgroups 
were too small.
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Table 9.2 Conditional probabilities between variables in model 9.5
Variable Probability distribution
vascular risk factors P (no VRF) 0.45
(VRF) P (one or more VRF) 0.55
patient’s age (A) P (A <50) 0.07
P (A e  [50 , 5 9 ]) 0.13
P (A e  [60 , 6 9 ]) 0.26
P (A e  [70 , 7 9 ] ) 0.33
P (A > 79 ) 0.21
atrial fibrillation (AF) P (AF present 1 A <50) 0.02
P (AFpresent 1 A e  [50 , 5 9 ]) 0.10
P (AF present 1 A e  [60 , 6 9 ]) 0.17
P (AF present 1 A e  [70 , 7 9 ]) 0.19
P (AF present 1 A > 79 ) 0.27
haemorrhagic risk P (no HRF) 0.66
factors (HRF) P (one minor HRF) 0.25
P (two minor HRF) 0.06
P (three minor HRF) 0.01
P (active peptic ulcer HRF) 0.02
cardiac source (CS) P (no CS) 0.90
P (one CS) 0.07
P (two CS) 0.03
arterial lesion (CA) P (no CA) 0.3
P (CA present) 0.7
number of CS (NCS) sum of CS and AF variables
embolic source for P (ESI NCS = 0 and no CA) 0.10
ischaemic stroke (ES) P (ES 1 NCS = 0 and CA) 0.05
P (ES 1 NCS = 1 and no CA) 0.80
P (ES 1 NCS = 1 and CA) 0.40
P (ES 1 NCS = 2 and no CA) 0.85
P (ES 1 NCS = 2 and CA) 0.50
P (ES 1 NCS = 3 and no CA) 0.95
P (ES 1 NCS = 3 and CA) 0.60
Abbreviations used are as in figure 9.5. The vertical bar ( I ) within the conditional 
probability statements should be read as “given that”.
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Table 9.2 (continued) Conditional probabilities between variables in model 9.5
Variable Probability distribution
therapy (T) P (T = no treatment 1 HRF = none and ES = no) 0.05
P (T = warfarin 1 HRF = none and ES = no) 0.05
P (T = aspirin 1 HRF = none and ES = no) 0.90
P (T = no treatment 1 HRF = none and ES = yes) 0.01
P (T = warfarin 1 HRF = none and ES = yes) 0.80
P (T = aspirin 1 HRF = none and ES = yes) 0.19
P (T = no treatment 1 HRF = one minor and ES = no) 0.05
P ( t  = warfarin 1 HRF = one minor and ES = no) 0.00
P (T = aspirin 1 HRF = one minor and ES = no) 0.95
P (T = no treatment 1 HRF = one minor and ES = yes) 0.01
P (T = warfarin 1 HRF = one minor and ES = yes) 0.80
P (T = aspirin 1 HRF = one minor and ES = yes) 0.19
P (T = no treatment 1 HRF = two minor and ES = no) 0.05
P (T = warfarin 1 HRF = two minor and ES = no) 0.00
P (T = aspirin 1 HRF = two minor and ES = no) 0.95
P (T = no treatment 1 HRF = two minor and ES = yes) 0.02
P (t = warfarin 1 HRF = two minor and ES = yes) 0.60
P (T = aspirin 1 HRF = two minor and ES = yes) 0.38
P (T = no treatment 1 HRF = three minor and ES = no) 0.05
P (T = warfarin 1 HRF = three minor and ES = no) 0.00
P (T = aspirin 1 HRF = three minor and ES = no) 0.95
P ( t = no treatment 1 HRF = three minor and ES = yes) 0.03
P (T = warfarin 1 HRF = three minor and ES = yes) 0.40
P (T = aspirin 1 HRF = three minor and ES = yes) 0.57
P (T = no treatment 1 HRF = peptic ulcer and ES = no) 1.00
P (T = warfarin 1 HRF = peptic ulcer and ES = no) 0.00
P (T = aspirin 1 HRF = peptic ulcer and ES = no) 0.00
P (T = no treatment 1 HRF = peptic ulcer and ES = yes) 0.95
P (T = warfarin 1 HRF = peptic ulcer and ES = yes) 0.01
P (T = aspirin 1 HRF = peptic ulcer and ES = yes) 0.04
ischaemic stroke P (R 1 T = no treatment and El = neither) 0.050
recurrence (R) P (R 1 T = warfarin and El = neither) 0.035
P (R 1 T = aspirin and El = neither) 0.040
P (R 1 T = no treatment and El = VRF only) 0.15
P (R 1 T = warfarin and El = VRF only) 0.11
P (R 1 T = aspirin and El = VRF only) 0.13
P (R 1 T = no treatment and El = AF only) 0.12
P (R 1 T = warfarin and El = AF only) 0.04
P (R 1 T = aspirin and El = AF only) 0.10
P (R 1 T = no treatment and El = both VRF and AF) 0.22
P (R 1 T = warfarin and El = both VRF and AF) 0.07
P (R 1 T = aspirin and El = both VRF and AF) 0.17
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Table 9.2 (continued) Conditional probabilities between variables in model 9.5
Variable Probability  distribution
either VRF or AF (El) logical link, possible values being
neither, VRF only, AF only, both
intracerebral P (ICH 1T = no treatment) 0.001
haemorrhage (ICH) P (ICH 1T = warfarin) 0.003
P (ICH 1T = aspirin) 0.001
other haemorrhagic P (OHl T = no treatment and HRF = none) 0.003
complications (OH) P (OH 1T = warfarin and HRF = none) 0.023
P (OH 1T = aspirin and HRF = none) 0.006
P (OH 1T = no treatment and HRF = one minor) 0.005
P (OH 1T ~  warfarin and HRF = one minor) 0.026
P (OHl T = aspirin and HRF = one minor) 0.008
P (OHl T = no treatment and HRF = two minor) 0.007
P (OHl T = warfarin and HRF = two minor) 0.028
P (OH 1T = aspirin and HRF = two minor) 0.009
P (OH 1T = no treatment and HRF = three minor) 0.008
P (OH 1T = warfarin and HRF = three minor) 0.030
P (OH 1T = aspirin and HRF = three minor) 0.010
P (OH 1 T = no treatment and HRF = active peptic ulcer) 0.30
P (OH 1 T = warfarin and HRF = active peptic ulcer) 0.95
P (OH 1 T = aspirin and HRF = active peptic ulcer) 0.80
9.2.3 Initial model assessment
Table 9.3 gives the marginal distributions of selected variables from model 9.5 after 
initialisation. This effectively gives the distribution of the variables in the model before 
any data from an individual patient are entered, and allows the appropriateness of the 
model assumptions to be judged. Variables from the graphical model which do not have
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parents are not included here since their distribution at initialisation is given explicitly by 
the probabilities in table 9.2.
Table 9.3 Marginal distributions of selected model 9.5 variables at initialisation
P (NCS = none) 0.7398 P (T = no treatment) 0.0594
P (NCS = 1) 0.2177 P (T = warfarin) 0.2117
P (NCS = 2) 0.0371 P (T = aspirin) 0.7288
P (NCS = 3) 0.0053
P (AF present) 0.1780 P(R) 0.0899
P (ES) 0.2431 P (ICH) 0.0014
P (El = neither) 0.3699 P (OH) 0.0163
P (El = VRF only) 0.4521
P (El = AF only) 0.0801
P (El = both) 0.0979
NCS, number of cardiac sources of emboli; T, therapy; AF, atrial fibrillation; R, ischaemic 
stroke recurrence; ES, embolic source of ischaemic stroke; ICH, intracerebral 
haemorrhage; El, either vascular risk factors (VRF) only, atrial fibrillation (AF) only, 
neither, or both present; OH, other haemorrhagic complications.
Table 9.4 gives the effects of inserting the values of single pieces of data on the annual 
risks of ischaemic stroke recurrence, haemorrhagic stroke, and other haemorrhagic 
complications. This enables the response of the model to the addition of evidence to be 
assessed: for example, answering “What is the risk of haemorrhagic stroke if the patient 
has atrial fibrillation?” It also highlights changes which should be made to the 
conditional probabilities specified in table 9.2, in order to obtain results which are more 
consistent with evidence from clinical practice.
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Table 9.4 Effects of evidence absorption on endpoint probabilities
single piece 
of evidence 
entered
R
initial evidence 
absorption analysis
ICH OH
revised evidence 
absorption analysis
R2 ICH2 OH2
VRF none 0.0450 0.0014 0.0163 0.0450 0.0014 0.0110
one or more 0.1266 0.0014 0.0163 0.1309 0.0014 0.0110
A <50 0.0888 0.0013 0.0151 0.0890 0.0013 0.0099
50-59 0.0893 0.0014 0.0157 0.0906 0.0014 0.0104
60-69 0.0898 0.0014 0.0162 0.0921 0.0014 0.0109
70-79 0.0900 0.0014 0.0164 0.0925 0.0014 0.0111
80+ 0.0905 0.0015 0.0170 0.0941 0.0015 0.0116
HRF none 0.0889 0.0015 0.0098 0.0914 0.0015 0.0098
one minor 0.0896 0.0014 0.0114 0.0920 0.0014 0.0114
two minor 0.0920 0.0013 0.0117 0.0938 0.0013 0.0117
three minor 0.0944 0.0012 0.0119 0.0956 0.0012 0.0119
active peptic 
ulcer
0.1170 0.0010 0.3064 0.1171 0.0010 0.0409
AF no 0.0886 0.0013 0.0150 0.0886 0.0013 0.0097
yes 0.0958 0.0021 0.0223 0.1089 0.0021 0.0168
CS none 0.0905 0.0013 0.0156 0.0928 0.0013 0.0103
one 0.0847 0.0021 0.0223 0.0873 0.0021 0.0168
two 0.0831 0.0022 0.0233 0.0859 0.0022 0.0177
CA no 0.0884 0.0015 0.0168 0.0911 0.0015 0.0115
yes 0.0934 0.0013 0.0150 0.0949 0.0013 0.0097
ES no 0.0937 0.0011 0.0130 0.0937 0.0011 0.0078
yes 0.0782 0.0025 0.0264 0.0876 0.0025 0.0208
El neither 0.0399 0.0013 0.0150 0.0399 0.0013 0.0097
VRF only 0.1285 0.0013 0.0150 0.1285 0.0013 0.0097
AFonly 0.0684 0.0021 0.0223 0.0684 0.0021 0.0168
both 0.1181 0.0021 0.0223 0.1420 0.0021 0.0168
T no treatment 0.1138 0.0010 0.1023 0.1138 0.0010 0.0156
warfarin 0.0673 0.0030 0.0241 0.0783 0.0030 0.0240
aspirin 0.0945 0.0010 0.0070 0.0945 0.0010 0.0068
Abbreviations used are as in figure 9.5. Endpoint risks are given in columns R, R2 
(recurrent ischaemic stroke), ICH, ICH2 (haemorrhagic stroke) and OH, OH2 (other 
haemorrhagic complication).
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Columns R (recurrent ischaemic stroke), ICH (haemorrhagic stroke), and OH (other 
haemorrhagic complication) of table 9.4 give the endpoint risks from this evidence 
absorption analysis of model 9.5. Presence of active peptic ulceration gives a rather high 
risk of other haemorrhagic complication (30.64%). Also, a high risk of haemorrhagic 
complication (10.23%) is estimated if no drug therapy is given. This arises from the 
structure of the model, where patients receiving no drug therapy are more likely to have 
haemorrhagic risk factors. These results led the probabilities of other haemorrhagic 
complications under no drug therapy, warfarin and aspirin to be revised from 0.05, 0.95 
and 0.80 to 0.038, 0.30 and 0.15 respectively. This evidence absorption analysis also 
suggests that anticoagulated patients who have both atrial fibrillation and vascular risk 
factors have lower risk of recurrent ischaemic stroke (11.81%) than those with vascular 
risk factors only (12.85%). The probability of recurrent stroke given warfarin and both 
these risk factors was therefore altered from 0.07 to 0.11. The results of these changes 
in probabilities on a repeat of this analysis are given in columns R2, ICH2, and OH2. 
However, there still exist results which at first appear counter-intuitive, but which may 
represent the true situation. For example, the probability of ischaemic stroke recurrence, 
in patients with embolic stroke or with cardiac source of emboli, is smaller than if the 
source is absent. This is caused by the higher likelihood of such patients being given the 
ischaemic stroke prevention drug warfarin. This is analogous to the situation which 
occurs in MI, where smokers have better potential to reduce the risk of recurrent MI, 
since they may remove a risk factor by stopping smoking.
To assess the influence of conditional probabilities which were primarily derived from 
discussions with the human expert, a sensitivity analysis was carried out. For example, 
the probability of AF being present in each of the five age groups is given as (0.02, 0.10, 
0.17, 0.19, 0.27) in table 9.2. These values are then adjusted, to (0.01, 0.05, 0.08, 0.10, 
0.14). Evidence that a patient is aged over 79 is then given to the model. The effect of 
changing these probabilities is assessed by looking at the percentage of such patients who 
would receive warfarin. The process is then repeated using a slightly different set of 
probabilities. This analysis allows the conditional probabilities which have a strong 
influence on the calculations within the model to be identified.
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Changes in the following groups of conditional probability estimates were tested: (1) 
distribution of AF prevalence across patient age groups, (2) prevalence of cardiac sources 
of emboli, (3) prevalence of carotid artery lesions, (4) probabilities of an embolic source 
of stroke, given the number of cardiac sources of emboli and presence or absence of 
carotid artery lesions, (5) choice of therapy given embolic source and bleeding risk factor 
data, (6) effect of therapies in the presence of AF with or without vascular risk factors 
present (particularly warfarin when AF is not present) and (7) the risk of other 
haemorrhagic complications given bleeding risk factor and therapy data.
For groups (1) to (4), the endpoint of interest was the probability of each type of 
therapy. In groups (5) to (7), annual risk of ischaemic stroke recurrence, haemorrhagic 
stroke and other haemorrhagic complications were monitored. Here, we give a detailed 
summary of the sensitivity analysis carried out on group (4) to illustrate the calculations 
performed.
Table 9.5 gives the changes made within the expert system to the conditional probability 
of embolic source of stroke, and the consequent changes in the probability of each 
therapeutic intervention. Column one of the table indicates the pieces of evidence which 
were absorbed into the model before the results in columns three to five were calculated.
Table 9.5 shows that the probability of no drug treatment does not change substantially 
when the conditional probability of an embolic stroke is altered. This is encouraging, 
since this probability should largely depend on whether a patient possesses any 
contraindication to warfarin or aspirin. The probability of a patient receiving warfarin or 
aspirin changes greatly with variation in the conditional probability of embolic stroke. As 
would be expected, the probability of a patient receiving warfarin increases with an 
increase in the probability of an embolic stroke. An increase of 0.1 in the probability of 
embolic stroke in a specific situation increases the probability of the patient being 
anticoagulated by about 0.07.
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Table 9.5 Sensitivity analysis for embolic stroke conditional probabilities
evidence 
absorbed by 
expert system
conditional probability altered in 
sensitivity analysis
P (T = 
no treatment)
P (T = 
warfarin)
P (T = 
aspirin)
NCS = 0, no P (ES 1 NCS = 0 and no CA) 0.15 0.0631 0.1433 0.7936
carotid artery P (ES 1 NCS = 0 and no CA) 0.10
lesion present P (ESI NCS = 0 and no CA) 0.05 0.0670 0.0698 0.8632
NCS = 0, P (ES 1 NCS = 0 and CA) 0.10 0.0651 0.1065 0.8284
carotid artery P (ES 1 NCS = 0 and CA) 0.05
lesion present P (ES 1 NCS = 0 and CA) 0.025 0.0680 0.0514 0.8806
NCS = 1, no P (ES 1 NCS = 1 and no CA) 0.85 0.0355 0.6579 0.3066
carotid artery P (ES 1 NCS = 1 and no CA) 0.80
lesion present P (ES 1 NCS = 1 and no CA) 0.75 0.0394 0.5844 0.3761
NCS = 1, P (ES 1 NCS = 1 and CA) 0.50 0.0493 0.4006 0.5501
carotid artery P (ES 1 NCS = 1 and CA) 0.40
lesion present P (ES 1 NCS = 1 and CA) 0.30 0.0572 0.2536 0.6893
NCS = 2, no P (ES 1 NCS = 2 and no CA) 0.90 0.0335 0.6947 0.2718
carotid artery P (ES 1 NCS = 2 and no CA) 0.85
lesion present P (ES 1 NCS = 2 and no CA) 0.80 0.0375 0.6212 0.3414
NCS = 2, P (ES 1 NCS = 2 and CA) 0.60 0.0454 0.4741 0.4805
carotid artery P (ES 1 NCS = 2 and CA) 0.50
lesion present P (ES 1 NCS = 2 and CA) 0.40 0.0532 0.3271 0.6197
NCS = 3, no P (ES 1 NCS = 3 and no CA) 0.975 0.0306 0.7498 0.2196
carotid artery P (ES 1 NCS = 3 and no CA) 0.95
lesion present P (ES 1 NCS = 3 and no CA) 0.90 0.0335 0.6947 0.2718
NCS = 3, P (ES 1 NCS = 3 and CA) 0.70 0.0414 0.5476 0.4109
carotid artery P (ES 1 NCS = 3 and CA) 0.60
lesion present P (ES 1 NCS = 3 and CA) 0.50 0.0493 0.4006 0.5501
Abbreviations used are as in figure 9.5. The second statement in each probability trio in 
column two gives the conditional probability actually used in model 9.5. Columns three 
to five of the table give the probabilities of each drug therapy after the evidence 
described in column one has been absorbed by the expert system.
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The other results of this sensitivity analysis indicate that changes in the prevalence of AF 
influence the probability of a patient being prescribed warfarin. The effect is not large, 
however: doubling the prevalence of AF changes the probability of an 80-year-old 
receiving warfarin from 0.1966 to 0.2604. Trebling the proportion of patients with 
cardiac sources of emboli changes the marginal probability of patients receiving warfarin 
from 0.1925 to 0.2312. Varying the prevalence of carotid stenosis or occlusion has little 
effect on the prescription of drug therapies. As indicated above, the probabilities of 
embolic source of stroke strongly influence the probability of a patient being given 
warfarin. Sizeable changes in the probabilities of the patient receiving warfarin or aspirin 
do not make large differences in the risks of stroke and other haemorrhagic outcomes. 
However, changes in the influence of therapies on ischaemic stroke recurrence and 
haemorrhagic complications greatly alter these endpoint probabilities, as one would 
expect.
9.2.4 Computing considerations
The prototype models were fitted using BUGS. This software allows the fitting of 
complex models in which conditional independence assumptions are appropriate, and 
which may not have exact analytical solutions. Estimates of the quantities of interest are 
achieved using a Bayesian approach and simulation techniques. BUGS requires the first 
stage in any analysis to be the construction of a graphical model. This is an ideal 
visualisation of the problem structure in the development of an expert system.
One attractive feature of BUGS is that it enables prior probability distributions to be 
placed on estimates of risk or conditional probabilities which have been derived from a 
discussion with a medical expert rather than from actual clinical data. This method has 
been illustrated in a case study in congenital heart disease. (Spiegelhalter et al, 1994)
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One major problem with the use of BUGS is that, because of its simulation approach, 
absorption of evidence and propagation of hypotheses take a long time. Typically
100,000 iterations were used as a burn-in period, followed by 50,000 iterations which 
were monitored. Although convergence issues will not be discussed in detail here, it 
should be noted that the rarity of some quantities (for instance, the annual risk of 
haemorrhagic stroke) may cause problems with the estimation of their risk. The 
simulation procedure must be repeated with each addition of new evidence. The 
software is therefore suitable for the development of an expert system model, but is less 
appropriate as an interactive tool for the application of the model.
Another detail of model fitting in BUGS which restricts the expert system development is 
the limitation on nesting of nodes, which effectively means that no variable node may 
have more than two parents. This is clearly restrictive at nodes such as “ischaemic 
stroke recurrence” which are influenced by many factors. Increases in the size and 
complexity of the model were therefore constrained by the BUGS modelling structure.
We therefore decided to use the software package HUGIN (Andersen et al, 1987) which 
performs the probability calculations for the expert system exactly, using a modification 
of the algorithm described by Lauritzen and Spiegelhalter (1988). HUGIN does not place 
restrictions on model structure and allows virtually instant absorption of evidence and 
exploration of hypotheses. We therefore implemented the basic layout of the prototype 
expert system in HUGIN and carried out some further testing of the applicability of the 
expert system, as described in the next section.
9.2.5 Further model assessment
Figure 9.6 gives the layout of the HUGIN version of our prototype anticoagulation model. 
In order to assess the similarities of this expert system model with reality, the effects of 
changes in available data were assessed. An analysis similar to that presented in table 9.4
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was performed. In general the results matched well with expert opinion, the only 
counter-intuitive result again being the apparent reduction in stroke recurrence rate in 
patients with cardiac sources of emboli due to their increased chance of receiving 
warfarin.
VRF
CS CA
AF HRF
OH
ICH
Figure 9.6 HUGIN version of the prototype expert system model 9.5. Conditional 
probabilities in this model are essentially the same as in the BUGS version; however, the 
more flexible model structuring available in HUGIN has been exploited. Each node 
represents one variable in the model. The labelling of the nodes is as follows: A, 
patient’s age; AF, atrial fibrillation; VRF, presence of vascular risk factors; CS, cardiac 
source of emboli; CA, carotid artery (stenosis or occlusion); ES, embolic source 
responsible for ischaemic stroke; HRF, presence of haemorrhagic risk factors; T, therapy 
(warfarin, aspirin, or no therapy); R, ischaemic stroke recurrence; ICH, intracerebral 
haemorrhage; OH, other haemorrhagic complication.
After this initial assessment of the expert system’s capabilities, data from five cases 
representing a variety of clinical presentations were extracted from the ASU database. 
For each patient, the available data were entered into the model and the effects of 
selecting warfarin, aspirin or no treatment were compared, again with respect to the 
outcome variables: ischaemic stroke recurrence, haemorrhagic stroke and other
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haemorrhagic complications. Table 9.6 presents the clinical characteristics of these 
patients. Table 9.7 gives a comparison of the effects of choosing each of the three 
therapeutic strategies, alongside the probability of the patients being allocated each of the 
three types of drug therapy.
Table 9.6 Clinical details of five cases from the ASU database
sex a g e VRF AF cs CA HRF
M 65 X X X one (minor)
M 60 S S X X none
F 82 S X X s one (minor)
M 73 s V X X two (minor)
F 52 X X X V none
The results in table 9.7 indicate that the expert system is a feasible means of assessing the 
effects of each drug therapy on the three endpoints of interest. In this prototype version 
of the model, it should be noted that, where complete data are available for the patients, 
the probabilities of each of the endpoint variables are drawn from a limited set of values. 
An advantage of the expert system model is that it does not require complete data to 
estimate such endpoint probabilities. One disadvantage is that it is not possible to assess 
the effect of giving warfarin to patients such as case 1, since the expert system 
knowledge base contains information that such patients have zero probability of 
receiving warfarin. This problem may be solved in subsequent versions of the expert 
system by assigning a very small, but non-zero, probability of warfarin being given to 
such cases.
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Table 9.7 Drug therapy prior probabilities, and effects of therapy on endpoints
Case drug therapy
probability 
patient receives 
each therapy
R ICH OH
1 no drug 0.05 0.15 0.001 0.005
warfarin 0.00 — — —
aspirin 0.95 0.13 0.001 0.008
2 no drug 0.01 0.22 0.001 0.003
warfarin 0.80 0.12 0.003 0.023
aspirin 0.19 0.17 0.001 0.006
3 no drug 0.04 0.15 0.001 0.005
warfarin 0.03 0.11 0.003 0.026
aspirin 0.93 0.13 0.001 0.008
4 no drug 0.02 0.22 0.001 0.007
warfarin 0.60 0.12 0.003 0.028
aspirin 0.38 0.17 0.001 0.009
5 no drug 0.04 0.05 0.001 0.003
warfarin 0.04 0.035 0.003 0.023
aspirin 0.92 0.04 0.001 0.006
R represents annual risk of ischaemic stroke recurrence; ICH represents annual risk of 
intracerebral haemorrhage; OH represents annual risk of other haemorrhagic 
complication.
The data in table 9.7 suggest that such an expert system could provide assistance in 
clinical decision-making. Further developments which are required include extending the 
model to include a more complete set of risk factors and other factors which affect 
anticoagulation decision-making, and devising a pilot study to compare the expert system 
output with decisions made in actual clinical practice.
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Chapter Ten 
Further development and evaluation of 
anticoagulation expert system
10.1 Introduction
In chapter 9 we developed a prototype expert system to aid decision-making in the 
anticoagulation of acute ischaemic stroke patients. The expert system had to be further 
extended in order to justify its use in clinical practice. There were two reasons for this. 
First, a more complete representation of the patient’s stroke risk factors and 
contraindications to anticoagulation had to be included. The individual relationships of 
these variables with the outcome measures and other variables in the expert system had 
to be clearly defined. Secondly, additional variables relating to conditions which were 
affected by anticoagulant or antiplatelet therapy (for example, myocardial infarction) had 
to be included to allow a full evaluation of the performance of the expert system in 
practice. We now outline the necessary changes to the expert system.
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10.2 Further expert system development
10.2.1 Addition of variables and restructuring
The changes to the expert system structure were as follows. The annual risk of 
myocardial infarction (Ml) was included as an outcome variable in the model. This is 
important for the evaluation of the system in practice, since the MI risk may depend on 
which, if any, drug is prescribed for the patient. Similarly, the annual risk of other 
ischaemic complications was included in the model. This is a more general category 
which includes conditions such as deep vein thrombosis and pulmonary 
thromboembolism. The full list of conditions in this category may be found in the 
description of the expert system evaluation (section 10.3, table 10.2).
The vascular risk factors hypertension, diabetes mellitus, previous MI and congestive 
cardiac failure (CCF) were presented separately within the expert system. The 
hypertension variable had three categories: no hypertension, antihypertensive-controlled 
hypertension, and uncontrolled hypertension. The age-specific prevalence of these 
vascular risk factors was identified. The embolic risk factor mitral stenosis was also 
included as an age-specific variable in the expert system. A variable indicating presence 
of mural thrombus on echocardiography was created.
Each risk factor for haemorrhagic complications of anticoagulant or antiplatelet therapy 
was linked to the drug therapy choice node in the expert system and its distribution 
estimated. These variables were: age over 80, presence of uncontrolled hypertension, 
possible poor compliance with any drugs prescribed. Peptic ulceration was also included 
separately from these variables in the model and linked to the drug therapy choice node. 
Its structure included three categories: no ulceration, presence of a dormant ulcer and 
presence of a recently active ulcer (within the 30 days prior to the ischaemic stroke).
A further meeting with the experienced stroke physician led to other changes in the 
expert system composition. The variable indicating absence or presence of a carotid
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artery lesion was expanded to account for the lesion’s severity. Four categories now 
exist: no carotid lesion, 30-69% stenosis, 70%-99% stenosis, or complete occlusion. 
The 70%-99% stenosis category was further subdivided into the patients likely to be 
considered for carotid endarterectomy and those not, since many patients are unsuitable 
for surgery due to frailty, poor prognosis due to stroke severity, and other 
contraindications to surgery. The carotid lesion node was linked to the drug therapy 
node.
The previous MI variable was expanded to contain four categories: no previous MI, 
recent anterior MI, old anterior or recent inferior MI, old inferior MI. Here, “recent” 
indicates that MI occurred in the 90 days prior to the ischaemic stroke, and “old” 
indicates that MI occurred prior to these 90 days. The new categories were created since 
recent MI and anterior MI were both considered to increase the risk of thrombus. A 
variable recording the patient’s history of accidental falls, which make anticoagulation 
dangerous, was added as an influencing factor on drug therapy choice.
Several new links between variables were suggested by the stroke physician, particularly 
regarding variables which affect drug therapy choice and stroke recurrence risk. A link 
was created between possible poor compliance with anticoagulant or antiplatelet therapy 
and each of haemorrhagic stroke risk and drug therapy choice. Atrial fibrillation, mural 
thrombus, mitral stenosis and CCF were all linked to the drug therapy variable. The 
influences of age and presence of uncontrolled hypertension on intracerebral 
haemorrhage risk were included. Links between ischaemic stroke recurrence and each of 
atrial fibrillation, mural thrombus, mitral stenosis, diabetes mellitus, recent anterior MI, 
congestive cardiac failure and hypertension status were inserted. The risks of ischaemic 
stroke recurrence depending on the type of carotid lesion were included.
The effect of warfarin or aspirin prescription on MI risk was assessed. Links were 
inserted between previous MI and MI risk, and diabetes mellitus and MI risk. Links were 
created to other ischaemic complication risk from diabetes mellitus, atrial fibrillation, 
mural thrombus, and mitral stenosis. The effect of warfarin or aspirin therapy on other 
ischaemic complication risk was included. Links to atrial fibrillation were inserted from
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mitral stenosis and from previous MI. The influences of CCF and previous MI on mural 
thrombus prevalence were estimated.
Possible links not added at this stage were the influence of hypertension on both the 
annual MI risk and the prevalence of atrial fibrillation.
These additions to the expert system model resulted in a more complex structure. Due 
to the additional links inserted, a vast number of probabilities must be calculated. For 
example, due to the large number of variables influencing drug therapy choice, a total of 
5760 probability distributions must be estimated. This is impractical with the levels of 
evidence available in published and unpublished knowledge sources. Similarly, 2880 
probabilities would have to be estimated for the risk of ischaemic stroke recurrence. 
Further changes to the graphical model structure were made to resolve these difficulties.
After discussion with the stroke physician, the following changes to the parent variables 
of the drug therapy node were made. A single node combining all minor 
contraindications to anticoagulant therapy was created. This included (1) history of falls, 
(2) age over 80, (3) poor compliance strongly suspected, (4) hypertension status (no 
hypertension, controlled hypertension, uncontrolled hypertension). This variable 
therefore contained six levels of haemorrhagic risk. The section of the revised graphical 
model relating the haemorrhagic risk variables to the drug therapy node is shown in 
figure 10.1.
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A2
HBP
PCHRF
Figure 10.1 Section of the revised graphical model relating minor contraindications to 
anticoagulation and drug therapy choice. Nodes are labelled as follows: A2, patient aged 
under or over 80; HBP, no hypertension, controlled hypertension or uncontrolled 
hypertension; F, history of accidental falls; PC, risk of poor compliance with drug 
therapy; HRF, number of minor risk factors for haemorrhage (0 to 5); T, therapy 
(warfarin, aspirin, or no therapy).
The effect of peptic ulceration was included through a binary variable stating whether 
active ulceration had occurred within the last 30 days. The carotid artery lesion variable 
was reduced to four levels by removing the assessment of suitability for carotid 
endarterectomy. Finally, a variable combining all embolic risk factors for ischaemic 
stroke was included. This contained five levels of risk depending on the absence or 
presence of each of atrial fibrillation, mural thrombus, mitral stenosis, and CCF. Figure 
10.2 shows the section of the graphical model relating these risk factors to the drug 
therapy node. In total, 240 different distributions of drug therapy choice must now be 
estimated.
Parent variables of the ischaemic stroke recurrence node were rearranged as follows. 
Vascular risk factors (hypertension status, diabetes mellitus, previous MI [whether or not 
an anterior MI had occurred within the previous 90 days], and CCF) were combined in a 
six-level recurrence risk variable. Figure 10.3 shows the section of the revised graphical 
model relating vascular risk factors to ischaemic stroke recurrence.
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MS
AF
CF MT
HR
Figure 10.2 Section of revised graphical model relating strong risk factors for recurrent 
ischaemic stroke and drug therapy choice. Nodes are labelled as follows: AF, atrial 
fibrillation; MS, mitral stenosis; MT, mural thrombus; CF, congestive cardiac failure; 
HR, number of embolic risk factors for recurrent stroke (0 to 4); T, therapy (warfarin, 
aspirin, or no therapy).
RA CF
DM HBP
VRF
Figure 10.3 Section of the revised graphical model relating vascular risk factors and 
ischaemic stroke recurrence risk. Nodes are labelled as follows: DM, diabetes mellitus; 
RA, recent (within past 90 days) anterior MI; CF, congestive cardiac failure; HBP, no 
hypertension, controlled hypertension or uncontrolled hypertension; VRF, number of 
vascular risk factors (0 to 5); R, ischaemic stroke recurrence.
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Other variables were included separately: atrial fibrillation, drug therapy, carotid artery 
lesion (measured at the four levels described above), mitral stenosis and mural thrombus. 
There are now 576 ischaemic stroke recurrence probabilities in the expert system.
10.2.2 Knowledge sources
A variety of sources provided the information required by this expanded expert system 
model. We describe the knowledge source for each link within the model. However, 
some variables were later combined to facilitate probability estimation.
Age-specific distributions of diabetes mellitus, hypertension and previous MI were 
obtained from 1118 patient records in the ASU database. The prevalence of CCF was 
obtained from an ASU research study on 144 patients. The experienced stroke physician 
estimated the prevalence of mitral stenosis and mural thrombus. CCF, mitral stenosis and 
mural thrombus were given age-specific distributions with an age structure similar to that 
found for diabetes, hypertension and previous MI.
The risk of intracerebral haemorrhage in each age group was derived from data published 
by the OCSP. (Bamford et al, 1988) The effect on intracerebral haemorrhage risk of 
uncontrolled hypertension was estimated by the experienced stroke physician.
The distribution of previous MI according to timing (less than or equal to, or more than 
90 days prior to stroke) and type (anterior or inferior) was derived. Timing was obtained 
from the ASU database. The prevalence and effect on ischaemic stroke and MI risk of 
each MI type were estimated by the experienced stroke physician. He also provided the 
distribution of AF according to mitral stenosis and previous MI, and the distribution of 
mural thrombus according to CCF and previous MI.
The distribution of carotid artery lesion types was obtained from ASU records on 1465 
patients. Since ischaemic stroke recurrence is an outcome variable in the expert system,
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the experienced stroke physician considered all carotid lesions to be relevant, regardless 
of whether they were responsible for the current stroke admission.
Ischaemic stroke recurrence risk was determined under several risk factors. One case- 
control study (Marini et al, 1993) showed mitral stenosis to be a strong risk factor for 
ischaemic stroke in persons aged 15-44. Patients with either mural thrombus or mitral 
stenosis were defined to have an absolute increase in ischaemic stroke risk of 20% by our 
experienced stroke physician. Their risk in combination was defined to be additive. The 
influences of diabetes mellitus, previous MI, CCF, and hypertension on ischaemic stroke 
recurrence rates were obtained, for patients with AF, from univariate analysis in one 
clinical trial (EAFT Study Group et al, 1995) and multivariate analysis in a meta-analysis 
of five randomised trials. (Laupacis et al, 1994) Ischaemic stroke risks of hypertension 
and CCF for patients without AF were obtained from the Framingham cohort study. 
(Wolf et al, 1991) The ischaemic stroke risk from severe (70-99%) carotid stenosis was 
taken primarily from the European Carotid Surgery Trial (ECST) (European Carotid 
Surgery Trialists Collaborative Group, 1991), with additional information taken from the 
North American Symptomatic Carotid Endarterectomy Trial (NASCET). (North 
American Symptomatic Carotid Endarterectomy Trial Collaborators, 1991) Information 
on moderate (30-69%) carotid stenosis and carotid occlusion was obtained from 
preliminary ECST results.
The results of the Antiplatelet Trialists Collaboration (Altman et al, 1994) were used to 
obtain the risk of intracerebral haemorrhage in patients prescribed aspirin, while those of 
the EAFT (EAFT Study Group, 1993) and a meta analysis (Laupacis et al, 1994) were 
used for patients prescribed warfarin.
The probabilities of each type of drug therapy (warfarin, aspirin, or no therapy) in the 
presence of each of poor compliance risk, mitral stenosis, mural thrombus, CCF, previous 
MI and each carotid lesion type were estimated by the experienced stroke physician.
The effects of diabetes mellitus, previous MI and drug therapy on MI risk were estimated. 
Diabetes mellitus has a relative risk of 1.9 for MI. (Negri et al, 1995) The effect of 
warfarin and no drug therapy on MI risk was obtained from two clinical trials of
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anticoagulation after MI. (Smith et al, 1990; Sixty Plus Reinfarction Study Research 
Group, 1980) The experienced stroke physician added information on the effect of 
aspirin on MI risk, and adjusted the results of these trials to our post-stroke population. 
He also estimated the effect of previous MI on MI risk.
The risk of haemorrhagic complications in patients prescribed warfarin was estimated 
from a study which investigated prediction of complications using factors known at the 
start of anticoagulation. (Landefeld and Goldman, 1989) The risk in patients given 
aspirin was estimated by the experienced stroke physician, based on EAFT results. (EAFT 
Study Group, 1993) He also estimated the prevalence of poor compliance with drug 
prescription. The prevalence of uncontrolled hypertension was estimated from the ASU 
database. The overall event rates for other haemorrhagic complications were adjusted to 
agree with those obtained in long-term follow-up of patients from the ASU using the 
record linkage method provided by the NHS Information and Statistics Division.
The stroke physician indicated that the risk of other ischaemic complications should 
depend on the presence or absence of mural thrombus, mitral stenosis, atrial fibrillation, 
diabetes mellitus and drug therapy choice. He suggested that embolic risk factors should 
have additive effects in combination. The effect of anticoagulation on other ischaemic 
complication risk was taken to be the same as its effect on MI risk. (Hirsh and Fuster, 
1994) Again, the overall event rates were adjusted to match the rates of events found in 
ASU patients followed up using record linkage.
10.2.3 Graphical model and probabilistic relationships
Figure 10.4 gives the graphical model for the revised expert system. Certain nodes 
involving logical links have been added to the graph to simplify some of the relationships 
between variables. Examples of this are the additional age (A2), previous MI (PMI2), 
uncontrolled hypertension (HBPU), and recently active peptic ulceration (AU) nodes. The 
probabilistic relationships between variables are given in appendix Cl.
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HBPU
Figure 10.4 Graphical representation of the expanded expert system. Each node 
represents one variable. Nodes are labelled as follows: A, patient’s age; A2, patient aged 
under or over 80; AF, atrial fibrillation; MS, mitral stenosis; MT, mural thrombus; DM, 
diabetes mellitus; PMI, previous MI (none, recent anterior, old anterior or recent inferior, 
old inferior); PMI2, previous MI (Y or N); RA, recent (within past 90 days) anterior MI; 
CF, congestive cardiac failure; HBP, no hypertension, controlled hypertension or 
uncontrolled hypertension; HBPU, uncontrolled hypertension (Y or N); VRF, number of 
vascular risk factors (0 to 5); HR, number of embolic risk factors for recurrent stroke (0 
to 4); CA, no carotid lesion, moderate stenosis, severe stenosis, or occlusion; F, history 
of accidental falls; PC, risk of poor compliance with drug therapy; HRF, number of 
minor risk factors for haemorrhage (0 to 5); U, no peptic ulcer, dormant ulcer, or 
recently (within past 30 days) active ulcer; AU, recently active ulcer (Y or N); T, therapy 
(warfarin, aspirin, or no therapy); R, ischaemic stroke recurrence; OI, other ischaemic 
complication; ICH, intracerebral haemorrhage; OH, other haemorrhagic complication; 
MI, myocardial infarction. Relationships between variables are quantified in the 
conditional probability tables in appendix Cl.
The stroke physician suggested that, in patients with a carotid artery lesion, the 
effectiveness of warfarin in ischaemic stroke prevention should be reduced by about one 
third. For example, if warfarin reduced the risk of ischaemic stroke by 58% in patients 
with atrial fibrillation (EAFT Study Group, 1993), this risk reduction would become 
39% in patients with atrial fibrillation and carotid artery stenosis or occlusion. This 
alteration was made with the constraint that warfarin should be more effective than 
aspirin, even in patients with carotid artery disease.
193
Chapter Ten: Further expert system development and evaluation
The EAFT results (EAFT Study Group et al, 1995) provided the effect of other risk 
factors on ischaemic stroke recurrence. However, these had to be altered when atrial 
fibrillation was absent. It was difficult to judge the effects of several risk factors in 
combination. More empirical evidence could be obtained from long-term patient follow 
up using record linkage to assess the combined effects of more than one risk factor.
The MI risks given in the American Heart Association guide to anticoagulation (Hirsh 
and Fuster, 1994) were drawn from clinical trials in post-MI patients. These figures 
therefore were adjusted when MI risk was being considered in patients without prior MI.
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10.3 Expert system evaluation
10.3.1 Introduction
Having produced an expanded and revised version of the expert system, the next logical 
step is to assess its performance on actual data from ischaemic stroke patients. This 
evaluation study compares information provided by the expert system with the drug 
prescription decisions made by several health care professionals from a variety of 
disciplines. Two methods of interpreting the information available from the expert 
system are explored, since the expert system does not directly make clinical management 
decisions; rather, it provides information on a set of key outcome measures under the 
three hypothetical therapeutic strategies.
10.3.2 Methods
The setting of this study was the weekly case review meeting in the ASU. Over three 
consecutive meetings, data from every patient with CT-confirmed acute ischaemic stroke 
was used to evaluate the expert system decision-making aid. Each member of clinical 
staff attending the meetings was requested to complete a form indicating his choice of 
secondary preventive therapy (none, aspirin only, warfarin only, both warfarin and 
aspirin). The staff participating in the study included ASU consultants, a geriatrician, a 
neurologist, and junior and senior house officers. Each member of staff completed the 
form independently of the other participants. Their decisions were based on information 
routinely presented at the review meeting: description of risk factors, symptoms and 
signs, and results of investigations including the CT or MR scan. Appropriate pieces of 
these data were entered in the expert system along with information easily available in 
the case notes.
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If warfarin was not chosen as the preferred therapeutic intervention, the respondent was 
asked to give the reasons for not prescribing warfarin. Participants could select any 
number of the following categories: poor compliance likely, patient’s age, poor control 
of hypertension, active ulceration present, poor prognosis, history of falls, large recent 
infarct on CT, low ischaemic stroke recurrence risk. If necessary, they could specify 
other reasons for not wishing to prescribe warfarin.
Table 10.1 shows the pattern of attendance of health care staff and hence responses to 
the survey. Difficulty in data analysis was caused by changes in personnel attending the 
ASU meeting. The outcome measure of the human decision-making was therefore 
defined as the consensus therapeutic strategy of the members of staff participating for a 
given patient. Any divisions in opinion were noted.
Table 10.1 Attendance patterns among participating members of staff
Member of staff Meeting 1 Meeting 2 Meeting 3
1 y X X
2 s S
3 s V V
4 s X X
5 X V S
6 X </ X
7 X X V
8 X V
Two methods were used for interpretation of the expert system advice. The first of these 
involved estimation, for each patient, of the total probability of an adverse event in any of 
these five groups: ischaemic stroke recurrence, haemorrhagic stroke, MI, other ischaemic 
complication, other haemorrhagic complication. This calculation was performed for each 
of the three therapeutic interventions: warfarin, aspirin and no drug prescription.
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Some weighting of the probabilities of events in each of the five groups would be 
desirable, since there are clearly differences in importance to the patient of, for example, 
ischaemic stroke and tonsil haemorrhage. Calculating such a weighting is difficult, 
however, since some adverse event groups contain a diverse range of conditions. Each 
condition may also contain a wide spectrum of severity. The second method of 
interpretation used in this study was a relatively straightforward weighting of categories 
according to NHS costs. Greater Glasgow Health Board (GGHB) economists provided 
the 1994 hospital discharge figures for each condition outlined within the five outcome 
groups. These conditions and their corresponding WHO International Classification of 
Diseases (revision 9) (World Health Organization, 1977) (ICD9) codes are given in table 
10.2. The discharge data were subdivided by specialty for each condition. Day-case and 
in-patient per diem costs were provided by the economists for each specialty.
These data were used to calculate a mean cost per admission for each ICD9 code, taking 
into account the average length of stay, the proportions of day-case and in-patient 
admissions, and the range of specialties which catered for the condition. The mean cost 
for an outcome group was derived by summing the costs for all conditions which made 
up the group, weighting them according to the relative frequency of their ICD9 code 
discharges. The calculations are summarised in equation 10.1.
mean cost in outcome group L = X  cq ®ijk ^ijk Cjk (10.1)
ieL j k
Here, cq is the proportion of group L admissions accounted for by ICD9 condition i. 0 ^  
is the proportion of admissions for condition i which are in specialty j  and of case type k , 
where case type is either day case or in-patient. A p is the mean length of stay for 
patients with discharge code i in specialty j  and case type k. (For day-cases, A takes a 
value of one.) Cjk gives the per diem cost for in-patients in specialty j  or the cost per 
day-case in specialty j.
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Table 10.2 ICD9 codes within each outcome group
Outcome group ICD9 codes
Ischaemic stroke 336.1,362.8 
433, 434,435,436
Myocardial
infarction
410, 410.9
Other ischaemic 
events
246.3, 253.8, 255.4, 289.5
415.1.444.8, 444.9,453.9 
557.0, 573.4, 593.8
602.8, 611.8, 620.8
Haemorrhagic
stroke
336.1
430, 431,432 
852, 853.0
Other haemorrhagic 
events
246.3, 252.8, 255.4, 280, 285.1, 289.5
360.4, 362.8, 363.6, 364.4, 372.7, 376.3, 379.2, 379.8,
386.8
423.0, 429.8, 448.7, 459.0, 474.8, 478.2
511.8, 523.8, 528.9, 529.8, 530.8, 533.9, 537.8, 568.8, 
569.3, 573.8, 577.8, 578.9, 593.8, 596.7, 596.8, 599.7,
599.8
602.1, 607.8, 608.8, 623.8, 624.5, 624.8, 627.1, 629.8, 
665.7
703.8, 719.1, 728.8, 782.7, 784.7, 784.8, 786.3 
862.2
920
10.3.3 Results
Twenty-four suitable cases were reviewed at the three ASU meetings. The median age 
was 78, with a range of 28 to 93. Four patients had atrial fibrillation as a risk factor.
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In general there was good agreement among the clinical staff as to which, if any, drug 
prescription should be made. There were three exceptions to this. Patient A was a 72 
year old man in atrial fibrillation. Two of the four observers suggested he should receive 
aspirin, citing possible poor compliance, age, and possible risk of falls as their reasons for 
not prescribing warfarin. The other observers suggested warfarin should be prescribed. 
This disagreement was mirrored by the expert system output, which estimated that 
warfarin would be prescribed with probability 0.50 and aspirin with probability 0.47.
The second case which led to differing answers from observers was patient B, an 84 year 
old man in atrial fibrillation. He had a previous, but not recent, MI. The observers were 
split as to whether he should be prescribed warfarin alone, or warfarin and aspirin in 
combination. In this case the expert system estimate was that warfarin prescription 
would be likely (probability 0.48). However, the expert system structure cannot as yet 
deal with the issue of combination therapy.
The case which provoked the most extensive discussion was that of patient C, an 89 year 
old double amputee. He was in atrial fibrillation and had previously suffered an MI. 
Although a majority of observers eventually chose aspirin, there were strong indications 
for warfarin tempered by some doubt as to the patient’s (superficially normal) cognitive 
function. The therapeutic decision taken in reality was to prescribe warfarin subject to 
an acceptable score being attained on the abbreviated mental test. Here the patient 
management uncertainty was reflected in the probabilities of each drug therapy obtained 
from the expert system: 0.48 for warfarin prescription and 0.49 for aspirin.
Figure 10.5 shows a comparison of the expert system output with the consensus 
decisions of the clinical staff. Each point on the figure represents data for an individual 
patient. The annual risks estimated by the expert system of each of five adverse event 
groups are summed, with equal weight given to each. This total risk is presented for 
warfarin and for aspirin prescription as the risk reduction achieved relative to no drug 
therapy. Any point in the top right quadrant of the graph indicates that each of warfarin 
and aspirin offers a reduction in the total risk of an adverse event. A point situated 
above the diagonal line represents a case where the expert system output indicated that 
warfarin offered a lower total risk than aspirin. For points below the diagonal line the
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total risk on aspirin was calculated to be lower than that on warfarin. For points in the 
lower right quadrant of the graph the expert system output indicated that aspirin offers 
benefit over no drug therapy, while warfarin does not.
Total risk 
reduction: 
warfarin vs 
no treatment 
(%/yr)
Consensus
prescription
10 -
O none 
x  warfarin 
□ aspirin
5 -
0 105
Total risk reduction: aspirin vs no treatment (%/yr)
Figure 10.5 Expert system results compared with clinical staff consensus decisions. 
Risk reduction calculated using simple summation of risks in the five adverse event 
categories.
It can be seen that for the three patients in whom the majority of clinical staff elected to 
prescribe warfarin, the expert system calculations indicated that warfarin provided the 
lowest probability of further adverse events. However, three other patients (C,D,E) who 
were prescribed aspirin have substantially lower total risks on warfarin according to the 
expert system output. The total risk of adverse events is only one aspect in the decision­
making process, however. The uncertainty concerning patient C was indicated in the 
expert system output: his probability of actually receiving warfarin was similar to that of 
him being given aspirin. In patients D and E a lack of positive indications for warfarin 
resulted in the calculated probability of receiving warfarin being low (0.03 and 0.026 
respectively).
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Table 10.3 shows the mean NHS cost of a hospital admission under each of the five 
adverse event categories. These costs to an extent reflect the differences in severity of 
events between the categories. Notably the NHS cost for patients with haemorrhagic 
stroke is lower than that for ischaemic stroke, largely due to the greater proportion of 
haemorrhagic stroke patients who die in the 30 days following stroke. This reduces the 
mean length of stay in hospital.
Table 10.3 Mean NHS costs of outcome events
Outcome Category Cost (£)
Myocardial infarction 1137.44
Ischaemic stroke 6978.79
Other ischaemic complication 1912.88
Haemorrhagic stroke 3821.01
Other haemorrhagic complication 649.40
Figure 10.6 shows the revised results when the adverse event probabilities are weighted 
by the mean costs of the adverse events in each category. The vertical scale on this 
figure shows “estimated expected annual NHS cost saved by prescribing warfarin rather 
than no therapeutic intervention.” The horizontal axis illustrates the same quantity for 
prescribing aspirin compared to no drug therapy. The average annual costs of 
prescribing aspirin (£1.57) and warfarin (£289.82, including anticoagulant clinic costs) 
were included in these calculations. The interpretation of the various quadrants and 
areas of the graph is analogous to that for figure 10.5.
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350 -
Expected 250 -  
cost saving: 
warfarin vs 150 — 
no treatm ent 
(£/yr) 50 -
-50 -
-150 -
-250 -
-250 -150 -50 50 150 250 350
Expected cost saving: aspirin vs no treatm ent (£/yr)
Figure 10.6 Expert system results compared with clinical staff consensus decisions. 
Risk reduction calculated using summation of risks in the five adverse event categories, 
weighted according to the mean NHS costs of one event.
This method of interpreting the expert system output results in close agreement with the 
clinical staff’s decisions. The only exception to this is patient C, the double amputee 
with questionable cognitive function, whose case was described in relation to figure 10.5.
10.3.4 Discussion
In the expert system evaluation, it is important to consider its output relating to the 
probability of each therapy being prescribed. Examining the adverse event risks in 
isolation may miss additional information in the expert system output on the suitability of 
anticoagulant or antiplatelet therapy. This is in part due to the expert system structure:
C onsensus
prescription
O  n on e  
*  warfarin 
°  aspirin
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contraindications to anticoagulation, for example, may reduce the calculated probability 
of the patient receiving warfarin, while not directly affecting the calculated risk of 
adverse events if warfarin was prescribed. This is because no substantial evidence exists 
in the literature on the effects of prescribing warfarin in patients who have strong 
contraindications to anticoagulation. The expert system structure could be altered to 
include estimates of such quantities from human experts.
Other ischaemic stroke risk factors could be included as indications for anticoagulation in 
the expert system. The factors diabetes mellitus, previous MI and controlled 
hypertension all strongly influence the absolute risk of recurrent ischaemic stroke, as was 
seen in patients D and E described in section 10.3.3. The expert system calculations 
resulted in low probabilities of their receiving warfarin, despite their high risk of stroke 
recurrence due to these risk factors.
In this study the probabilities of each drug therapy type in general agree with the actions 
suggested by the clinical staff. The median probability, generated by the expert system, 
of warfarin being prescribed was 0.48 in patients who were recommended 
anticoagulation by the consensus decision of the human experts. The median probability 
of aspirin being prescribed was 0.91 in patients for whom the clinical staff recommended 
aspirin. However, the probability that the patient received no treatment did not 
correspond with the actual decisions of the human experts. The median probability of 
“no therapy” was 0.06 in patients recommended no drug therapy, 0.03 in those 
prescribed warfarin, and 0.06 in those prescribed aspirin. This insensitivity is partly due 
to the absence of prognostic factors from the expert system: no drug therapy was chosen 
by the clinicians when the short-term prognosis or the swallowing status was poor.
Assessment of an expert system in this area of clinical management poses problems. The 
first of these is that a “gold standard” for treatment selection does not exist. There are 
general guidelines on indications for and contraindications to anticoagulation. However, 
difficulty occurs when several indications and contraindications must be considered at the 
same time. It then becomes a problem, even for experienced stroke clinicians, to judge 
which therapy is the most beneficial. The uncertainties over which treatment to prescribe 
to patients A, B and C illustrate this. The design of this evaluation perhaps increased the
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uncertainty among the human observers: one observer expressed the opinion that he 
would like to meet with the patients to assess their suitability for anticoagulation, rather 
than basing the decision on case details alone.
The lack of a “gold standard” for treatment selection results in difficulty in assessing the 
performance of the expert system. In the example of patient C, is there a fundamental 
error in the knowledge-base of the expert system, or is it merely presenting the evidence 
on the patient in an easily accessible form which was not previously available? This 
could best be answered by interpretation of the results of a randomised trial evaluation of 
the expert system by a group of experienced stroke physicians.
The use of NHS costs to assist interpretation of the expert system output has obvious 
weaknesses. The method does not take into account patient preferences in relation to 
any of the adverse events which may occur. Conditions which have high mortality rates 
will be imder-weighted in the calculations, since these do not consume hospital resources 
in the way that milder chronic conditions do. One alternative method of interpreting the 
expert system output could include figures such as losses to production and lost earnings 
in the costing of the adverse events. A more desirable, but harder to implement, method 
would be to calculate condition-specific quality adjusted life years (QALY) profiles over 
time. (Torrance, 1986) These could be obtained for each of the adverse events, and then 
the cost per QALY gained for each of the therapeutic interventions could be calculated. 
An alternative method of calculating utility functions for each of the adverse events 
would be to use healthy years equivalents (HYE). (Mehrez and Gafni, 1989) HYEs are 
said to represent individual patient preferences more fully than QALYs.
This exploratory study prompted several alterations to the expert system structure. The 
most important of these is that prognostic factors from the index stroke event should be 
included in the expert system knowledge-base. The results from the expert system 
indicating that aspirin or even warfarin may be beneficial in patients who subsequently 
died within a few days of their stroke illustrates the problem of ignoring prognostic 
information. The influence of excess alcohol intake on the risk of poor compliance with 
prescribed therapy should also be considered. Finally, the expert system knowledge-base
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should be altered to include the indications for and the effects of warfarin and aspirin in 
combination.
Another feature of the expert system knowledge-base which should be evaluated is the 
knowledge acquired from the experienced stroke physician. This could be done by 
obtaining estimates of the quantities required from a number of other clinicians 
experienced in the area, and comparing their estimates with those currently in use in the 
expert system. Another possible method would be to perform a sensitivity analysis of 
these quantities, to determine which were influential on the final output of the expert 
system. Alternative estimates of the quantities found to be influential could then be 
sought from other human experts, in order to check the validity of the estimates currently 
in place.
This study emphasised practical uses for uncertain patient data, since the expert system 
does not require definite information on a given variable. The physician may enter the 
strength of evidence as a probability that the event has occurred, if some uncertainty 
exists. For example, this may occur through a suggestion that a frail patient might have a 
history of falls, although no definite evidence is available. Similarly, a carotid stenosis 
may be present on Doppler ultrasound but it may be difficult to determine whether it is 
moderate or severe.
In conclusion, this evaluation has shown that the output of the expert system 
corresponded well with the decisions of clinical staff who were experienced in stroke 
care. After suitable changes to the expert system structure have been made, its 
performance should be evaluated in a large-scale study involving less specialised 
physicians in order to assess its potential contribution to clinical management decision­
making in acute stroke.
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Chapter Eleven 
Conclusions
11.1 Summary and implications of results
Chapter 2 showed that diagnostic scoring systems were of little practical use in the 
differential diagnosis of haemorrhagic and ischaemic stroke. This indicates that CT 
scanning is an essential first step to enable appropriate clinical management of stroke, 
although diagnostic scoring systems may provide useful information in situations where 
CT scanning is unavailable. The results of chapter 3 excluded the DD polymorphism of 
the ACE gene from being a major risk factor for acute stroke. The search for an 
appropriate genetic marker for stroke will therefore continue, through experimental 
animal studies and case-control studies in humans. Chapters 4 and 5 investigated the 
capabilities of MCTT and SPECT scanning in acute ischaemic stroke prognosis. Although 
MCTT scanning is convenient and quick to perform, it was a poor predictor of functional 
outcome. SPECT performed rather better in the prediction of functional outcome. 
However, it is difficult to provide a 24-hour SPECT service which would enable patients
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to be scanned soon after stroke. This early scanning improves the prognostic power of 
SPECT. In addition, SPECT did not appear to give better outcome prediction than 
achieved in studies which related clinical features and functional outcome.
Chapter 6 compared three established neurological scales and a prognostic score based 
on clinical features in terms of their prognostic accuracy. The NIHSS was the best 
predictor of outcome three months after acute stroke. An attempt to derive a new 
prognostic score from the ASU database confirmed the prognostic power of the NIHSS 
and identified three clinical features (atrial fibrillation, loss of consciousness at stroke 
onset, and total limb power) which added to the predictive power of the NIHSS. A score 
based on six simple clinical features was also derived. In the localised setting of its 
development, this clinical score predicted outcome almost as accurately as the more 
complex score involving the NIHSS. Simplified versions of these two prognostic scores 
were developed in order to facilitate their calculation in clinical practice. Chapter 7 
showed that the adverse effect of hyperglycaemia on survival after acute stroke is not 
due to a relationship between stroke severity and plasma glucose level. A randomised 
controlled clinical trial of glycaemic control in the hours immediately following acute 
stroke should therefore be performed in order to assess whether the adverse effect of 
hyperglycaemia may be reduced.
Chapter 8 reported on the development of a computer program to streamline the 
checking of the entry and exclusion criteria of concurrent clinical trials. This program 
achieved its aim of ascertaining the appropriate clinical trials in a quick and efficient 
manner. It has yet to be fully implemented as a routine part of acute stroke unit patient 
management. Chapters 9 and 10 utilised expert system methodology to assist clinical 
management relating to secondary prevention of stroke in ischaemic stroke patients. The 
expert system gave output on the consequences of long-term anticoagulation and 
antiplatelet therapy which was consistent with decisions made by human experts. The 
initial evaluation of the expert system suggested that it may be a valuable tool in the 
management of acute stroke. An important feature of the expert system is that it 
combines clinical data, knowledge from clinical trials results and from humans 
experienced in stroke care to provide output which is tailored to the individual patient.
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11.2 Future work
One question which remains to be answered regards the method by which prognostic 
information should be incorporated in the patient management process. Provision of 
prognostic information influences the management of head injured patients. (Murray et 
al, 1993) One possibility within the acute stroke expert system would be to allow 
prognostic variables to influence directly the probabilities of each therapeutic 
intervention being prescribed. This would clearly increase the complexity of the expert 
system. An alternative solution would be to limit the use of the expert system to patients 
in whom the probability of poor functional outcome was relatively low. This could be 
done using either the NIHSS alone or prognostic score 6C derived in chapter 6.
Having demonstrated the use of expert system methodology in one aspect of acute 
stroke management, this could be extended to other issues. The uncertainties associated 
with the control of hypertension directly after acute stroke could be dealt with using 
expert system techniques. Similarly, selection of patients in whom the benefits of carotid 
endarterectomy would exceed the risks could be performed using output generated by an 
expert system. Expert system techniques allow results of large clinical trials and general 
“rules of thumb” for patient management to be tailored to the individual patient.
The evaluation of the system in 24 patients in chapter 10 prompted several changes to be 
made to the expert system. Having made these changes to the system, the next step 
should be to evaluate the effects of the introduction of the expert system in clinical 
practice on actual clinical management decisions. Funding has been obtained for such an 
evaluation through a training fellowship in health services research provided by the 
Medical Research Council. In any large-scale evaluation of the expert system, attention 
would have to be paid to methods of interpreting the expert system outcome. The 
costing measure associated with each adverse event in the evaluation in chapter 10 was 
rather crude: quantities which are more strongly related to individual patient preferences 
are desirable. Use of measures based on health economics techniques, such as QALYs 
and HYEs, should be further explored. However, such quantities would have to be 
obtained from a pilot study since they have not previously been calculated for any of the
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stroke syndromes. (Forbes, 1993) If this approach proved intractable, the probabilities 
of adverse events under each of the therapeutic strategies could be presented directly to 
the duty clinician for his or her own interpretation.
Traditional patient randomisation would not be appropriate for the expert system 
evaluation, since contamination between the “expert system” and “no expert system” 
groups could occur at the doctor or ward level. If randomisation was carried out at 
patient level, the influence of the expert system on patient management may be 
underestimated. Larger randomisation units, such as consultant or ward, could be used. 
The sample size required would have to be inflated due to the intra-class correlation 
between patients within each randomisation unit. The results of this evaluation would 
give the final verdict on whether the expert system could be a valuable addition to 
everyday clinical practice.
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Appendix Al: Clinical trials enrolment program
Appendix A1
KPWin source code for the clinical trial selection program.
^include desscrob.src 
program().
topic program.
if list_length(?window_list) > 0 then close_window(last(?window_list)).
W I N (). 
w1 is
window(,27,4,36,15,,[ChildWindow,visible],?WIN:!whandle,black,white,). 
setup().
Iterate().
Trial is remove(?Trial,last(?Trial)).
Number is list_length(?Trial).
if ?Number is 0 then NoTrialO else Details(?Number). 
program().
topic setup.
reset([mark:enrol,program:Trial,program:Iterate:TrialChoice:Territory,program 
:Iterate:TrialChoice:OnsetTime,program:Iterate:TrialChoice:Age,program:Iterat 
e :TrialChoice:Previous,program:Iterate:TrialChoice:Coma,program:Iterate:Trial 
Choice:Ischaemic,program:Iterate:TrialChoice:Seizure,program:Iterate:TrialCho 
ice:Warfarin,program:Iterate:TrialChoice:Q T ,program:Iterate:TrialChoice:H B ,pr 
ogram:Iterate:TrialChoice:M I ,program:Iterate:TrialChoice:Prog,program:Iterate 
:TrialChoice:bpd,program:Iterate:TrialChoice:b p s ,program:Iterate:TrialChoice: 
Trauma,program:Iterate:TrialChoice:ACEI,program:Iterate:info]). 
set_file_pos('\kpwinpp\samples\trial3.txt',0). 
end.(*setup*)
topic Iterate, 
repeat
info is read_line('\kpwinpp\samples\trial3.txt',1) and 
info is string_replace(?info,1/,1,[],100) and 
info is string_to_list(?info,/,t) and 
info is rest(?info) and 
TrialChoice() 
until first(?info) is EOF.
topic TrialChoice.
if element(?info,2) is 0 then Iterate (). 
flag3 is F. 
flag4 is F. 
flag5 is F.
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Truncate(element(?info,3)).
if ?List2 = [] or one_of(?List2,?Territory) then flag3 is T. 
Truncate(element(?info,4))-
if ?List2 = [] or one_of(?List2,?OnsetTime) then flag4 is T. 
Truncate(element(?info,9) ) .
if ?List2 = [] or one_of(?List2,?Ischaemic) then flag5 is T. 
if ?flag3 is T and ?flag4 is T and ?flag5 is T and
] or ?Age > element(?info,5) and 
] or ?Age < element(?info,6) and 
] or ?Previous is element(?info,7) and 
'] or ?Coma is element(?info,8) and 
[] or TTrauma is element(?info,10) and 
[] or ?Warfarin is element(?info,11) and
[] or ?QT is element(?info,12) and
[] or ?HB is element(?info,13) and
[] or ?MI is element(?info,14) and
[] or ?Prog is element(?info,15) and
((element(?info,16) = [] or ?bpd > element(?info,16) and 
element(?info,17) = [] or ?bpd < element(?info,17)) or
(element(?info,18) = [] or ?bps > element(?info,18) and 
element(?info,19) = [] or ?bps < element(?info,19))) and
element(?info,20) = [] or 7ACEI is element(?info,20) and
element(?info,21) = [] or ?Seizure is element(?info,21)
then program:Trial gets first(?info).
element
element
element
element
element
element
element
element
element
element
(?info,5) = [ 
(?info,6) = [ 
(?info,7) = [ 
(?info,8) = [ 
(?info,10) 
(?info,11) 
(?info,12) 
(?info,13) 
(?info,14) 
(?info,15)
topic Truncate(string).
Size is string_length(?string).
List is string_copy(?string,2,?Size-2). 
List2 is string_to_list(?List,','). 
end.(^truncate*)
topic Territory.
text('#e#n Which arterial territory is the stroke in?'). 
Ib1 is list_box(['supratentorial - mca1 supratentorial - 
aca1,1supratentorial - pea','infratentorial - 
vb'],Assign1,9,5,19,,,,[list_select_event]). 
pause().
topic Assignl(selection).
Territory is ?selection.
end.
end. (*territory*)
topic OnsetTime.
text('#e#n What is the maximum time which#n may have elapsed 
since onset?').
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Ib1 is list_box(['Less than 6 hours','Less than 12 hours','Less 
than 24 hours','Less than 48 hours','Less than 7 
days 1],Assign2,8,5,,,,, [list_select_event]). 
pause().
topic Assign2(selection).
OnsetTime is ?selection.
end.
end. (*OnsetTime*)
topic Age.
text('#e#n What age is the patient?'). 
ed1 is edit_line(,Assign3,15,5,6). 
set_focus(?ed1). 
pause2().
topic pause2.
button(Continue,continue,13,11). 
wait().
if get_text(?ed1) is [] then set_focus(?ed1) and pause2(). 
end.
topic Assign3(). 
continue().
if get_text(?ed1) < 1 or get_text(?ed1) > 120 then Age().
Age is get_text(?ed1). 
end. 
end.(*Age*)
topic Previous.
text('#e#n Was the patient significantly disabled#n before the 
stroke? (Rankin grade >= 2)').
Ib1 is list_box([Yes,No],Assign4,15,5,,,,,[list_select_event]). 
pause().
topic Assign4(selection).
Previous is ?selection. 
end.
end. (*Previous*) 
topic Coma.
text('#e#n Is the patient conscious?#n (able to localise
pain)').
Ib1 is list_box([Yes,No],Assign5,15,5,,,,,[list_select_event]). 
pause().
topic Assign5(selection).
Coma is ?selection.
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end. 
end.(*Coma*)
topic Ischaemic.
text('#e#n If performed, did the CT exclude#n haemorrhage?1). 
Ib1 is l i s t b o x ([Yes,No,'CT not 
done'],Assign6,11,5,,,,,[list_select_event]). 
pause().
topic Assign6(selection).
Ischaemic is ?selection. 
end.
end.(*Ischaemic*) 
topic Trauma.
text('#e#n Is there evidence of significant head#n trauma?1). 
Ib1 is list_box([Yes,No],Assign7,15,5,,,,,[list_select_event]). 
pause().
topic Assign7(selection).
Trauma is ?selection. 
end. 
end.(*Trauma*)
topic Warfarin.
text('#e#n Is the patient on Warfarin?').
Ib1 is list_box([Yes,No],Assign8,15,5,,,,,[list_select_event]). 
pause().
topic Assign8(selection).
Warfarin is ?selection. 
end.
end.(*Warfarin*) 
topic QT.
text('#e#n Is the ECG QT interval < 0.45 seconds?').
Ib1 is l i s t b o x ([Yes,No],Assign9,15,5,,,,,[list_select_event]). 
pause().
topic Assign9(selection).
QT is ?selection. 
end. 
end.(*QT*)
topic HB.
text('#e#n Is the patient in heart block?#n ( > 1st degree)'). 
Ib1 is list_box([Yes,No],Assignl0,15,5,,,,,[list_select_event]) 
pause().
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topic Assignl0 (selection).
HB is ?selection. 
end. 
end.(*HB*)
topic MI.
text('#e#n Has the patient suffered MI in the past#n six
weeks?').
lbl is list_box([Yes,No],Assignl1,15,5,,,,,[list_select_event]). 
pause().
topic Assignl1 (selection).
MI is ?selection. 
end. 
end.(*MI*)
topic Prog.
text('#e#n Has the course of the stroke been#n progressive?'). 
Ib1 is list_box([Yes,No],Assignl2,15,5,,,,,[list_select_event]). 
pause().
topic Assignl2 (selection).
Prog is ?selection. 
end. 
end.(*Prog*)
topic bpd.
text('#e#n What is the diastolic blood pressure?'). 
ed2 is edit_line(,Assignl3d,15,5,6). 
set_focus(?ed2). 
pause3().
topic pause3.
button(Continue,continue,13,11). 
wait ().
if gettext(?ed2) is [] then set_focus(?ed2) and pause3(). 
end.
topic Assignl3d(). 
continue().
if get_text(?ed2) <30 or get_text(?ed2) > 150 then b p d (). 
bpd is get_text(?ed2). 
end. 
end.(*bpd*)
topic bps.
text('#e#n What is the systolic blood pressure?').
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ed3 is edit_line(,Assignl3s,15,5,6). 
set_focus(?ed3). 
pause4().
topic pause4.
button(Continue,continue,13,11). 
wait ().
if get_text(?ed3) is [] then set_focus(?ed3) and pause4(). 
end.
topic Assignl3s(). 
continue().
if get_text(?ed3) <50 or get_text(?ed3) > 250 then b p s (). 
bps is get_text(?ed3). 
end. 
end.(*bps*)
topic ACEI.
text('#e#n Are ACE inhibitors clearly indicated#n or 
contraindicated, or is the patient#n already taking an ACE inhibitor?1).
Ib1 is list_box([Yes,No],Assignl4,15,6,,,,,[list_select_event]). 
pause().
topic Assignl4 (selection).
ACEI is ?selection. 
end. 
end.(*ACEI*)
topic Seizure.
text('#e#n Is there evidence of seizure activity?1).
Ib1 is list_box([Yes,No],Assignl5,15,5,,,,,[list_select_event]). 
pause().
topic Assignl5 (selection).
Seizure is ?selection. 
end. 
end.
end. (*TrialChoice*)
topic pause.
button(Continue,continue,13,11). 
wait ().
if get_list_box(?lb1) is [] then pause(). 
end.(*pause*)
end.(*Iterate*)
topic NoTrial.
216
Appendix Al: Clinical trials enrolment program
text('#e#n#n#n The patient is not eligible for any trial'). 
b1 is button(Exit,action,10,8). 
b2 is button(Restart,action,19,8). 
wait().
topic action(item).
if ?item is Exit then e x i t k p O  else continue() and program(). 
end.
end.(*NoTrial*)
topic Details(num).
if ?num is 1 then text(concat('#e#n This patient potentially is 
eligible for the #n # m ',?Trial,'#m trial.1)) else
text('#e#n This patient potentially is eligible for the#n following 
trials (in order of priority):#n1) and state(?num).
topic state(lines). 
to_go is ?lines. 
repeat
text(concat('#n#t # m ',element(?Trial,?lines-
?to_go+1),'#m ')) and
to_go is ?to_go-1 
until ?to_go is 0. 
end.
if ?num>1 then text(1#n#n Click on trial name to check further#n 
criteria for a given trial1) else
text('#n#n Click on the trial name to check#n further criteria for 
this trial').
b1 is button(Exit,action,10,13). 
b2 is button(Restart,action,19,13). 
wait () .
topic action(item).
if ?item is Exit then exit_kp() else continue() and program(). 
end.
end.(*details*)
end.(*program*)
Topic 'WIN'.
CreateFonts ( ) .
CreateObjects ( ) . 
hyper_display (green2). 
show window (?!wHandle).
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topic WindowEventTopic ( info, event, handle ). 
end.
topic CreateObjects.
WIN:IwHandle is screen_object ( [window, WindowEventTopic, 1, 1, 91.42, 
30, 'Clinical Trial Allocation', [showchildren, siblings, titlebar, 
thickframe], , black, 8519679, ],1 ). 
end. (* CreateObjects *)
topic CreateFonts. 
fontList is [[-0.8125, 0, 400, F, F, F, 0, 1, 34, Arial]]. 
fontHandleList is apply ( create_char_font, ?fontList ). 
end. 
end.
topic 'no risk'.
clarify('#e#n No risk of pregnancy is defined as being#n post-menopausal, 
surgically sterilised or#n having had a negative pregnancy test').
end.
topic alcohol.
clarify('#e#n Alcohol abuse is defined as consumption^ of 14 or more 
units per week on a regular#n basis for women; 21 or more units per#n week on 
a regular basis for men; one unit#n equals one glass of wine or one half 
pint#n of beer.'), 
end.
topic 'major coexisting illness'.
clarify('#e#n Major coexisting illness is defined as:-#n#n cardiac failure 
(NYHA grade IV)^n systemic malignancy#n renal or hepatic failure#n 
dementia'). 
end.
topic G I .
clarify('#e#n#n GI disease includes ulcers and bleeding').
end.
topic 'systemic malignant'.
clarify('#e#n#n Systemic malignant disease is significant#n only if it has 
occurred in the last 5 years'), 
end.
topic cardiovascular.
if ?mark:item is Remacemide then clarify('#e#n For the Remacemide trial, 
cardiovascular#n disease is defined as:#n severe hypertension (dbp >120 
mmHg ) # n  valvular heart disease#n congestive heart failure (NYHA grades IIl#n 
and IV)').
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if ?mark:item is Selfotel then clarify(1U&Un For the Selfotel trial, 
cardiovascular#n disease is defined as:#n ventricular arrhythmia, unstable 
angina , U n decompensated heart failure , U n severe hypertension'), 
end.
topic 'every day activities'.
clarify ( ' UeUnUn Every day activities are defined as:#n#n dressing,washing, 
bathing, eating , U n walking or using the toilet'), 
end.
topic 'neurological disease'.
clarify ( ' UeUnUn Neurological disease is defined a s : U n U n tumour, 
infarction, dementia'). 
end.
topic liver.
clarify('U&UnUn Liver failure is defined as:#n prothrombin time prolonged 
by#n >=5 seconds pre-treatment'), 
end.
topic renal.
if ?mark:item is 'Posterior SK' then clarify ( ' Ue UnUn Renal failure is 
defined as:#n creatinine > 200 umol per litre').
if ?mark:item is Perindopril then clarify ( ' Ue UnUn Renal failure is defined 
as:#n serum creatinine > 200 umol per litre, or#n urea > 10 mmol per litre'), 
end.
topic 'cardiac failure'.
clarify ( ' Ue UnUn Cardiac failure is defined as NYHA#n grades II, III or 
IV' ) . 
end.
topic 'disallowed medications'.
if ?mark:item is Perindopril then clarify ( ' Ue Un Disallowed medications for 
the Perindopril#n trial are: potassium supplements, lithium , Un neuroleptics,
imipramine-type anti-#n depressants and cardiovascular drug#n therapy 
maintained or initiated after stroke#n onset (excluding aspirin, heparin)').
if ?mark:item is Selfotel then clarify ( ' UeUn Disallowed concomitant 
medications#n during the first 72hrs are: thrombolytics, Un centrally-acting 
Ca++ channel blockers Un (nimodipine, nicardipine, felodipine, Un loradipine, 
amlodipine) and nifedipine'), 
end.
topic clarify(ex), 
wc is
window(,27,20,36,9,,[ChildWindow,visible],TWIN:!wHandle,black,white,). 
text(?ex). 
set focus(?w1).
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end.
topic mark(item).
set_file_pos('c:\kpwinpp\samples\details.txt',0). 
questions is
read('c :\kpwinpp\samples\details.txt',concat('//',?item)
answers is read('c :\kpwinpp\samples\details.txt1,concat('**',?item),'**'). 
questions is string_to_list(?questions,'/'). 
answers is string_to_list(?answers,1 *') . 
apply(furtherq,?questions,?answers).
text(concat('#e#n#n The patient has satisfied the entry criteria#n for the 
',?item,1 trial.')). 
enrol gets ?item.
program:Trial is remove(?program:Trial,?item).
if list_length(?program:Trial) is 0 then report ().
bO is button('Test Other Trial Details 1,action,6,10).
b1 is button(Exit,action,8,1 3) .
b2 is button(Restart,action, 1 9,1 3).
w ait().
topic action(choice).
if ?choice is 'Test Other Trial Details' then continue() and 
program:Details(list_length(?program:Trial)). 
if ?choice is Exit then exit_kp().
if ?choice is Restart then continue() and program(). 
end.
topic report().
if list_length(?enrol) is 0 then program:NoTrial(). 
if list_length(?enrol) is 1 then text(concat('#e#n#n Detailed 
questioning has confirmed that#n the patient is eligible for the ',?enrol , ' # n  
trial')) else
text('# e # n # n  Detailed questioning has confirmed that#n the patient 
is eligible for the following trials#n (in order of priority)') and 
state(list_length(?enrol)).
if one_of(?enrol,'Posterior SK') then text('#n#n #fred You should 
discuss this patient with the#n duty consultant before proceeding with#n the 
Posterior SK trial').
if one_of(?enrol,'Selfotel') and ?program:Iterate:TrialChoice:Ischaemic 
is 'CT not done' then text('#n#n #fred CT should be performed as soon as#n 
possible after dosing to exclude brain#n stem ischaemia, tumour and 
intracranial#n haemorrhage').
b1 is button(Exit,action,10,13). 
b2 is button(Restart,action, 1 9,1 3). 
wait () .
topic action(item).
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if ?item is Exit then exit_kp() else continue() and program(). 
end.
topic state(lines). 
to_go is ?lines. 
repeat
text(concat(1#n#t 1,element(?enrol,?lines-?to_go+1))) and
to_go is ?to_go-1 
until ?to_go is 0. 
end.
end.
topic furtherq(q,a).
set_display_window(?w1). 
text(concat('#e#n 1,?q)).
Ib1 is l i s t b o x ([Yes,No],,15,8,,,,,[list_select_event]). 
hold().
topic hold.
button(Continue,continue,13,12). 
wait().
if get_list_box(?lb1) is [] then hold(). 
if get_list_box(?lb1) <> ?a then warn(). 
end.
topic warn().
set_display_window(?w1 ) .
text(concat(1#e#n#fred Ut WARNING#fblack #n#n The selection
you have made #fred (',get_list_box(?lb1),')#fblack will#n result in the 
patient being ineligible for#n the ',?mark:item,' trial. Do you wish to#n 
alter the selection?')).
b1 is button(Yes,input,10,10). 
b2 is button(No,input,22,10). 
w ait().
topic input(i).
if ?i is Yes then continue() else
program:Trial is remove(?program:Trial,?mark:item) and 
if list_length(?program:Trial) is 0 then report() else 
program:Details(list_length(?program:Trial)). 
end. (*input*)
end.(*warn*)
end.(*furtherq*)
end.(*mark*)
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Conditional probability tables quantifying relationships between variables in model 9.2.
Abbreviations used are as in figure 9.2.
Variable Probability distribution
patient’s age (A) P (A <60) 0.20
P (A s  [60 , 69]) 0.26
P (A e [70 , 79]) 0.33
P (A > 79) 0.21
atrial fibrillation (AF) P (AFIA <60) 0.14
P (AF I A > 60 and A £ 69) 0.17
P (AFIA>70and A <79) 0.19
P (AF I A > 79 ) 0.21
haemorrhagic risk P (no HRF) 0.66
factors (HRF) P (one or more HRF) 0.34
therapy (T) P (T = no treatment I no AF, no HRF) 0.95
P (T = warfarin I no AF, no HRF) 0.05
P (T = no treatment I AF, no HRF) 0.20
P (T = warfarin I AF, no HRF) 0.80
P (T = no treatment I no AF, HRF) 0.99
P (T = warfarin I no AF, HRF) 0.01
P (T = no treatment I AF, HRF) 0.98
P (T = warfarin I AF, HRF) 0.02
ischaemic stroke P ( R = yes I no AF, T = warfarin) 0.03
recurrence (R) P ( R = yes I AF, T = warfarin) 0.06
P ( R = yes I no AF, T = no treatment) 0.08
P ( R = yes I AF, T = no treatment) 0.14
intracerebral P (ICH IT = no treatment) 0.001
haemorrhage (ICH) P (ICH I T = warfarin) 0.003
other haemorrhagic P (OH I T = warfarin, no HRF) 0.028
complications (OH) P (OH I T = no treatment, no HRF) 0.001
P (OH I T = warfarin, 1 or more HRF) 0.300 
P (OH I T = no treatment, 1 or more HRF) 0.002
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Conditional probability tables quantifying relationships between variables in model 9.3.
Abbreviations used are as in figure 9.3.
Variable Probability distribution
vascular risk factors P (no VRF) 0.45
(VRF) P (one or more VRF) 0.55
patient’s age (A) P (A <50) 0.07
P (A g [50 , 59]) 0.13
P (A g [60 , 69]) 0.26
P (A g [70 , 79]) 0.33
P (A > 79 ) 0.21
atrial fibrillation P (AF present 1 A <50) 0.02
(AF) P (AF present 1 A g [50 , 59]) 0.10
P (AF present 1 A g [60 , 69]) 0.17
P (AF present 1 A g [70 , 79]) 0.19
P (AF present 1 A > 79 ) 0.27
haemorrhagic risk P (no HRF) 0.66
factors (HRF) P (one minor HRF) 0.25
P (two minor HRF) 0.06
P (three minor HRF) 0.01
P (active peptic ulcer HRF) 0.02
ischaemic stroke P (R 1 T = no treatment and E l = neither) 0.05
recurrence (R) P (R 1 T = warfarin and E l = neither) 0.02
P (R 1 T = aspirin and E l = neither) 0.04
P (R 1 T = no treatment and E l = VRF only) 0.15
P (R 1 T = warfarin and E l = VRF only) 0.05
P (R 1 T = aspirin and E l = VRF only) 0.13
P (R 1 T = no treatment and E l = AF only) 0.12
P (R 1I T = warfarin and E l = AF only) 0.04
P (Rl T = aspirin and E l = AF only) 0.10
P (R 1T = no treatment and E l = both VRF and AF) 0.22
P (R 1T = warfarin and E l = both VRF and AF) 0.07
P (R 1T = aspirin and E l = both VRF and AF) 0.17
223
Appendix B2: Model 3 conditional probabilities
Conditional probability tables quantifying relationships between variables in model 9.3.
Variable Probability distribution
therapy (T) P (T = no treatment 1 HRF = none and AF = no) 0.05
P (T = warfarin 1 HRF = none and AF = no) 0.05
P (T = aspirin 1 HRF = none and AF = no) 0.90
P (T = no treatment 1 HRF = none and AF = yes) 0.01
P (T = warfarin 1 HRF = none and AF = yes) 0.80
P (T = aspirin 1 HRF = none and AF = yes) 0.19
P (T = no treatment 1 HRF = one minor and AF = no) 0.05
P (T = warfarin 1 HRF = one minor and AF = no) 0.00
P (T = aspirin 1 HRF = one minor and AF = no) 0.95
P (T = no treatment 1 HRF = one minor and AF = yes) 0.01
P (T = warfarin 1 HRF = one minor and AF = yes) 0.70
P (T = aspirin 1 HRF = one minor and AF = yes) 0.29
P (T = no treatment 1 HRF = two minor and AF = no) 0.05
P (T = warfarin 1 HRF = two minor and AF = no) 0.00
P (T = aspirin 1 HRF = two minor and AF = no) 0.95
P (T = no treatment 1 HRF = two minor and AF = yes) 0.02
P (T = warfarin 1 HRF = two minor and AF = yes) 0.60
P (T = aspirin 1 HRF = two minor and AF = yes) 0.38
P (T = no treatment 1 HRF = three minor and AF = no) 0.05
P (T = warfarin 1 HRF = three minor and AF = no) 0.00
P (T = aspirin 1 HRF = three minor and AF = no) 0.95
P (T = no treatment 1 HRF = three minor and AF = yes) 0.03
P (T = warfarin 1 HRF = three minor and AF = yes) 0.40
P (T = aspirin 1 HRF = three minor and AF = yes) 0.57
P (T = no treatment 1 HRF = active peptic ulcer and AF = no) 1.00
P (T = warfarin 1 HRF = active peptic ulcer and AF = no) 0.00
P (T = aspirin 1 HRF = active peptic ulcer and AF = no) 0.00
P (T = no treatment 1 HRF = active peptic ulcer and AF = yes) 0.95
P (T = warfarin 1 HRF = active peptic ulcer and AF = yes) 0.01
P (T = aspirin 1 HRF = active peptic ulcer and AF = yes) 0.04
either VRF or logical link, possible values being
AF (El) neither, VRF only, AF only, both
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Conditional probability tables quantifying relationships between variables in model 9.3.
Variable Probability distribution
intracerebral P (ICH 1 T = no treatment) 0.001
haemorrhage (ICH) P (ICH 1 T = warfarin) 0.003
P (ICH IT = aspirin) 0.001
other haemorrhagic P (OH 1T = no treatment and HRF = none) 0.003
complications (OH) P (OH 1T = warfarin and HRF = none) 0.023
P (OH 1T = aspirin and HRF = none) 0.006
P (OHI T = no treatment and HRF = one minor) 0.005
P (OH 1T = warfarin and HRF = one minor) 0.026
P (OH 1T = aspirin and HRF = one minor) 0.008
P (OH 1T = no treatment and HRF = two minor) 0.007
P (OH 1T = warfarin and HRF = two minor) 0.028
P (OH 1T = aspirin and HRF = two minor) 0.009
P (OH 1T = no treatment and HRF = three minor) 0.008
P (OHI T = warfarin and HRF = three minor) 0.030
P (OH 1T = aspirin and HRF = three minor) 0.010
P (OH 1 T = no treatment and HRF = active peptic ulcer) 0.30
P (OH 1 T = warfarin and HRF = active peptic ulcer) 0.95
P (OH 1 T = aspirin and HRF = active peptic ulcer) 0.80
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Conditional probability tables quantifying relationships between variables in model 9.4.
Abbreviations used are as in figure 9.4.
Variable Probability distribution
vascular risk factors P (no VRF) 0.45
(VRF) P (one or more VRF) 0.55
patient’s age (A) P (A <50) 0.07
P (A g  [50 , 59]) 0.13
P (A e [60 , 69]) 0.26
P (A g  [70 , 79]) 0.33
P (A > 79 ) 0.21
atrial fibrillation (AF) P (AF present 1 A <50) 0.02
P (AF present 1 A g  [50 , 59]) 0.10
P (AF present 1 A g  [60 , 69]) 0.17
P (AF present 1 A g  [70 , 79]) 0.19
P (AF present 1 A > 79 ) 0.27
haemorrhagic risk P (no HRF) 0 .6 6
factors (HRF) P (one minor HRF) 0.25
P (two minor HRF) 0.06
P (three minor HRF) 0.01
P (active peptic ulcer HRF) 0.02
cardiac source (CS) P (no CS) 0.85
P (one or more CS) 0.15
carotid artery stenosis P (no CA) 0.7
or occlusion (CA) P (CA present) 0.3
number of cardiac 
sources (NCS)
sum of CS and AF variables
embolic source for P (ES 1 NCS = 0 and no CA) 0.4
ischaemic stroke (ES) P (ES 1 NCS = 0 and CA) 0.2
P (ES 1 NCS > 1 and no CA) 0.7
P (ES 1 NCS > 1 and CA) 0.4
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Conditional probability tables quantifying relationships between variables in model 9.4.
Variable Probability distribution
therapy (T) P (T = no treatment I HRF = none and ES = no) 0.05
P (T = warfarin I HRF = none and ES = no) 0.05
P (T = aspirin I HRF = none and ES = no) 0.90
P (T = no treatment I HRF = none and ES = yes) 0.01
P (T = warfarin I HRF = none and ES = yes) 0.80
P (T = aspirin I HRF = none and ES = yes) 0.19
P (T = no treatment I HRF = one minor and ES = no) 0.05
P (T = warfarin I HRF = one minor and ES = no) 0.00
P (T = aspirin I HRF = one minor and ES = no) 0.95
P (T = no treatment I HRF = one minor and ES = yes) 0.01
P (T = warfarin I HRF = one minor and ES = yes) 0.70
P (T = aspirin I HRF = one minor and ES = yes) 0.29
P (T = no treatment I HRF = two minor and ES = no) 0.05
P (T = warfarin I HRF = two minor and ES = no) 0.00
P (T = aspirin I HRF = two minor and ES = no) 0.95
P (T = no treatment I HRF = two minor and ES = yes) 0.02
P (T = warfarin I HRF = two minor and ES = yes) 0.60
P (T = aspirin I HRF = two minor and ES = yes) 0.38
P (T = no treatment I HRF = three minor and ES = no) 0.05
P (T = warfarin I HRF = three minor and ES = no) 0.00
P (T = aspirin I HRF = three minor and ES = no) 0.95
P (T = no treatment I HRF = three minor and ES = yes) 0.03
P (T = warfarin I HRF = three minor and ES = yes) 0.40
P (T = aspirin I HRF = three minor and ES = yes) 0.57
P (T = no treatment I HRF = active peptic ulcer and ES = no) 1.00
P (T = warfarin I HRF = active peptic ulcer and ES = no) 0.00
P (T = aspirin I HRF = active peptic ulcer and ES = no) 0.00
P (T = no treatment I HRF = active peptic ulcer and ES = yes) 0.95
P (T = warfarin I HRF = active peptic ulcer and ES = yes) 0.01
P (T = aspirin I HRF = active peptic ulcer and ES = yes) 0.04
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Conditional probability tables quantifying relationships between variables in model 9.4.
Variable Probability distribution
ischaemic stroke P (R 1 T = no treatment and E l = neither) 0.050
recurrence (R) P (R 1 T = warfarin and E l = neither) 0.035
P (R 1 T = aspirin and E l = neither) 0.040
P (R 1 T = no treatment and E l = VRF only) 0.15
P (R 1 T = warfarin and E l = VRF only) 0.11
P (R 1 T = aspirin and E l = VRF only) 0.13
P (R 1 T = no treatment and E l = AF only) 0.12
P (R 1 T = warfarin and E l = AF only) 0.04
P (R 1 T = aspirin and E l = AF only) 0.10
P (R 1 T = no treatment and E l = both VRF and AF) 0.22
P (R 1 T = warfarin and E l = both VRF and AF) 0.07
P (R 1 T = aspirin and E l = both VRF and AF) 0.17
either VRF or AF logical link, possible values being
(El) neither, VRF only, AF only, both
intracerebral P (ICH 1 T = no treatment) 0.001
haemorrhage (ICH) P (ICH 1 T = warfarin) 0.003
P (ICH IT  = aspirin) 0.001
other haemorrhagic P (OHI T = no treatment and HRF = none) 0.003
complications (OH) P (OH 1T = warfarin and HRF = none) 0.023
P (OH 1T = aspirin and HRF = none) 0.006
P (OH 1T = no treatment and HRF = one minor) 0.005
P (OH 1T = warfarin and HRF = one minor) 0.026
P (OH 1T = aspirin and HRF = one minor) 0.008
P (OH 1T = no treatment and HRF = two minor) 0.007
P (OH 1T = warfarin and HRF = two minor) 0.028
P (OH 1T = aspirin and HRF = two minor) 0.009
P (OH 1T = no treatment and HRF = three minor) 0.008
P (OH 1T = warfarin and HRF = three minor) 0.030
P (OH 1T = aspirin and HRF = three minor) 0.010
P (OH 1 T = no treatment and HRF = active peptic ulcer) 0.30
P (OH 1 T = warfarin and HRF = active peptic ulcer) 0.95
P (OH 1 T = aspirin and HRF = active peptic ulcer) 0.80
228
Appendix C1
Conditional probability tables quantifying relationships between variables in the expanded
expert system model.
Age
P (age < 50) 0.07
P (age e [50 , 59]) 0.13
P (age e [60 , 69]) 0.26
P (age e [70,79]) 0.33
P (age > 79) 0.21
History of falls P (History of falls) = 0.05
Poor compliance likely P (Poor compliance likely) = 0.12
Carotid artery (CA) stenosis or occlusion
P (no CA lesion) 0.72
P (CA stenosis, 30-69%) 0.08
P (CA stenosis, 70-99%) 0.14
P (CA occlusion) 0.06
Peptic ulcer (PU)
P (no PU) 0.94
P (dormant PU) 0.055
P (PU active within last 14 days) 0.005
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Age-specific prevalence of CCF, diabetes mellitus, mitral stenosis
CCF diabetes mellitus mitral stenosis
age < 50 0.02 0.04 0.0057
age e [50 , 591 0.10 0.12 0.0047
age e [60 , 69] 0.14 0.10 0.0047
age e [70 , 79] 0.13 0.09 0.0047
age > 79 0.12 0.07 0.0057
Previous Ml
recent old anterior or old inferior MI none
anterior MI recent inferior MI
age < 50 0.0022 0.020 0.0178 0.96
age e [50 , 59] 0.0083 0.075 0.0667 0.85
age e [60 , 69] 0.0116 0.105 0.0934 0.79
age e [70 , 79] 0.0105 0.095 0.0845 0.81
age > 79 0.0100 0.090 0.0800 0.82
Hypertension (HBP)
no HBP controlled HBP uncontrolled HBP
age < 50 0.74 0.19 0.07
age e [50 , 59] 0.54 0.24 0.22
age e [60 , 69] 0.50 0.32 0.18
age <= [70 , 79] 0.55 0.27 0.18
age > 79 0.67 0.23 0.10
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Atrial fibrillation
previous MI no yes
mitral stenosis no yes no yes
age < 50 0.018 0.2 0.025 0.3
age e [50 , 59] 0.09 0.3 0.125 0.4
age e [60 , 69] 0.15 0.4 0.21 0.5
age e [70 , 79] 0.17 0.5 0.24 0.6
age > 79 0.24 0.6 0.34 0.7
Mural thrombus
CCF yes no
previous MI recent anterior 0.30 0.25
old anterior or recent inferior 0.04 0.02
old inferior 0.017 0.007
none 0.017 0.007
Myocardial infarction
diabetes mellitus no yes
previous MI no yes no yes
therapy none 0.04 0.14 0.08 0.20
warfarin 0.027 0.08 0.054 0.12
aspirin 0.032 0.10 0.064 0.15
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Other haemorrhagic complications
(1) No peptic ulcer present
age <79 >79
controlled
HBP
poor
compliance
drug
therapy
none warfarin aspirin none warfarin aspirin
no no 0.0035 0.0140 0.0049 0.0117 0.0467 0.0175
no yes 0.0035 0.0053 0.0044 0.0117 0.0175 0.0149
yes no 0.0061 0.0245 0.0072 0.0175 0.0700 0.0263
yes yes 0.0061 0.0088 0.0070 0.0175 0.0263 0.0228
(2) Dormant peptic ulcer
age <79 >79
controlled
HBP
poor
compliance
drug
therapy
none warfarin aspirin none warfarin aspirin
no no 0.0117 0.0467 0.0175 0.0333 0.1313 0.0438
no yes 0.0117 0.0175 0.0149 0.0333 0.0508 0.0438
yes no 0.0175 0.0700 0.0263 0.0508 0.1925 0.0753
yes yes 0.0175 0.0263 0.0228 0.0508 0.0753 0.0665
(3) Recently active peptic ulcer
age <79 >79
controlled
HBP
poor
compliance
drug
therapy
none warfarin aspirin none warfarin aspirin
no no 0.0350 0.1400 0.0490 0.1173 0.4673 0.1750
no yes 0.0350 0.0525 0.0438 0.1173 0.1750 0.1488
yes no 0.0613 0.2450 0.0718 0.1750 0.7000 0.2625
yes yes 0.0613 0.0875 0.0700 0.1750 0.2625 0.2275
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Intracerebral haemorrhage
drug therapy none warfarin aspirin
controlled HBP? no yes no yes no yes
age < 50 2.5 xlO'5 1.5 xlO"5 7.5 xlO'5 4.5 xlO'5 3.75 xlO'5 2.25 xlO'5
age g  [50 , 59] 2.5 xlO"4 1.5 xlO"4 7.5 xlO-4 4.5 xlO-4 3.75 xlO'5 2.25 xlO"
age g  [60 , 69] 8.5 xlO-4 5.5 xlO"* 0.00255 0.00165 0.001275 8.25 xlO-4
age g  [70 ,79] 0.0016 0.0010 0.0048 0.003 0.0024 0.0015
age > 79 0.0024 0.0016 0.0072 0.0048 0.0036 0.0024
Other ischaemic complications
(1) No atrial fibrillation present
diabetes
mellitus
no yes
mitral
stenosis
mural
thrombus
drug
therapy
none warfarin aspirin none warfarin aspirin
no no 0.009 0.006 0.007 0.018 0.012 0.014
no yes 0.018 0.012 0.014 0.036 0.024 0.028
yes no 0.018 0.012 0.014 0.036 0.024 0.028
yes yes 0.036 0.024 0.028 0.072 0.048 0.056
(2) Atrial fibrillation present
diabetes
mellitus
no yes
mitral
stenosis
mural
thrombus
drug
therapy
none warfarin aspirin none warfarin aspirin
no no 0.018 0.012 0.014 0.036 0.024 0.0228
no yes 0.036 0.024 0.028 0.072 0.048 0.056
yes no 0.036 0.024 0.028 0.072 0.048 0.056
yes yes 0.072 0.048 0.056 0.144 0.096 0.112
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Ischaemic stroke recurrence
(1) Atrial fibrillation present, mitral stenosis absent, mural thrombus absent
carotid artery lesion none 30-69%
stenosis
70-99%
stenosis
occlusion
number of vascular risk 
factors
drug therapy
0 none 0.033 0.078 0.106 0.090
0 warfarin 0.083 0.117 0.158 0.137
0 aspirin 0.100 0.140 0.190 0.160
1 none 0.038 0.094 0.139 0.115
1 warfarin 0.096 0.142 0.208 0.172
1 aspirin 0.115 0.170 0.250 0.210
2 none 0.043 0.108 0.150 0.128
2 warfarin 0.108 0.163 0.225 0.193
2 aspirin 0.130 0.195 0.270 0.225
3 none 0.047 0.117 0.161 0.137
3 warfarin 0.117 0.175 0.242 0.205
3 aspirin 0.140 0.210 0.290 0.250
4 none 0.050 0.122 0.167 0.142
4 warfarin 0.125 0.183 0.250 0.213
4 aspirin 0.150 0.220 0.300 0.260
5 none 0.053 0.127 0.172 0.147
5 warfarin 0.133 0.192 0.258 0.222
5 aspirin 0.160 0.230 0.310 0.270
(2) Atrial fibrillation present, either mitral stenosis or mural thrombus present
carotid artery lesion none 30-69%
stenosis
70-99%
stenosis
occlusion
number of vascular risk 
factors
drug therapy
0 none 0.100 0.145 0.173 0.157
0 warfarin 0.250 0.283 0.325 0.300
0 aspirin 0.300 0.340 0.390 0.360
1 none 0.105 0.161 0.206 0.182
1 warfarin 0.263 0.308 0.375 0.342
1 aspirin 0.315 0.370 0.450 0.410
2 none 0.110 0.175 0.217 0.195
2 warfarin 0.275 0.329 0.392 0.354
2 aspirin 0.330 0.395 0.470 0.425
3 none 0.114 0.184 0.228 0.204
3 warfarin 0.283 0.342 0.408 0.375
3 aspirin 0.340 0.410 0.490 0.450
4 none 0.117 0.189 0.234 0.209
4 warfarin 0.292 0.350 0.417 0.383
4 aspirin 0.350 0.420 0.500 0.460
5 none 0.120 0.194 0.239 0.214
5 warfarin 0.300 0.358 0.425 0.392
5 aspirin 0.360 0.430 0.510 0.470
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Ischaemic stroke recurrence (continued)
(3) Atrial fibrillation present, mitral stenosis and mural thrombus present
carotid arteiy lesion none 30-69%
stenosis
70-99%
stenosis
occlusion
number of vascular risk 
factors
drug therapy
0 none 0.167 0.212 0.240 0.224
0 warfarin 0.417 0.450 0.492 0.467
0 aspirin 0.500 0.540 0.590 0.560
1 none 0.172 0.228 0.273 0.249
1 warfarin 0.429 0.475 0.542 0.508
1 aspirin 0.515 0.570 0.650 0.610
2 none 0.177 0.242 0.284 0.262
2 warfarin 0.442 0.496 0.558 0.521
2 aspirin 0.530 0.595 0.670 0.625
3 none 0.181 0.251 0.295 0.271
3 warfarin 0.450 0.508 0.575 0.542
3 aspirin 0.540 0.610 0.690 0.650
4 none 0.184 0.256 0.301 0.276
4 warfarin 0.458 0.517 0.583 0.550
4 aspirin 0.550 0.620 0.700 0.660
5 none 0.187 0.261 0.306 0.281
5 warfarin 0.467 0.525 0.592 0.558
5 aspirin 0.560 0.630 0.710 0.670
(4) Atrial fibrillation absent, mitral stenosis absent, mural thrombus absent
carotid artery lesion none 30-69%
stenosis
70-99%
stenosis
occlusion
number of vascular risk 
factors
drug therapy
0 none 0.020 0.052 0.090 0.071
0 warfarin 0.025 0.058 0.100 0.079
0 aspirin 0.030 0.070 0.120 0.090
1 none 0.030 0.075 0.135 0.105
1 warfarin 0.037 0.083 0.150 0.116
1 aspirin 0.045 0.100 0.180 0.140
2 none 0.040 0.090 0.151 0.120
2 warfarin 0.050 0.104 0.167 0.135
2 aspirin 0.060 0.125 0.200 0.160
3 none 0.046 0.104 0.165 0.134
3 warfarin 0.058 0.116 0.183 0.149
3 aspirin 0.070 0.140 0.220 0.180
4 none 0.054 0.113 0.173 0.143
4 warfarin 0.067 0.125 0.192 0.158
4 aspirin 0.080 0.150 0.230 0.190
5 none 0.060 0.120 0.180 0.150
5 warfarin 0.075 0.133 0.200 0.166
5 aspirin 0.090 0.160 0.240 0.200
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Ischaemic stroke recurrence (continued)
(5) Atrial fibrillation absent, either mitral stenosis or mural thrombus present
carotid artery lesion none 30-69%
stenosis
70-99%
stenosis
occlusion
number of vascular risk 
factors
drug therapy
0 none 0.087 0.119 0.157 0.138
0 warfarin 0.192 0.225 0.267 0.242
0 aspirin 0.230 0.270 0.320 0.290
1 none 0.097 0.142 0.202 0.172
1 warfarin 0.204 0.250 0.317 0.283
1 aspirin 0.245 0.300 0.380 0.340
2 none 0.107 0.157 0.218 0.187
2 warfarin 0.217 0.271 0.333 0.300
2 aspirin 0.260 0.325 0.400 0.360
3 none 0.113 0.171 0.232 0.201
3 warfarin 0.225 0.283 0.350 0.317
3 aspirin 0.270 0.340 0.420 0.380
4 none 0.121 0.180 0.240 0.210
4 warfarin 0.233 0.292 0.358 0.325
4 aspirin 0.280 0.350 0.430 0.390
5 none 0.127 0.187 0.247 0.217
5 warfarin 0.242 0.300 0.367 0.333
5 aspirin 0.290 0.360 0.440 0.400
(6) Atrial fibrillation absent, mitral stenosis and mural thrombus present
carotid artery lesion none 30-69%
stenosis
70-99%
stenosis
occlusion
number of vascular risk 
factors
drug therapy
0 none 0.154 0.186 0.224 0.205
0 warfarin 0.358 0.392 0.433 0.408
0 aspirin 0.430 0.470 0.520 0.490
1 none 0.164 0.209 0.269 0.239
1 warfarin 0.371 0.417 0.483 0.450
1 aspirin 0.445 0.500 0.580 0.540
2 none 0.174 0.224 0.285 0.254
2 warfarin 0.383 0.438 0.500 0.467
2 aspirin 0.460 0.525 0.600 0.560
3 none 0.180 0.238 0.299 0.268
3 warfarin 0.392 0.450 0.517 0.483
3 aspirin 0.470 0.540 0.620 0.580
4 none 0.188 0.247 0.307 0.277
4 warfarin 0.400 0.458 0.525 0.492
4 aspirin 0.480 0.550 0.630 0.590
5 none 0.194 0.254 0.314 0.284
5 warfarin 0.408 0.467 0.533 0.500
5 aspirin 0.490 0.560 0.640 0.600
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Drug therapy prescription
(1) No recently active peptic ulceration, no carotid artery lesion
number of embolic risk factors 0 1 2 3 4
number of risk factors 
for haemorrhage
drug therapy
0 none 0.05 0.02 0.01 0.01 0.01
0 warfarin 0.05 0.60 0.80 0.90 0.95
0 aspirin 0.90 0.38 0.19 0.09 0.04
1 none 0.06 0.03 0.02 0.01 0.01
1 warfarin 0.03 0.50 0.70 0.75 0.80
1 aspirin 0.91 0.47 0.28 0.24 0.19
2 none 0.08 0.05 0.03 0.03 0.03
2 warfarin 0.02 0.30 0.40 0.45 0.50
2 aspirin 0.90 0.65 0.57 0.52 0.47
3 none 0.09 0.05 0.04 0.04 0.03
3 warfarin 0.01 0.15 0.20 0.25 0.27
3 aspirin 0.90 0.80 0.76 0.71 0.70
4 none 0.1 0.05 0.04 0.03 0.02
4 warfarin 0.0 0.05 0.10 0.12 0.13
4 aspirin 0.9 0.90 0.86 0.85 0.85
5 none 0.1 0.1 0.04 0.03 0.03
5 warfarin 0.0 0.0 0.03 0.05 0.06
5 aspirin 0.9 0.9 0.93 0.92 0.91
(2) No recently active peptic ulceration, carotid occlusion or 30-69% stenosis
number of embolic risk factors 0 1 2 3 4
number of risk factors 
for haemorrhage
drug therapy
0 none 0.05 0.02 0.01 0.01 0.01
0 warfarin 0.0475 0.57 0.76 0.855 0.91
0 aspirin 0.9025 0.41 0.23 0.135 0.08
1 none 0.06 0.03 0.02 0.01 0.01
1 warfarin 0.0285 0.475 0.665 0.7125 0.76
1 aspirin 0.9115 0.495 0.315 0.2775 0.23
2 none 0.08 0.05 0.03 0.03 0.03
2 warfarin 0.019 0.285 0.38 0.4275 0.475
2 aspirin 0.901 0.665 0.59 0.5425 0.495
3 none 0.09 0.05 0.04 0.04 0.03
3 warfarin 0.0095 0.1425 0.19 0.2375 0.2565
3 aspirin 0.9005 0.8075 0.77 0.7225 0.7135
4 none 0.1 0.05 0.04 0.03 0.02
4 warfarin 0.0 0.0475 0.095 0.114 0.1235
4 aspirin 0.9 0.9025 0.865 0.856 0.8565
5 none 0.1 0.1 0.04 0.03 0.03
5 warfarin 0.0 0.0 0.0285 0.0475 0.057
5 aspirin 0.9 0.9 0.9315 0.9225 0.913
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Drug therapy prescription (continued)
(3) No recently active peptic ulceration. 70-99% carotid artery stenosis
number of embolic risk factors 0 1 2 3 4
number of risk factors 
for haemorrhage
drug therapy
0 none 0.05 0.02 0.01 0.01 0.005
0 warfarin 0.0525 0.63 0.84 0.945 0.99
0 aspirin 0.8975 0.35 0.15 0.045 0.005
1 none 0.06 0.03 0.02 0.01 0.01
1 warfarin 0.0315 0.525 0.735 0.7875 0.84
1 aspirin 0.9085 0.445 0.245 0.2025 0.15
2 none 0.08 0.05 0.03 0.03 0.03
2 warfarin 0.021 0.315 0.42 0.4725 0.525
2 aspirin 0.899 0.635 0.55 0.4975 0.445
3 none 0.09 0.05 0.04 0.04 0.03
3 warfarin 0.0105 0.1575 0.21 0.2625 0.2835
3 aspirin 0.8995 0.7925 0.75 0.6975 0.6865
4 none 0.1 0.05 0.04 0.03 0.02
4 warfarin 0.0 0.0525 0.105 0.126 0.1365
4 aspirin 0.9 0.8975 0.855 0.844 0.8435
5 none 0.1 0.1 0.04 0.03 0.03
5 warfarin 0.0 0.0 0.0315 0.0525 0.063
5 aspirin 0.9 0.9 0.9285 0.9175 0.907
(4) Recently active peptic ulceration, any carotid lesion status
number of embolic risk factors 0 1 2 3 4
number of risk factors 
for haemorrhage
drug therapy
0 none 1 0.95 0.95 0.95 0.95
0 warfarin 0 0.01 0.015 0.018 0.02
0 aspirin 0 0.04 0.035 0.032 0.03
1 none 1 0.952 0.953 0.953 0.953
1 warfarin 0 0.008 0.012 0.015 0.017
1 aspirin 0 0.04 0.035 0.032 0.03
2 none 1 0.966 0.969 0.968 0.969
2 warfarin 0 0.004 0.006 0.008 0.009
2 aspirin 0 0.03 0.025 0.024 0.022
3 none 1 0.978 0.982 0.98 0.980
3 warfarin 0 0.002 0.003 0.004 0.005
3 aspirin 0 0.02 0.015 0.016 0.015
4 none 1 0.989 0.9935 0.99 0.99
4 warfarin 0 0.001 0.0015 0.002 0.003
4 aspirin 0 0.01 0.005 0.008 0.007
5 none 1 1 1 1 1
5 warfarin 0 0 0 0 0
5 aspirin 0 0 0 0 0
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